{"idB": "906709_12_item1_p53_s1", "idA": "906709_11_item1_p111_s0", "sentA": "is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis.", "sentB": "NKTR-102 is a novel macromolecular chemotherapeutic designed to enhance the anti-cancer effects of topo I inhibition while minimizing its toxicities.", "type": 1, "words": ["<tag1>", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis.", "<tag2>", "NKTR-102", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities.", "<tag3>"], "wordsA": ["is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis."], "wordsB": ["NKTR-102", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p43_s3", "idA": "906709_11_item1_p130_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "With respect to the $235.0 million in milestones due upon certain filings and commercial launch milestones for NKTR-118, when filing occurs in the US and in the EU or Japan, Nektar will be entitled to up to $95.0 million of those milestones.", "type": 1, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "With", "respect", "to", "the", "$235.0", "million", "in", "milestones", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "when", "filing", "occurs", "in", "the", "US", "and", "in", "the", "EU", "or", "Japan,", "Nektar", "will", "be", "entitled", "to", "up", "to", "$95.0", "million", "of", "those", "milestones.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["With", "respect", "to", "the", "$235.0", "million", "in", "milestones", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "when", "filing", "occurs", "in", "the", "US", "and", "in", "the", "EU", "or", "Japan,", "Nektar", "will", "be", "entitled", "to", "up", "to", "$95.0", "million", "of", "those", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p61_s1", "idA": "906709_11_item1_p176_s0", "sentA": "These therapies are only partially effective in treating the disease.", "sentB": "Anthracyclines and taxanes are the among the most active and widely used chemotherapeutic agents for breast cancer, but the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease.", "type": 1, "words": ["<tag1>", "These", "therapies", "are", "only", "partially", "effective", "in", "treating", "the", "disease.", "<tag2>", "Anthracyclines", "and", "taxanes", "are", "the", "among", "the", "most", "active", "and", "widely", "used", "chemotherapeutic", "agents", "for", "breast", "cancer,", "but", "the", "increased", "use", "of", "these", "agents", "at", "an", "early", "stage", "of", "disease", "often", "renders", "tumors", "resistant", "to", "these", "drugs", "by", "the", "time", "the", "disease", "recurs,", "thereby", "reducing", "the", "number", "of", "treatment", "options", "for", "metastatic", "disease.", "<tag3>"], "wordsA": ["These", "therapies", "are", "only", "partially", "effective", "in", "treating", "the", "disease."], "wordsB": ["Anthracyclines", "and", "taxanes", "are", "the", "among", "the", "most", "active", "and", "widely", "used", "chemotherapeutic", "agents", "for", "breast", "cancer,", "but", "the", "increased", "use", "of", "these", "agents", "at", "an", "early", "stage", "of", "disease", "often", "renders", "tumors", "resistant", "to", "these", "drugs", "by", "the", "time", "the", "disease", "recurs,", "thereby", "reducing", "the", "number", "of", "treatment", "options", "for", "metastatic", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p53_s2", "idA": "906709_11_item1_p17_s4", "sentA": "An example of a drug candidate that uses this approach to avoid first-pass metabolism is NKTR-140, a protease inhibitor in the early stages of discovery research.", "sentB": "Unlike irinotecan, a first generation topo I inhibitor that exhibits a high initial peak concentration and short half-life, NKTR-102 s unique pro-drug design results in a lowered initial peak concentration of active topo I inhibitor in the blood.", "type": 1, "words": ["<tag1>", "An", "example", "of", "a", "drug", "candidate", "that", "uses", "this", "approach", "to", "avoid", "first-pass", "metabolism", "is", "NKTR-140,", "a", "protease", "inhibitor", "in", "the", "early", "stages", "of", "discovery", "research.", "<tag2>", "Unlike", "irinotecan,", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "NKTR-102", "s", "unique", "pro-drug", "design", "results", "in", "a", "lowered", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood.", "<tag3>"], "wordsA": ["An", "example", "of", "a", "drug", "candidate", "that", "uses", "this", "approach", "to", "avoid", "first-pass", "metabolism", "is", "NKTR-140,", "a", "protease", "inhibitor", "in", "the", "early", "stages", "of", "discovery", "research."], "wordsB": ["Unlike", "irinotecan,", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "NKTR-102", "s", "unique", "pro-drug", "design", "results", "in", "a", "lowered", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s10", "idA": "906709_11_item1_p18_s1", "sentA": "We are currently using this platform with oncolytics, which typically have sub-optimal half-lives that can limit their therapeutic efficacy.", "sentB": "We are currently in the process of compiling the data from this expanded study and performing verification procedures on preliminary interim results from the patients enrolled to date.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy.", "<tag2>", "We", "are", "currently", "in", "the", "process", "of", "compiling", "the", "data", "from", "this", "expanded", "study", "and", "performing", "verification", "procedures", "on", "preliminary", "interim", "results", "from", "the", "patients", "enrolled", "to", "date.", "<tag3>"], "wordsA": ["We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy."], "wordsB": ["We", "are", "currently", "in", "the", "process", "of", "compiling", "the", "data", "from", "this", "expanded", "study", "and", "performing", "verification", "procedures", "on", "preliminary", "interim", "results", "from", "the", "patients", "enrolled", "to", "date."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p22_s0", "idA": "906709_11_item1_p206_s2", "sentA": "From 1989 to 1992, he worked as an environmental consultant with Environ Corporation, a human health and environmental consulting firm.", "sentB": "PEGylated peptidic compound that binds to and stimulates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent.", "type": 1, "words": ["<tag1>", "From", "1989", "to", "1992,", "he", "worked", "as", "an", "environmental", "consultant", "with", "Environ", "Corporation,", "a", "human", "health", "and", "environmental", "consulting", "firm.", "<tag2>", "PEGylated", "peptidic", "compound", "that", "binds", "to", "and", "stimulates", "the", "erythropoietin", "receptor", "and", "thus", "acts", "as", "an", "erythropoiesis", "stimulating", "agent.", "<tag3>"], "wordsA": ["From", "1989", "to", "1992,", "he", "worked", "as", "an", "environmental", "consultant", "with", "Environ", "Corporation,", "a", "human", "health", "and", "environmental", "consulting", "firm."], "wordsB": ["PEGylated", "peptidic", "compound", "that", "binds", "to", "and", "stimulates", "the", "erythropoietin", "receptor", "and", "thus", "acts", "as", "an", "erythropoiesis", "stimulating", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p45_s1", "idA": "906709_11_item1_p20_s1", "sentA": "We are in the early stages of discovery research with a number of peptides that utilize this proprietary approach.", "sentB": "The KODIAC study includes two 12-week, randomized, placebo-controlled efficacy studies (with approximately 630 randomized patients each) and an open-label, randomized, 52-week long-term safety study with a usual care comparator arm.", "type": 1, "words": ["<tag1>", "We", "are", "in", "the", "early", "stages", "of", "discovery", "research", "with", "a", "number", "of", "peptides", "that", "utilize", "this", "proprietary", "approach.", "<tag2>", "The", "KODIAC", "study", "includes", "two", "12-week,", "randomized,", "placebo-controlled", "efficacy", "studies", "(with", "approximately", "630", "randomized", "patients", "each)", "and", "an", "open-label,", "randomized,", "52-week", "long-term", "safety", "study", "with", "a", "usual", "care", "comparator", "arm.", "<tag3>"], "wordsA": ["We", "are", "in", "the", "early", "stages", "of", "discovery", "research", "with", "a", "number", "of", "peptides", "that", "utilize", "this", "proprietary", "approach."], "wordsB": ["The", "KODIAC", "study", "includes", "two", "12-week,", "randomized,", "placebo-controlled", "efficacy", "studies", "(with", "approximately", "630", "randomized", "patients", "each)", "and", "an", "open-label,", "randomized,", "52-week", "long-term", "safety", "study", "with", "a", "usual", "care", "comparator", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p56_s0", "idA": "906709_11_item1_p62_s2", "sentA": "By applying our proprietary pro-drug polymer conjugate technology to irinotecan, NKTR-102 has the potential to be a more effective and tolerable anti-tumor agent.", "sentB": "Clinical studies have shown that NKTR-102 has an extended pharmacokinetic profile and remains in circulation throughout the entire chemotherapy cycle, providing sustained exposure to topo I inhibition.", "type": 1, "words": ["<tag1>", "By", "applying", "our", "proprietary", "pro-drug", "polymer", "conjugate", "technology", "to", "irinotecan,", "NKTR-102", "has", "the", "potential", "to", "be", "a", "more", "effective", "and", "tolerable", "anti-tumor", "agent.", "<tag2>", "Clinical", "studies", "have", "shown", "that", "NKTR-102", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition.", "<tag3>"], "wordsA": ["By", "applying", "our", "proprietary", "pro-drug", "polymer", "conjugate", "technology", "to", "irinotecan,", "NKTR-102", "has", "the", "potential", "to", "be", "a", "more", "effective", "and", "tolerable", "anti-tumor", "agent."], "wordsB": ["Clinical", "studies", "have", "shown", "that", "NKTR-102", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p45_s2", "idA": "906709_11_item1_p64_s2", "sentA": "The study s primary endpoint is objective response rate (ORR) per RECIST 1.0 (standard criteria measuring tumor response) with certain secondary endpoints including safety, as well as progression-free survival and overall survival.", "sentB": "The 12-week efficacy studies will compare response rate among placebo and two different doses of NKTR-118 with primary endpoint at 12 weeks.", "type": 1, "words": ["<tag1>", "The", "study", "s", "primary", "endpoint", "is", "objective", "response", "rate", "(ORR)", "per", "RECIST", "1.0", "(standard", "criteria", "measuring", "tumor", "response)", "with", "certain", "secondary", "endpoints", "including", "safety,", "as", "well", "as", "progression-free", "survival", "and", "overall", "survival.", "<tag2>", "The", "12-week", "efficacy", "studies", "will", "compare", "response", "rate", "among", "placebo", "and", "two", "different", "doses", "of", "NKTR-118", "with", "primary", "endpoint", "at", "12", "weeks.", "<tag3>"], "wordsA": ["The", "study", "s", "primary", "endpoint", "is", "objective", "response", "rate", "(ORR)", "per", "RECIST", "1.0", "(standard", "criteria", "measuring", "tumor", "response)", "with", "certain", "secondary", "endpoints", "including", "safety,", "as", "well", "as", "progression-free", "survival", "and", "overall", "survival."], "wordsB": ["The", "12-week", "efficacy", "studies", "will", "compare", "response", "rate", "among", "placebo", "and", "two", "different", "doses", "of", "NKTR-118", "with", "primary", "endpoint", "at", "12", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p59_s1", "idA": "906709_11_item1_p66_s1", "sentA": "The American Cancer Society estimated that about 207,090 new cases of invasive breast cancer were diagnosed and nearly 39,840 women died of breast cancer in the United States in 2010.", "sentB": "The chance of developing invasive breast cancer at some time in a woman s life is a little less than one in eight (12%).", "type": 1, "words": ["<tag1>", "The", "American", "Cancer", "Society", "estimated", "that", "about", "207,090", "new", "cases", "of", "invasive", "breast", "cancer", "were", "diagnosed", "and", "nearly", "39,840", "women", "died", "of", "breast", "cancer", "in", "the", "United", "States", "in", "2010.", "<tag2>", "The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(12%).", "<tag3>"], "wordsA": ["The", "American", "Cancer", "Society", "estimated", "that", "about", "207,090", "new", "cases", "of", "invasive", "breast", "cancer", "were", "diagnosed", "and", "nearly", "39,840", "women", "died", "of", "breast", "cancer", "in", "the", "United", "States", "in", "2010."], "wordsB": ["The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(12%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p58_s0", "idA": "906709_11_item1_p69_s2", "sentA": "Median lines of prior therapy for women enrolled into the original study was three, with forty-seven percent of the women having received prior treatment with pegylated liposomal doxorubicin (PLD).", "sentB": "Randomization will be stratified by geographic region, prior treatment with eribulin and whether or not the patient has triple negative breast cancer.", "type": 1, "words": ["<tag1>", "Median", "lines", "of", "prior", "therapy", "for", "women", "enrolled", "into", "the", "original", "study", "was", "three,", "with", "forty-seven", "percent", "of", "the", "women", "having", "received", "prior", "treatment", "with", "pegylated", "liposomal", "doxorubicin", "(PLD).", "<tag2>", "Randomization", "will", "be", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "has", "triple", "negative", "breast", "cancer.", "<tag3>"], "wordsA": ["Median", "lines", "of", "prior", "therapy", "for", "women", "enrolled", "into", "the", "original", "study", "was", "three,", "with", "forty-seven", "percent", "of", "the", "women", "having", "received", "prior", "treatment", "with", "pegylated", "liposomal", "doxorubicin", "(PLD)."], "wordsB": ["Randomization", "will", "be", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "has", "triple", "negative", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p58_s2", "idA": "906709_11_item1_p69_s4", "sentA": "Secondary endpoints in the study included best clinical response, clinical benefit, CA-125 response (a known ovarian cancer blood marker) safety, progression-free survival and overall survival.", "sentB": "Secondary endpoints and objectives also include clinical benefit rate, duration of response, pharmacokinetic data, safety profiles, quality-of-life measurements, and pharmacoeconomic implications.", "type": 1, "words": ["<tag1>", "Secondary", "endpoints", "in", "the", "study", "included", "best", "clinical", "response,", "clinical", "benefit,", "CA-125", "response", "(a", "known", "ovarian", "cancer", "blood", "marker)", "safety,", "progression-free", "survival", "and", "overall", "survival.", "<tag2>", "Secondary", "endpoints", "and", "objectives", "also", "include", "clinical", "benefit", "rate,", "duration", "of", "response,", "pharmacokinetic", "data,", "safety", "profiles,", "quality-of-life", "measurements,", "and", "pharmacoeconomic", "implications.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "in", "the", "study", "included", "best", "clinical", "response,", "clinical", "benefit,", "CA-125", "response", "(a", "known", "ovarian", "cancer", "blood", "marker)", "safety,", "progression-free", "survival", "and", "overall", "survival."], "wordsB": ["Secondary", "endpoints", "and", "objectives", "also", "include", "clinical", "benefit", "rate,", "duration", "of", "response,", "pharmacokinetic", "data,", "safety", "profiles,", "quality-of-life", "measurements,", "and", "pharmacoeconomic", "implications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p57_s2", "idA": "906709_11_item1_p69_s5", "sentA": "In 2010, we announced that we are expanding this Phase 2 study to include approximately 50 additional women who had previously received PLD therapy to continue to evaluate the every 21-day dose schedule of single-agent NKTR-102 in this subset of women.", "sentB": "The BEACON study plans to include approximately 160 investigator sites worldwide including sites in North America, Eastern and Western Europe, and certain countries in Asia/Pacific.", "type": 1, "words": ["<tag1>", "In", "2010,", "we", "announced", "that", "we", "are", "expanding", "this", "Phase", "2", "study", "to", "include", "approximately", "50", "additional", "women", "who", "had", "previously", "received", "PLD", "therapy", "to", "continue", "to", "evaluate", "the", "every", "21-day", "dose", "schedule", "of", "single-agent", "NKTR-102", "in", "this", "subset", "of", "women.", "<tag2>", "The", "BEACON", "study", "plans", "to", "include", "approximately", "160", "investigator", "sites", "worldwide", "including", "sites", "in", "North", "America,", "Eastern", "and", "Western", "Europe,", "and", "certain", "countries", "in", "Asia/Pacific.", "<tag3>"], "wordsA": ["In", "2010,", "we", "announced", "that", "we", "are", "expanding", "this", "Phase", "2", "study", "to", "include", "approximately", "50", "additional", "women", "who", "had", "previously", "received", "PLD", "therapy", "to", "continue", "to", "evaluate", "the", "every", "21-day", "dose", "schedule", "of", "single-agent", "NKTR-102", "in", "this", "subset", "of", "women."], "wordsB": ["The", "BEACON", "study", "plans", "to", "include", "approximately", "160", "investigator", "sites", "worldwide", "including", "sites", "in", "North", "America,", "Eastern", "and", "Western", "Europe,", "and", "certain", "countries", "in", "Asia/Pacific."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p54_s0", "idA": "906709_11_item1_p71_s2", "sentA": "Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.", "sentB": "The large NKTR-102 molecule is inactive when administered.", "type": 1, "words": ["<tag1>", "Ovarian", "cancer", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system.", "<tag2>", "The", "large", "NKTR-102", "molecule", "is", "inactive", "when", "administered.", "<tag3>"], "wordsA": ["Ovarian", "cancer", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system."], "wordsB": ["The", "large", "NKTR-102", "molecule", "is", "inactive", "when", "administered."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p77_s1", "idA": "906709_11_item1_p71_s2", "sentA": "Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.", "sentB": "The program is significantly behind schedule.", "type": 1, "words": ["<tag1>", "Ovarian", "cancer", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system.", "<tag2>", "The", "program", "is", "significantly", "behind", "schedule.", "<tag3>"], "wordsA": ["Ovarian", "cancer", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system."], "wordsB": ["The", "program", "is", "significantly", "behind", "schedule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p11_s0", "idA": "906709_11_item1_p73_s0", "sentA": "The Phase 2 clinical study is designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "The Phase 1 clinical study is a prospective, open-label study that will assess the safety, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or older with severe hemophilia A. When used for prophylaxis, Baxter s ADVATE requires patients to infuse every two to three days to reduce the occurrence of bleeding episodes.", "type": 1, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "The", "Phase", "1", "clinical", "study", "is", "a", "prospective,", "open-label", "study", "that", "will", "assess", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "previously-treated", "patients", "aged", "12", "years", "or", "older", "with", "severe", "hemophilia", "A.", "When", "used", "for", "prophylaxis,", "Baxter", "s", "ADVATE", "requires", "patients", "to", "infuse", "every", "two", "to", "three", "days", "to", "reduce", "the", "occurrence", "of", "bleeding", "episodes.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["The", "Phase", "1", "clinical", "study", "is", "a", "prospective,", "open-label", "study", "that", "will", "assess", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "previously-treated", "patients", "aged", "12", "years", "or", "older", "with", "severe", "hemophilia", "A.", "When", "used", "for", "prophylaxis,", "Baxter", "s", "ADVATE", "requires", "patients", "to", "infuse", "every", "two", "to", "three", "days", "to", "reduce", "the", "occurrence", "of", "bleeding", "episodes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p10_s1", "idA": "906709_11_item1_p89_s1", "sentA": "In a typical collaboration involving our PEGylation technology, we license our proprietary intellectual property related to our PEGylation technology or proprietary conjugated drug molecules in consideration for upfront payments, development milestone payments and royalties from sales of the resulting commercial product as well as sales milestones.", "sentB": "In addition to incorporating our PEGylation technology, BAX 855 is also based on Baxter s ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process.", "type": 1, "words": ["<tag1>", "In", "a", "typical", "collaboration", "involving", "our", "PEGylation", "technology,", "we", "license", "our", "proprietary", "intellectual", "property", "related", "to", "our", "PEGylation", "technology", "or", "proprietary", "conjugated", "drug", "molecules", "in", "consideration", "for", "upfront", "payments,", "development", "milestone", "payments", "and", "royalties", "from", "sales", "of", "the", "resulting", "commercial", "product", "as", "well", "as", "sales", "milestones.", "<tag2>", "In", "addition", "to", "incorporating", "our", "PEGylation", "technology,", "BAX", "855", "is", "also", "based", "on", "Baxter", "s", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method]", "full-length", "rFVIII", "molecule", "and", "plasma/albumin-free", "(PAF)", "manufacturing", "process.", "<tag3>"], "wordsA": ["In", "a", "typical", "collaboration", "involving", "our", "PEGylation", "technology,", "we", "license", "our", "proprietary", "intellectual", "property", "related", "to", "our", "PEGylation", "technology", "or", "proprietary", "conjugated", "drug", "molecules", "in", "consideration", "for", "upfront", "payments,", "development", "milestone", "payments", "and", "royalties", "from", "sales", "of", "the", "resulting", "commercial", "product", "as", "well", "as", "sales", "milestones."], "wordsB": ["In", "addition", "to", "incorporating", "our", "PEGylation", "technology,", "BAX", "855", "is", "also", "based", "on", "Baxter", "s", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method]", "full-length", "rFVIII", "molecule", "and", "plasma/albumin-free", "(PAF)", "manufacturing", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p43_s4", "idA": "906709_11_item1_p90_s6", "sentA": "The agreement expires on a country-by-country basis upon the expiration of Affymax s royalty obligations.", "sentB": "The remaining milestone payments are due upon the commercial launches of NKTR-118 in those regions.", "type": 1, "words": ["<tag1>", "The", "agreement", "expires", "on", "a", "country-by-country", "basis", "upon", "the", "expiration", "of", "Affymax", "s", "royalty", "obligations.", "<tag2>", "The", "remaining", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "NKTR-118", "in", "those", "regions.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "on", "a", "country-by-country", "basis", "upon", "the", "expiration", "of", "Affymax", "s", "royalty", "obligations."], "wordsB": ["The", "remaining", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "NKTR-118", "in", "those", "regions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p15_s0", "idA": "906709_11_item1_p93_s0", "sentA": "We were a party to a collaborative research, development and commercialization agreement with Bayer Schering Pharma AG related to the development of an inhaled powder formulation of Ciprofloxacin for the treatment of chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.", "sentB": "PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Roche s PEGASYS (PEG-interferon alfa-2a) and Amgen s Neulasta (pegfilgrastim).", "type": 1, "words": ["<tag1>", "We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "Ciprofloxacin", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients.", "<tag2>", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)", "and", "Amgen", "s", "Neulasta", "(pegfilgrastim).", "<tag3>"], "wordsA": ["We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "Ciprofloxacin", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients."], "wordsB": ["PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)", "and", "Amgen", "s", "Neulasta", "(pegfilgrastim)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p10_s2", "idA": "906709_12_item1_p0_s3", "sentA": "We create our innovative drug candidates by using our proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities.", "sentB": "As a new molecular structure, NKTR-181 s abuse deterrent property does not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "type": 1, "words": ["<tag1>", "We", "create", "our", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "drugs", "to", "create", "new", "molecular", "entities.", "<tag2>", "As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag3>"], "wordsA": ["We", "create", "our", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "drugs", "to", "create", "new", "molecular", "entities."], "wordsB": ["As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s5", "idA": "906709_12_item1_p18_s4", "sentA": "A primary example of reducing transport across the blood-brain barrier is NKTR-118, an orally-available peripheral opioid antagonist that is in Phase 3 clinical studies with our partner AstraZeneca.", "sentB": "The safety analyses also showed no clinically relevant imbalances in serious adverse events (SAEs), including externally adjudicated major cardiovascular events, across the three treatment arms in KODIAC-04, -05 and -07.", "type": 1, "words": ["<tag1>", "A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca.", "<tag2>", "The", "safety", "analyses", "also", "showed", "no", "clinically", "relevant", "imbalances", "in", "serious", "adverse", "events", "(SAEs),", "including", "externally", "adjudicated", "major", "cardiovascular", "events,", "across", "the", "three", "treatment", "arms", "in", "KODIAC-04,", "-05", "and", "-07.", "<tag3>"], "wordsA": ["A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca."], "wordsB": ["The", "safety", "analyses", "also", "showed", "no", "clinically", "relevant", "imbalances", "in", "serious", "adverse", "events", "(SAEs),", "including", "externally", "adjudicated", "major", "cardiovascular", "events,", "across", "the", "three", "treatment", "arms", "in", "KODIAC-04,", "-05", "and", "-07."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s8", "idA": "906709_12_item1_p18_s4", "sentA": "A primary example of reducing transport across the blood-brain barrier is NKTR-118, an orally-available peripheral opioid antagonist that is in Phase 3 clinical studies with our partner AstraZeneca.", "sentB": "All other common AEs were distributed similarly across the three treatment arms.", "type": 1, "words": ["<tag1>", "A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca.", "<tag2>", "All", "other", "common", "AEs", "were", "distributed", "similarly", "across", "the", "three", "treatment", "arms.", "<tag3>"], "wordsA": ["A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca."], "wordsB": ["All", "other", "common", "AEs", "were", "distributed", "similarly", "across", "the", "three", "treatment", "arms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p49_s0", "idA": "906709_12_item1_p21_s0", "sentA": "Peptides are important in modulating many physiological processes in the body.", "sentB": "Opioids attach to specific proteins called opioid receptors.", "type": 1, "words": ["<tag1>", "Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body.", "<tag2>", "Opioids", "attach", "to", "specific", "proteins", "called", "opioid", "receptors.", "<tag3>"], "wordsA": ["Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body."], "wordsB": ["Opioids", "attach", "to", "specific", "proteins", "called", "opioid", "receptors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p49_s1", "idA": "906709_12_item1_p21_s0", "sentA": "Peptides are important in modulating many physiological processes in the body.", "sentB": "When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur.", "type": 1, "words": ["<tag1>", "Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body.", "<tag2>", "When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur.", "<tag3>"], "wordsA": ["Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body."], "wordsB": ["When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s6", "idA": "906709_12_item1_p21_s0", "sentA": "Peptides are important in modulating many physiological processes in the body.", "sentB": "The most common adverse events (AEs) in the naloxegol treatment arms in both trials were abdominal pain, diarrhea and nausea.", "type": 1, "words": ["<tag1>", "Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body.", "<tag2>", "The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea.", "<tag3>"], "wordsA": ["Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body."], "wordsB": ["The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p55_s1", "idA": "906709_12_item1_p21_s0", "sentA": "Peptides are important in modulating many physiological processes in the body.", "sentB": "The trial reported no imbalances in SAEs.", "type": 1, "words": ["<tag1>", "Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body.", "<tag2>", "The", "trial", "reported", "no", "imbalances", "in", "SAEs.", "<tag3>"], "wordsA": ["Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body."], "wordsB": ["The", "trial", "reported", "no", "imbalances", "in", "SAEs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p21_s2", "idA": "906709_12_item1_p28_s6", "sentA": "Enter into Strategic and High-Value Partnerships to Bring Certain of Our Drug Candidates to Market We decide on a drug candidate-by-drug candidate basis how far to advance clinical development (e.g. Phase 1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches.", "sentB": "We have also developed robust manufacturing processes for generating second generation PEGylation reagents that allow us to utilize the full potential of these newer approaches.", "type": 1, "words": ["<tag1>", "Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches.", "<tag2>", "We", "have", "also", "developed", "robust", "manufacturing", "processes", "for", "generating", "second", "generation", "PEGylation", "reagents", "that", "allow", "us", "to", "utilize", "the", "full", "potential", "of", "these", "newer", "approaches.", "<tag3>"], "wordsA": ["Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches."], "wordsB": ["We", "have", "also", "developed", "robust", "manufacturing", "processes", "for", "generating", "second", "generation", "PEGylation", "reagents", "that", "allow", "us", "to", "utilize", "the", "full", "potential", "of", "these", "newer", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p52_s4", "idA": "906709_12_item1_p45_s1", "sentA": "The KODIAC study includes two 12-week, randomized, placebo-controlled efficacy studies (with approximately 630 randomized patients each) and an open-label, randomized, 52-week long-term safety study with a usual care comparator arm.", "sentB": "The studies enrolled approximately 630 patients each.", "type": 1, "words": ["<tag1>", "The", "KODIAC", "study", "includes", "two", "12-week,", "randomized,", "placebo-controlled", "efficacy", "studies", "(with", "approximately", "630", "randomized", "patients", "each)", "and", "an", "open-label,", "randomized,", "52-week", "long-term", "safety", "study", "with", "a", "usual", "care", "comparator", "arm.", "<tag2>", "The", "studies", "enrolled", "approximately", "630", "patients", "each.", "<tag3>"], "wordsA": ["The", "KODIAC", "study", "includes", "two", "12-week,", "randomized,", "placebo-controlled", "efficacy", "studies", "(with", "approximately", "630", "randomized", "patients", "each)", "and", "an", "open-label,", "randomized,", "52-week", "long-term", "safety", "study", "with", "a", "usual", "care", "comparator", "arm."], "wordsB": ["The", "studies", "enrolled", "approximately", "630", "patients", "each."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p52_s2", "idA": "906709_12_item1_p45_s2", "sentA": "The 12-week efficacy studies will compare response rate among placebo and two different doses of NKTR-118 with primary endpoint at 12 weeks.", "sentB": "KODIAC-04 and KODIAC-05 were replicate, multicenter- randomized, double-blind, placebo-controlled pivotal trials of 12 weeks duration that evaluated 12.5 mg and 25 mg naloxegol administered once-daily.", "type": 1, "words": ["<tag1>", "The", "12-week", "efficacy", "studies", "will", "compare", "response", "rate", "among", "placebo", "and", "two", "different", "doses", "of", "NKTR-118", "with", "primary", "endpoint", "at", "12", "weeks.", "<tag2>", "KODIAC-04", "and", "KODIAC-05", "were", "replicate,", "multicenter-", "randomized,", "double-blind,", "placebo-controlled", "pivotal", "trials", "of", "12", "weeks", "duration", "that", "evaluated", "12.5", "mg", "and", "25", "mg", "naloxegol", "administered", "once-daily.", "<tag3>"], "wordsA": ["The", "12-week", "efficacy", "studies", "will", "compare", "response", "rate", "among", "placebo", "and", "two", "different", "doses", "of", "NKTR-118", "with", "primary", "endpoint", "at", "12", "weeks."], "wordsB": ["KODIAC-04", "and", "KODIAC-05", "were", "replicate,", "multicenter-", "randomized,", "double-blind,", "placebo-controlled", "pivotal", "trials", "of", "12", "weeks", "duration", "that", "evaluated", "12.5", "mg", "and", "25", "mg", "naloxegol", "administered", "once-daily."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s7", "idA": "906709_12_item1_p45_s3", "sentA": "There is a three month safety extension following one of the two 12-week studies.", "sentB": "In KODIAC-07, the safety extension of KODIAC-04, the occurrence of AEs and SAEs was lower than in KODIAC-04 and -05.", "type": 1, "words": ["<tag1>", "There", "is", "a", "three", "month", "safety", "extension", "following", "one", "of", "the", "two", "12-week", "studies.", "<tag2>", "In", "KODIAC-07,", "the", "safety", "extension", "of", "KODIAC-04,", "the", "occurrence", "of", "AEs", "and", "SAEs", "was", "lower", "than", "in", "KODIAC-04", "and", "-05.", "<tag3>"], "wordsA": ["There", "is", "a", "three", "month", "safety", "extension", "following", "one", "of", "the", "two", "12-week", "studies."], "wordsB": ["In", "KODIAC-07,", "the", "safety", "extension", "of", "KODIAC-04,", "the", "occurrence", "of", "AEs", "and", "SAEs", "was", "lower", "than", "in", "KODIAC-04", "and", "-05."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s3", "idA": "906709_12_item1_p46_s0", "sentA": "Data from a Phase 2 study conducted by us showed that NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements in patients taking opioids with chronic OIC.", "sentB": "For both KODIAC-04 and -05, the 25 mg dose of naloxegol demonstrated statistically significant results for the primary endpoint.", "type": 1, "words": ["<tag1>", "Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC.", "<tag2>", "For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint.", "<tag3>"], "wordsA": ["Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC."], "wordsB": ["For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s4", "idA": "906709_12_item1_p46_s0", "sentA": "Data from a Phase 2 study conducted by us showed that NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements in patients taking opioids with chronic OIC.", "sentB": "In KODIAC-04, the 12.5 mg dose of naloxegol demonstrated statistically significant results for the primary endpoint and in KODIAC-05 the 12.5 mg dose did not meet statistical significance for the primary endpoint.", "type": 1, "words": ["<tag1>", "Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC.", "<tag2>", "In", "KODIAC-04,", "the", "12.5", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint", "and", "in", "KODIAC-05", "the", "12.5", "mg", "dose", "did", "not", "meet", "statistical", "significance", "for", "the", "primary", "endpoint.", "<tag3>"], "wordsA": ["Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC."], "wordsB": ["In", "KODIAC-04,", "the", "12.5", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint", "and", "in", "KODIAC-05", "the", "12.5", "mg", "dose", "did", "not", "meet", "statistical", "significance", "for", "the", "primary", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p55_s2", "idA": "906709_12_item1_p46_s1", "sentA": "The study also showed that there was no apparent reversal of opioid-mediated analgesia with any of the NKTR-118 dose groups, as measured by no change in Numeric Rating Scale pain scores, no evidence of opioid withdrawal, and no increase in mean daily opioid use.", "sentB": "In addition, there were a low number of major adverse cardiovascular events, as adjudicated by an independent external committee, and there was no imbalance of these events across naloxegol and UC arms.", "type": 1, "words": ["<tag1>", "The", "study", "also", "showed", "that", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "pain", "scores,", "no", "evidence", "of", "opioid", "withdrawal,", "and", "no", "increase", "in", "mean", "daily", "opioid", "use.", "<tag2>", "In", "addition,", "there", "were", "a", "low", "number", "of", "major", "adverse", "cardiovascular", "events,", "as", "adjudicated", "by", "an", "independent", "external", "committee,", "and", "there", "was", "no", "imbalance", "of", "these", "events", "across", "naloxegol", "and", "UC", "arms.", "<tag3>"], "wordsA": ["The", "study", "also", "showed", "that", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "pain", "scores,", "no", "evidence", "of", "opioid", "withdrawal,", "and", "no", "increase", "in", "mean", "daily", "opioid", "use."], "wordsB": ["In", "addition,", "there", "were", "a", "low", "number", "of", "major", "adverse", "cardiovascular", "events,", "as", "adjudicated", "by", "an", "independent", "external", "committee,", "and", "there", "was", "no", "imbalance", "of", "these", "events", "across", "naloxegol", "and", "UC", "arms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p55_s3", "idA": "906709_12_item1_p46_s1", "sentA": "The study also showed that there was no apparent reversal of opioid-mediated analgesia with any of the NKTR-118 dose groups, as measured by no change in Numeric Rating Scale pain scores, no evidence of opioid withdrawal, and no increase in mean daily opioid use.", "sentB": "There were no increases from baseline levels in mean daily pain scores or mean total daily opioid dose in either the naloxegol or the UC arm.", "type": 1, "words": ["<tag1>", "The", "study", "also", "showed", "that", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "pain", "scores,", "no", "evidence", "of", "opioid", "withdrawal,", "and", "no", "increase", "in", "mean", "daily", "opioid", "use.", "<tag2>", "There", "were", "no", "increases", "from", "baseline", "levels", "in", "mean", "daily", "pain", "scores", "or", "mean", "total", "daily", "opioid", "dose", "in", "either", "the", "naloxegol", "or", "the", "UC", "arm.", "<tag3>"], "wordsA": ["The", "study", "also", "showed", "that", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "pain", "scores,", "no", "evidence", "of", "opioid", "withdrawal,", "and", "no", "increase", "in", "mean", "daily", "opioid", "use."], "wordsB": ["There", "were", "no", "increases", "from", "baseline", "levels", "in", "mean", "daily", "pain", "scores", "or", "mean", "total", "daily", "opioid", "dose", "in", "either", "the", "naloxegol", "or", "the", "UC", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p17_s1", "idA": "906709_12_item1_p49_s0", "sentA": "Depending on the population studied and the definitions used, OIC occurs in up to 40-90% of patients taking opioids.", "sentB": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "type": 1, "words": ["<tag1>", "Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "OIC", "occurs", "in", "up", "to", "40-90%", "of", "patients", "taking", "opioids.", "<tag2>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag3>"], "wordsA": ["Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "OIC", "occurs", "in", "up", "to", "40-90%", "of", "patients", "taking", "opioids."], "wordsB": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p55_s4", "idA": "906709_12_item1_p50_s0", "sentA": "Clinically, OIC is the most prevalent side effect of opioid therapy.", "sentB": "Additionally, there were no reports of opioid withdrawal AEs which could be attributed to naloxegol.", "type": 1, "words": ["<tag1>", "Clinically,", "OIC", "is", "the", "most", "prevalent", "side", "effect", "of", "opioid", "therapy.", "<tag2>", "Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol.", "<tag3>"], "wordsA": ["Clinically,", "OIC", "is", "the", "most", "prevalent", "side", "effect", "of", "opioid", "therapy."], "wordsB": ["Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p54_s2", "idA": "906709_12_item1_p62_s3", "sentA": "Each schedule originally followed a two-stage Simon design and a total of 71 patients were initially included in the study that was completed in the first half of 2010.", "sentB": "In the trial, a total of 534 patients received naloxegol once daily for up to 52 weeks, while 270 patients received UC for OIC during the same treatment period.", "type": 1, "words": ["<tag1>", "Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "included", "in", "the", "study", "that", "was", "completed", "in", "the", "first", "half", "of", "2010.", "<tag2>", "In", "the", "trial,", "a", "total", "of", "534", "patients", "received", "naloxegol", "once", "daily", "for", "up", "to", "52", "weeks,", "while", "270", "patients", "received", "UC", "for", "OIC", "during", "the", "same", "treatment", "period.", "<tag3>"], "wordsA": ["Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "included", "in", "the", "study", "that", "was", "completed", "in", "the", "first", "half", "of", "2010."], "wordsB": ["In", "the", "trial,", "a", "total", "of", "534", "patients", "received", "naloxegol", "once", "daily", "for", "up", "to", "52", "weeks,", "while", "270", "patients", "received", "UC", "for", "OIC", "during", "the", "same", "treatment", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p55_s0", "idA": "906709_12_item1_p62_s8", "sentA": "We are currently in the process of compiling and performing verification procedures on the preliminary interim results from the patients enrolled to date in this study.", "sentB": "On February 26, 2013, AstraZeneca announced positive top-line results from KODIAC-08.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "in", "the", "process", "of", "compiling", "and", "performing", "verification", "procedures", "on", "the", "preliminary", "interim", "results", "from", "the", "patients", "enrolled", "to", "date", "in", "this", "study.", "<tag2>", "On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "KODIAC-08.", "<tag3>"], "wordsA": ["We", "are", "currently", "in", "the", "process", "of", "compiling", "and", "performing", "verification", "procedures", "on", "the", "preliminary", "interim", "results", "from", "the", "patients", "enrolled", "to", "date", "in", "this", "study."], "wordsB": ["On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "KODIAC-08."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p57_s2", "idA": "906709_12_item1_p64_s1", "sentA": "According to the World Health Organization, about 230,000 women globally are diagnosed each year with ovarian cancer.", "sentB": "A petition for the decontrol of naloxegol was submitted to the DEA in March 2012 and subsequently accepted for review.", "type": 1, "words": ["<tag1>", "According", "to", "the", "World", "Health", "Organization,", "about", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer.", "<tag2>", "A", "petition", "for", "the", "decontrol", "of", "naloxegol", "was", "submitted", "to", "the", "DEA", "in", "March", "2012", "and", "subsequently", "accepted", "for", "review.", "<tag3>"], "wordsA": ["According", "to", "the", "World", "Health", "Organization,", "about", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer."], "wordsB": ["A", "petition", "for", "the", "decontrol", "of", "naloxegol", "was", "submitted", "to", "the", "DEA", "in", "March", "2012", "and", "subsequently", "accepted", "for", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p57_s1", "idA": "906709_12_item1_p65_s0", "sentA": "A NKTR-102 Phase 2 clinical study was initiated in June 2008 to evaluate the efficacy and safety of NKTR-102 monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "AstraZeneca has conducted the studies necessary to evaluate the abuse potential and dependence-producing properties of naloxegol in support of obtaining decontrol.", "type": 1, "words": ["<tag1>", "A", "NKTR-102", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "AstraZeneca", "has", "conducted", "the", "studies", "necessary", "to", "evaluate", "the", "abuse", "potential", "and", "dependence-producing", "properties", "of", "naloxegol", "in", "support", "of", "obtaining", "decontrol.", "<tag3>"], "wordsA": ["A", "NKTR-102", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["AstraZeneca", "has", "conducted", "the", "studies", "necessary", "to", "evaluate", "the", "abuse", "potential", "and", "dependence-producing", "properties", "of", "naloxegol", "in", "support", "of", "obtaining", "decontrol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p51_s1", "idA": "906709_12_item1_p65_s2", "sentA": "According to recent data presented at the American Society of Clinical Oncology in 2010, it is estimated that up to 43.5% of colorectal cancer cases have this mutation in the KRAS gene and do not respond to EGFR-inhibitors, such as cetuximab.", "sentB": "It is estimated that approximately 40 50% (11-18 million) of those OIC sufferers achieve the desired treatment outcomes with current options that include over-the-counter and prescription laxatives.", "type": 1, "words": ["<tag1>", "According", "to", "recent", "data", "presented", "at", "the", "American", "Society", "of", "Clinical", "Oncology", "in", "2010,", "it", "is", "estimated", "that", "up", "to", "43.5%", "of", "colorectal", "cancer", "cases", "have", "this", "mutation", "in", "the", "KRAS", "gene", "and", "do", "not", "respond", "to", "EGFR-inhibitors,", "such", "as", "cetuximab.", "<tag2>", "It", "is", "estimated", "that", "approximately", "40", "50%", "(11-18", "million)", "of", "those", "OIC", "sufferers", "achieve", "the", "desired", "treatment", "outcomes", "with", "current", "options", "that", "include", "over-the-counter", "and", "prescription", "laxatives.", "<tag3>"], "wordsA": ["According", "to", "recent", "data", "presented", "at", "the", "American", "Society", "of", "Clinical", "Oncology", "in", "2010,", "it", "is", "estimated", "that", "up", "to", "43.5%", "of", "colorectal", "cancer", "cases", "have", "this", "mutation", "in", "the", "KRAS", "gene", "and", "do", "not", "respond", "to", "EGFR-inhibitors,", "such", "as", "cetuximab."], "wordsB": ["It", "is", "estimated", "that", "approximately", "40", "50%", "(11-18", "million)", "of", "those", "OIC", "sufferers", "achieve", "the", "desired", "treatment", "outcomes", "with", "current", "options", "that", "include", "over-the-counter", "and", "prescription", "laxatives."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p100_s1", "idA": "906709_13_item1_p10_s1", "sentA": "The molecule has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system (CNS)-related side effects, such as sedation and respiratory depression, which are commonly associated with standard opioid therapies.", "sentB": "This hyper-excitability results in transmission of abnormal pain signals from the periphery to the central nervous system (CNS).", "type": 1, "words": ["<tag1>", "The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies.", "<tag2>", "This", "hyper-excitability", "results", "in", "transmission", "of", "abnormal", "pain", "signals", "from", "the", "periphery", "to", "the", "central", "nervous", "system", "(CNS).", "<tag3>"], "wordsA": ["The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies."], "wordsB": ["This", "hyper-excitability", "results", "in", "transmission", "of", "abnormal", "pain", "signals", "from", "the", "periphery", "to", "the", "central", "nervous", "system", "(CNS)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p89_s1", "idA": "906709_13_item1_p10_s1", "sentA": "The molecule has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system (CNS)-related side effects, such as sedation and respiratory depression, which are commonly associated with standard opioid therapies.", "sentB": "Pupillometry data from the study demonstrated that NKTR-181 s centrally-mediated opioid effects are dose-dependent and indicates that the molecule enters the brain slowly, which has the potential to reduce the euphoria and other CNS side effects that are associated with current opioids.", "type": 1, "words": ["<tag1>", "The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies.", "<tag2>", "Pupillometry", "data", "from", "the", "study", "demonstrated", "that", "NKTR-181", "s", "centrally-mediated", "opioid", "effects", "are", "dose-dependent", "and", "indicates", "that", "the", "molecule", "enters", "the", "brain", "slowly,", "which", "has", "the", "potential", "to", "reduce", "the", "euphoria", "and", "other", "CNS", "side", "effects", "that", "are", "associated", "with", "current", "opioids.", "<tag3>"], "wordsA": ["The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies."], "wordsB": ["Pupillometry", "data", "from", "the", "study", "demonstrated", "that", "NKTR-181", "s", "centrally-mediated", "opioid", "effects", "are", "dose-dependent", "and", "indicates", "that", "the", "molecule", "enters", "the", "brain", "slowly,", "which", "has", "the", "potential", "to", "reduce", "the", "euphoria", "and", "other", "CNS", "side", "effects", "that", "are", "associated", "with", "current", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p110_s0", "idA": "906709_13_item1_p11_s0", "sentA": "In May 2012, the development program for NKTR-181 for the treatment of moderate to severe chronic pain was granted Fast Track designation by the FDA.", "sentB": "On April 17, 2013, the FDA issued another complete response letter identifying issues related to a supplier that provided the canister filling unit for LEVADEX .", "type": 1, "words": ["<tag1>", "In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA.", "<tag2>", "On", "April", "17,", "2013,", "the", "FDA", "issued", "another", "complete", "response", "letter", "identifying", "issues", "related", "to", "a", "supplier", "that", "provided", "the", "canister", "filling", "unit", "for", "LEVADEX", ".", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA."], "wordsB": ["On", "April", "17,", "2013,", "the", "FDA", "issued", "another", "complete", "response", "letter", "identifying", "issues", "related", "to", "a", "supplier", "that", "provided", "the", "canister", "filling", "unit", "for", "LEVADEX", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p93_s0", "idA": "906709_13_item1_p11_s0", "sentA": "In May 2012, the development program for NKTR-181 for the treatment of moderate to severe chronic pain was granted Fast Track designation by the FDA.", "sentB": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "type": 1, "words": ["<tag1>", "In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA.", "<tag2>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA."], "wordsB": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p9_s0", "idA": "906709_13_item1_p11_s0", "sentA": "In May 2012, the development program for NKTR-181 for the treatment of moderate to severe chronic pain was granted Fast Track designation by the FDA.", "sentB": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "type": 1, "words": ["<tag1>", "In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA.", "<tag2>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA."], "wordsB": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s2", "idA": "906709_13_item1_p11_s1", "sentA": "We also have additional proprietary preclinical and clinical drug candidates being developed for pain relief.", "sentB": "REG1 is being developed for use in patients suffering from acute coronary syndrome, including those who undergo coronary revascularization procedures, which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting.", "type": 1, "words": ["<tag1>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief.", "<tag2>", "REG1", "is", "being", "developed", "for", "use", "in", "patients", "suffering", "from", "acute", "coronary", "syndrome,", "including", "those", "who", "undergo", "coronary", "revascularization", "procedures,", "which", "include", "percutaneous", "coronary", "intervention", "(PCI)", "and", "coronary", "artery", "bypass", "grafting.", "<tag3>"], "wordsA": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief."], "wordsB": ["REG1", "is", "being", "developed", "for", "use", "in", "patients", "suffering", "from", "acute", "coronary", "syndrome,", "including", "those", "who", "undergo", "coronary", "revascularization", "procedures,", "which", "include", "percutaneous", "coronary", "intervention", "(PCI)", "and", "coronary", "artery", "bypass", "grafting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s6", "idA": "906709_13_item1_p11_s1", "sentA": "We also have additional proprietary preclinical and clinical drug candidates being developed for pain relief.", "sentB": "Of the 295 patients that entered the study, only 9 (3%) patients were unable to achieve meaningful pain relief with NKTR-181.", "type": 1, "words": ["<tag1>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief.", "<tag2>", "Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "(3%)", "patients", "were", "unable", "to", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181.", "<tag3>"], "wordsA": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief."], "wordsB": ["Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "(3%)", "patients", "were", "unable", "to", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p59_s0", "idA": "906709_13_item1_p12_s1", "sentA": "This molecule is designed to address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "The large etirinotecan pegol molecule is inactive when administered.", "type": 1, "words": ["<tag1>", "This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "The", "large", "etirinotecan", "pegol", "molecule", "is", "inactive", "when", "administered.", "<tag3>"], "wordsA": ["This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["The", "large", "etirinotecan", "pegol", "molecule", "is", "inactive", "when", "administered."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p100_s0", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "Chronic neuropathic pain arises from nerves injured or damaged by systemic disease, infection, toxins, or physical trauma that are in a continuous state of hyper-excitability, often due to aberrant sodium channel firing.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "Chronic", "neuropathic", "pain", "arises", "from", "nerves", "injured", "or", "damaged", "by", "systemic", "disease,", "infection,", "toxins,", "or", "physical", "trauma", "that", "are", "in", "a", "continuous", "state", "of", "hyper-excitability,", "often", "due", "to", "aberrant", "sodium", "channel", "firing.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["Chronic", "neuropathic", "pain", "arises", "from", "nerves", "injured", "or", "damaged", "by", "systemic", "disease,", "infection,", "toxins,", "or", "physical", "trauma", "that", "are", "in", "a", "continuous", "state", "of", "hyper-excitability,", "often", "due", "to", "aberrant", "sodium", "channel", "firing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s4", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "As a result, NKTR-192 will no longer be developed as an oral formulation and has returned to preclinical development where we are exploring its potential as an injectable therapy to treat migraine and acute cancer pain.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "As", "a", "result,", "NKTR-192", "will", "no", "longer", "be", "developed", "as", "an", "oral", "formulation", "and", "has", "returned", "to", "preclinical", "development", "where", "we", "are", "exploring", "its", "potential", "as", "an", "injectable", "therapy", "to", "treat", "migraine", "and", "acute", "cancer", "pain.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["As", "a", "result,", "NKTR-192", "will", "no", "longer", "be", "developed", "as", "an", "oral", "formulation", "and", "has", "returned", "to", "preclinical", "development", "where", "we", "are", "exploring", "its", "potential", "as", "an", "injectable", "therapy", "to", "treat", "migraine", "and", "acute", "cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p4_s4", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "The FDA advisory committee meeting, which had been originally scheduled for March 10-11, 2014, is being rescheduled due to scheduling conflicts.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "The", "FDA", "advisory", "committee", "meeting,", "which", "had", "been", "originally", "scheduled", "for", "March", "10-11,", "2014,", "is", "being", "rescheduled", "due", "to", "scheduling", "conflicts.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["The", "FDA", "advisory", "committee", "meeting,", "which", "had", "been", "originally", "scheduled", "for", "March", "10-11,", "2014,", "is", "being", "rescheduled", "due", "to", "scheduling", "conflicts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p52_s3", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "The advisory committee meeting, which had been originally scheduled for March 10-11, 2014, is being rescheduled due to scheduling conflicts.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "The", "advisory", "committee", "meeting,", "which", "had", "been", "originally", "scheduled", "for", "March", "10-11,", "2014,", "is", "being", "rescheduled", "due", "to", "scheduling", "conflicts.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["The", "advisory", "committee", "meeting,", "which", "had", "been", "originally", "scheduled", "for", "March", "10-11,", "2014,", "is", "being", "rescheduled", "due", "to", "scheduling", "conflicts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p111_s0", "idA": "906709_13_item1_p13_s6", "sentA": "In February 2013, Baxter initiated a Phase 3 multi-center, open-label clinical study called PROLONG-ATE that will enroll more than 100 previously treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "BAX 855 and Long-Acting Therapies for Hemophilia A, Agreement with Subsidiaries of Baxter International Inc.", "type": 1, "words": ["<tag1>", "In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "BAX", "855", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxter", "International", "Inc.", "<tag3>"], "wordsA": ["In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["BAX", "855", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxter", "International", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p56_s0", "idA": "906709_13_item1_p13_s6", "sentA": "In February 2013, Baxter initiated a Phase 3 multi-center, open-label clinical study called PROLONG-ATE that will enroll more than 100 previously treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "If the FDA does not require a future clinical trial or other significant studies to assess the cardiovascular safety (CV Safety Study) of naloxegol prior to an approval decision, AstraZeneca is required to pay us a $35.0 million milestone.", "type": 1, "words": ["<tag1>", "In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(CV", "Safety", "Study)", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "required", "to", "pay", "us", "a", "$35.0", "million", "milestone.", "<tag3>"], "wordsA": ["In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(CV", "Safety", "Study)", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "required", "to", "pay", "us", "a", "$35.0", "million", "milestone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s12", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "This unusual lack of a placebo rebound caused the Phase 2 study to miss the primary endpoint in the study, which was based upon the average change in a patient s pain score from pre-randomization baseline to the end of the double-blind, randomized treatment period of the study.", "type": 1, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study,", "which", "was", "based", "upon", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "pre-randomization", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period", "of", "the", "study.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study,", "which", "was", "based", "upon", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "pre-randomization", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p9_s5", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "This lack of a placebo rebound in the maintenance phase of the trial caused the Phase 2 study to miss the primary endpoint, which was the average change in a patient s pain score from baseline to the end of the double-blind, randomized treatment period.", "type": 1, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "This", "lack", "of", "a", "placebo", "rebound", "in", "the", "maintenance", "phase", "of", "the", "trial", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint,", "which", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["This", "lack", "of", "a", "placebo", "rebound", "in", "the", "maintenance", "phase", "of", "the", "trial", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint,", "which", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p143_s1", "idA": "906709_13_item1_p15_s0", "sentA": "In 2011, Bayer achieved agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "sentB": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc. which ends in 2014.", "type": 1, "words": ["<tag1>", "In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag2>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014.", "<tag3>"], "wordsA": ["In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "wordsB": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s2", "idA": "906709_13_item1_p16_s0", "sentA": "and are currently marketed by our collaboration partners.", "sentB": "Further, there are currently patients continuing in the study either on drug or in follow-up.", "type": 1, "words": ["<tag1>", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners.", "<tag2>", "Further,", "there", "are", "currently", "patients", "continuing", "in", "the", "study", "either", "on", "drug", "or", "in", "follow-up.", "<tag3>"], "wordsA": ["and", "are", "currently", "marketed", "by", "our", "collaboration", "partners."], "wordsB": ["Further,", "there", "are", "currently", "patients", "continuing", "in", "the", "study", "either", "on", "drug", "or", "in", "follow-up."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p81_s0", "idA": "906709_13_item1_p16_s1", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "sentB": "Gram-negative pneumonias are often the result of complications of other patient conditions or surgeries.", "type": 1, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag2>", "Gram-negative", "pneumonias", "are", "often", "the", "result", "of", "complications", "of", "other", "patient", "conditions", "or", "surgeries.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "wordsB": ["Gram-negative", "pneumonias", "are", "often", "the", "result", "of", "complications", "of", "other", "patient", "conditions", "or", "surgeries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p133_s5", "idA": "906709_13_item1_p16_s3", "sentA": "We retained all of our rights to BAY41-6551 and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "If quantities of the Polymer Materials ordered by Amgen exceed specified quantities (with each specified quantity representing a small portion of the quantity that we historically supplied to Amgen), significant additional payments become payable to us in return for guaranteeing supply of additional quantities of the Polymer Materials.", "type": 1, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "If", "quantities", "of", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "exceed", "specified", "quantities", "(with", "each", "specified", "quantity", "representing", "a", "small", "portion", "of", "the", "quantity", "that", "we", "historically", "supplied", "to", "Amgen),", "significant", "additional", "payments", "become", "payable", "to", "us", "in", "return", "for", "guaranteeing", "supply", "of", "additional", "quantities", "of", "the", "Polymer", "Materials.", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["If", "quantities", "of", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "exceed", "specified", "quantities", "(with", "each", "specified", "quantity", "representing", "a", "small", "portion", "of", "the", "quantity", "that", "we", "historically", "supplied", "to", "Amgen),", "significant", "additional", "payments", "become", "payable", "to", "us", "in", "return", "for", "guaranteeing", "supply", "of", "additional", "quantities", "of", "the", "Polymer", "Materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s4", "idA": "906709_13_item1_p16_s3", "sentA": "We retained all of our rights to BAY41-6551 and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "Roche would also pay us additional consideration for any future orders of the PEGylation materials for MIRCERA beyond the initial quantities ordered as part of the initial arrangement.", "type": 1, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "Roche", "would", "also", "pay", "us", "additional", "consideration", "for", "any", "future", "orders", "of", "the", "PEGylation", "materials", "for", "MIRCERA", "beyond", "the", "initial", "quantities", "ordered", "as", "part", "of", "the", "initial", "arrangement.", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["Roche", "would", "also", "pay", "us", "additional", "consideration", "for", "any", "future", "orders", "of", "the", "PEGylation", "materials", "for", "MIRCERA", "beyond", "the", "initial", "quantities", "ordered", "as", "part", "of", "the", "initial", "arrangement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p106_s1", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "In 2006, we amended and restated this agreement.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "In", "2006,", "we", "amended", "and", "restated", "this", "agreement.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["In", "2006,", "we", "amended", "and", "restated", "this", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p122_s0", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "REG1 Anticoagulation System (pegnivacogin), Agreement with Regado Biosciences, Inc.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "REG1", "Anticoagulation", "System", "(pegnivacogin),", "Agreement", "with", "Regado", "Biosciences,", "Inc.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["REG1", "Anticoagulation", "System", "(pegnivacogin),", "Agreement", "with", "Regado", "Biosciences,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s3", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "These procedures put patients at risk for therapy-related bleeding complications.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "These", "procedures", "put", "patients", "at", "risk", "for", "therapy-related", "bleeding", "complications.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["These", "procedures", "put", "patients", "at", "risk", "for", "therapy-related", "bleeding", "complications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p130_s0", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "Overview of Select Licensing Partnerships for Approved Products Neulasta , Agreement with Amgen, Inc.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "Overview", "of", "Select", "Licensing", "Partnerships", "for", "Approved", "Products", "Neulasta", ",", "Agreement", "with", "Amgen,", "Inc.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["Overview", "of", "Select", "Licensing", "Partnerships", "for", "Approved", "Products", "Neulasta", ",", "Agreement", "with", "Amgen,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p133_s4", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "Amgen has no minimum purchase commitments.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "Amgen", "has", "no", "minimum", "purchase", "commitments.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["Amgen", "has", "no", "minimum", "purchase", "commitments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p137_s0", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "Somavert , Agreement with Pfizer, Inc.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "Somavert", ",", "Agreement", "with", "Pfizer,", "Inc.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["Somavert", ",", "Agreement", "with", "Pfizer,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p140_s0", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "Macugen , Agreement with Valeant Pharmaceuticals International, Inc.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "Macugen", ",", "Agreement", "with", "Valeant", "Pharmaceuticals", "International,", "Inc.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["Macugen", ",", "Agreement", "with", "Valeant", "Pharmaceuticals", "International,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s5", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "This sale is further discussed in Note 7 of Item 8, Financial Statements and Supplementary Data.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "This", "sale", "is", "further", "discussed", "in", "Note", "7", "of", "Item", "8,", "Financial", "Statements", "and", "Supplementary", "Data.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["This", "sale", "is", "further", "discussed", "in", "Note", "7", "of", "Item", "8,", "Financial", "Statements", "and", "Supplementary", "Data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p63_s3", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "Secondary endpoints and objectives also include clinical benefit rate, duration of response, pharmacokinetic data, safety profiles, quality-of-life measurements, and pharmacoeconomic implications.", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "Secondary", "endpoints", "and", "objectives", "also", "include", "clinical", "benefit", "rate,", "duration", "of", "response,", "pharmacokinetic", "data,", "safety", "profiles,", "quality-of-life", "measurements,", "and", "pharmacoeconomic", "implications.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["Secondary", "endpoints", "and", "objectives", "also", "include", "clinical", "benefit", "rate,", "duration", "of", "response,", "pharmacokinetic", "data,", "safety", "profiles,", "quality-of-life", "measurements,", "and", "pharmacoeconomic", "implications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p93_s5", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "The HAL study compared drug liking between each treatment group (oxycodone 40 mg, placebo, and NKTR-181 100 mg, 200 mg, and 400 mg).", "type": 1, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "The", "HAL", "study", "compared", "drug", "liking", "between", "each", "treatment", "group", "(oxycodone", "40", "mg,", "placebo,", "and", "NKTR-181", "100", "mg,", "200", "mg,", "and", "400", "mg).", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["The", "HAL", "study", "compared", "drug", "liking", "between", "each", "treatment", "group", "(oxycodone", "40", "mg,", "placebo,", "and", "NKTR-181", "100", "mg,", "200", "mg,", "and", "400", "mg)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p84_s1", "idA": "906709_13_item1_p1_s0", "sentA": "Our current proprietary pipeline is comprised of drug candidates across several therapeutic areas including oncology, pain, anti-infectives and immunology.", "sentB": "The global INHALE development program is comprised of two prospective, randomized, double-blind, placebo-controlled, large multi-center global programs involving centers in North America, South America, Europe, Japan, Australia and Asia.", "type": 1, "words": ["<tag1>", "Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "several", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives", "and", "immunology.", "<tag2>", "The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Japan,", "Australia", "and", "Asia.", "<tag3>"], "wordsA": ["Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "several", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives", "and", "immunology."], "wordsB": ["The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Japan,", "Australia", "and", "Asia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p100_s2", "idA": "906709_13_item1_p20_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body.", "sentB": "Existing therapies that block sodium channels have been shown to provide effective pain relief but are typically associated with significant unwanted CNS side effects, including dizziness, ataxia and somnolence.", "type": 1, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body.", "<tag2>", "Existing", "therapies", "that", "block", "sodium", "channels", "have", "been", "shown", "to", "provide", "effective", "pain", "relief", "but", "are", "typically", "associated", "with", "significant", "unwanted", "CNS", "side", "effects,", "including", "dizziness,", "ataxia", "and", "somnolence.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body."], "wordsB": ["Existing", "therapies", "that", "block", "sodium", "channels", "have", "been", "shown", "to", "provide", "effective", "pain", "relief", "but", "are", "typically", "associated", "with", "significant", "unwanted", "CNS", "side", "effects,", "including", "dizziness,", "ataxia", "and", "somnolence."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p117_s1", "idA": "906709_13_item1_p20_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body.", "sentB": "In July 2007, as a result of a divestiture agreement between Eyetech and Ophthotech Corporation (Ophthotech), Opthotech acquired from Eyetech certain technology rights and other assets owned or controlled by Eyetech relating to particular anti-platelet-derived growth factor aptamers, or anti-PDGFs, including Fovista .", "type": 1, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body.", "<tag2>", "In", "July", "2007,", "as", "a", "result", "of", "a", "divestiture", "agreement", "between", "Eyetech", "and", "Ophthotech", "Corporation", "(Ophthotech),", "Opthotech", "acquired", "from", "Eyetech", "certain", "technology", "rights", "and", "other", "assets", "owned", "or", "controlled", "by", "Eyetech", "relating", "to", "particular", "anti-platelet-derived", "growth", "factor", "aptamers,", "or", "anti-PDGFs,", "including", "Fovista", ".", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body."], "wordsB": ["In", "July", "2007,", "as", "a", "result", "of", "a", "divestiture", "agreement", "between", "Eyetech", "and", "Ophthotech", "Corporation", "(Ophthotech),", "Opthotech", "acquired", "from", "Eyetech", "certain", "technology", "rights", "and", "other", "assets", "owned", "or", "controlled", "by", "Eyetech", "relating", "to", "particular", "anti-platelet-derived", "growth", "factor", "aptamers,", "or", "anti-PDGFs,", "including", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p124_s1", "idA": "906709_13_item1_p20_s4", "sentA": "Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs.", "sentB": "In the Phase 2 study, which involved 640 patients, Regado reported that when compared to standard of care heparin, REG1 demonstrated both a rapid and predictable anticoagulant effect, the ability to precisely modulate or eliminate that effect in real time, as well as several important clinical and pharmacoeconomic benefits.", "type": 1, "words": ["<tag1>", "Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs.", "<tag2>", "In", "the", "Phase", "2", "study,", "which", "involved", "640", "patients,", "Regado", "reported", "that", "when", "compared", "to", "standard", "of", "care", "heparin,", "REG1", "demonstrated", "both", "a", "rapid", "and", "predictable", "anticoagulant", "effect,", "the", "ability", "to", "precisely", "modulate", "or", "eliminate", "that", "effect", "in", "real", "time,", "as", "well", "as", "several", "important", "clinical", "and", "pharmacoeconomic", "benefits.", "<tag3>"], "wordsA": ["Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs."], "wordsB": ["In", "the", "Phase", "2", "study,", "which", "involved", "640", "patients,", "Regado", "reported", "that", "when", "compared", "to", "standard", "of", "care", "heparin,", "REG1", "demonstrated", "both", "a", "rapid", "and", "predictable", "anticoagulant", "effect,", "the", "ability", "to", "precisely", "modulate", "or", "eliminate", "that", "effect", "in", "real", "time,", "as", "well", "as", "several", "important", "clinical", "and", "pharmacoeconomic", "benefits."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p108_s1", "idA": "906709_13_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "Either party may terminate the agreement upon a material, uncured default of the other party.", "type": 1, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p133_s6", "idA": "906709_13_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "The term of the Agreement runs through October 29, 2020.", "type": 1, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "The", "term", "of", "the", "Agreement", "runs", "through", "October", "29,", "2020.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["The", "term", "of", "the", "Agreement", "runs", "through", "October", "29,", "2020."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p136_s2", "idA": "906709_13_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "In connection with Roche s exercise of the license extension option in December 2009, we received a payment of $31.0 million.", "type": 1, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s6", "idA": "906709_13_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "We share a portion of the payments we receive from UCB with Enzon Pharmaceuticals, Inc. which ends in 2014.", "type": 1, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p72_s3", "idA": "906709_13_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.", "type": 1, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "It", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["It", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s10", "idA": "906709_13_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "NKTR-181 performed as expected as an opioid analgesic throughout the study with patients continuing to show a reduction in pain scores throughout the randomized phase of the study.", "type": 1, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "NKTR-181", "performed", "as", "expected", "as", "an", "opioid", "analgesic", "throughout", "the", "study", "with", "patients", "continuing", "to", "show", "a", "reduction", "in", "pain", "scores", "throughout", "the", "randomized", "phase", "of", "the", "study.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["NKTR-181", "performed", "as", "expected", "as", "an", "opioid", "analgesic", "throughout", "the", "study", "with", "patients", "continuing", "to", "show", "a", "reduction", "in", "pain", "scores", "throughout", "the", "randomized", "phase", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p104_s1", "idA": "906709_13_item1_p22_s0", "sentA": "reduce immune response to certain macromolecules with the potential to prolong their effectiveness with repeated doses.", "sentB": "NKTR-214 is engineered to selectively activate IL-2 receptors on cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors on regulatory T cells that dampen the immune response to tumors.", "type": 1, "words": ["<tag1>", "reduce", "immune", "response", "to", "certain", "macromolecules", "with", "the", "potential", "to", "prolong", "their", "effectiveness", "with", "repeated", "doses.", "<tag2>", "NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors.", "<tag3>"], "wordsA": ["reduce", "immune", "response", "to", "certain", "macromolecules", "with", "the", "potential", "to", "prolong", "their", "effectiveness", "with", "repeated", "doses."], "wordsB": ["NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s7", "idA": "906709_13_item1_p22_s1", "sentA": "We have a broad range of approaches that we may use when designing our own drug candidates, some of which are further described below.", "sentB": "During the titration phase, 53 patients (18%) discontinued treatment because of adverse events, most of which are those commonly associated with opioids.", "type": 1, "words": ["<tag1>", "We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "further", "described", "below.", "<tag2>", "During", "the", "titration", "phase,", "53", "patients", "(18%)", "discontinued", "treatment", "because", "of", "adverse", "events,", "most", "of", "which", "are", "those", "commonly", "associated", "with", "opioids.", "<tag3>"], "wordsA": ["We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "further", "described", "below."], "wordsB": ["During", "the", "titration", "phase,", "53", "patients", "(18%)", "discontinued", "treatment", "because", "of", "adverse", "events,", "most", "of", "which", "are", "those", "commonly", "associated", "with", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p80_s4", "idA": "906709_13_item1_p23_s1", "sentA": "In addition, this approach can enable oral administration of subcutaneously or intravenously delivered small molecule drugs that have low bioavailability when delivered orally.", "sentB": "In addition, the agreement may also be terminated by either party for certain product safety concerns, the product s failure to meet certain minimum commercial profile requirements or uncured material breaches by the other party.", "type": 1, "words": ["<tag1>", "In", "addition,", "this", "approach", "can", "enable", "oral", "administration", "of", "subcutaneously", "or", "intravenously", "delivered", "small", "molecule", "drugs", "that", "have", "low", "bioavailability", "when", "delivered", "orally.", "<tag2>", "In", "addition,", "the", "agreement", "may", "also", "be", "terminated", "by", "either", "party", "for", "certain", "product", "safety", "concerns,", "the", "product", "s", "failure", "to", "meet", "certain", "minimum", "commercial", "profile", "requirements", "or", "uncured", "material", "breaches", "by", "the", "other", "party.", "<tag3>"], "wordsA": ["In", "addition,", "this", "approach", "can", "enable", "oral", "administration", "of", "subcutaneously", "or", "intravenously", "delivered", "small", "molecule", "drugs", "that", "have", "low", "bioavailability", "when", "delivered", "orally."], "wordsB": ["In", "addition,", "the", "agreement", "may", "also", "be", "terminated", "by", "either", "party", "for", "certain", "product", "safety", "concerns,", "the", "product", "s", "failure", "to", "meet", "certain", "minimum", "commercial", "profile", "requirements", "or", "uncured", "material", "breaches", "by", "the", "other", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p52_s2", "idA": "906709_13_item1_p23_s3", "sentA": "Two primary examples of reducing transport across the blood-brain barrier are naloxegol, an orally-available peripherally-acting opioid antagonist that is in late stage clinical development in collaboration with AstraZeneca, and NKTR-171, a novel peripherally-acting sodium channel blocker that is currently in IND-enabling studies for the treatment of neuropathic pain.", "sentB": "The FDA is currently planning to hold an advisory committee meeting to discuss the cardiovascular safety and potential additional safety study requirements for the peripheral mu-opioid receptor antagonist class of drugs, including naloxegol.", "type": 1, "words": ["<tag1>", "Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "in", "late", "stage", "clinical", "development", "in", "collaboration", "with", "AstraZeneca,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "IND-enabling", "studies", "for", "the", "treatment", "of", "neuropathic", "pain.", "<tag2>", "The", "FDA", "is", "currently", "planning", "to", "hold", "an", "advisory", "committee", "meeting", "to", "discuss", "the", "cardiovascular", "safety", "and", "potential", "additional", "safety", "study", "requirements", "for", "the", "peripheral", "mu-opioid", "receptor", "antagonist", "class", "of", "drugs,", "including", "naloxegol.", "<tag3>"], "wordsA": ["Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "in", "late", "stage", "clinical", "development", "in", "collaboration", "with", "AstraZeneca,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "IND-enabling", "studies", "for", "the", "treatment", "of", "neuropathic", "pain."], "wordsB": ["The", "FDA", "is", "currently", "planning", "to", "hold", "an", "advisory", "committee", "meeting", "to", "discuss", "the", "cardiovascular", "safety", "and", "potential", "additional", "safety", "study", "requirements", "for", "the", "peripheral", "mu-opioid", "receptor", "antagonist", "class", "of", "drugs,", "including", "naloxegol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p104_s2", "idA": "906709_13_item1_p24_s0", "sentA": "Small Molecule Pro-Drug Releasable Polymer Conjugates The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase its efficacy and improve its side effect profile.", "sentB": "This receptor selectivity is intended to increase efficacy and improve safety over existing immunostimulatory cytokine drugs.", "type": 1, "words": ["<tag1>", "Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "its", "efficacy", "and", "improve", "its", "side", "effect", "profile.", "<tag2>", "This", "receptor", "selectivity", "is", "intended", "to", "increase", "efficacy", "and", "improve", "safety", "over", "existing", "immunostimulatory", "cytokine", "drugs.", "<tag3>"], "wordsA": ["Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "its", "efficacy", "and", "improve", "its", "side", "effect", "profile."], "wordsB": ["This", "receptor", "selectivity", "is", "intended", "to", "increase", "efficacy", "and", "improve", "safety", "over", "existing", "immunostimulatory", "cytokine", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p60_s1", "idA": "906709_13_item1_p24_s2", "sentA": "With our technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "Because etirinotecan pegol is a large molecule, based on preclinical studies we believe that it may penetrate the leaky vasculature within the tumor environment more readily than normal vasculature, concentrating and trapping etirinotecan pegol in tumor tissue.", "type": 1, "words": ["<tag1>", "With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "Because", "etirinotecan", "pegol", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "etirinotecan", "pegol", "in", "tumor", "tissue.", "<tag3>"], "wordsA": ["With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["Because", "etirinotecan", "pegol", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "etirinotecan", "pegol", "in", "tumor", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p76_s2", "idA": "906709_13_item1_p24_s3", "sentA": "We are using this approach with the oncolytic drug candidate in our pipeline, etirinotecan pegol, a next-generation topoisomerase I-inhibitor, currently in Phase 3 clinical development in metastatic breast cancer, and Phase 2 clinical development in ovarian and colorectal cancers.", "sentB": "Worldwide, over 1.2 million people are diagnosed annually with colorectal cancer and, according to the World Health Organization, there are 690,000 deaths annually from colorectal cancers.", "type": 1, "words": ["<tag1>", "We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "clinical", "development", "in", "ovarian", "and", "colorectal", "cancers.", "<tag2>", "Worldwide,", "over", "1.2", "million", "people", "are", "diagnosed", "annually", "with", "colorectal", "cancer", "and,", "according", "to", "the", "World", "Health", "Organization,", "there", "are", "690,000", "deaths", "annually", "from", "colorectal", "cancers.", "<tag3>"], "wordsA": ["We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "clinical", "development", "in", "ovarian", "and", "colorectal", "cancers."], "wordsB": ["Worldwide,", "over", "1.2", "million", "people", "are", "diagnosed", "annually", "with", "colorectal", "cancer", "and,", "according", "to", "the", "World", "Health", "Organization,", "there", "are", "690,000", "deaths", "annually", "from", "colorectal", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p120_s2", "idA": "906709_13_item1_p24_s4", "sentA": "Our customized approaches with large molecule polymer conjugates have enabled numerous successful PEGylated biologics on the market today.", "sentB": "Patients receiving the combination of Fovista (1.5 mg) and Lucentis gained a mean of 10.6 letters of vision at 24 weeks on the Early Treatment Diabetic Retinopathy Study standardized eye chart, compared to 6.5 letters for patients receiving Lucentis monotherapy (p=0.019), representing a statistically significant 62% additional benefit.", "type": 1, "words": ["<tag1>", "Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "enabled", "numerous", "successful", "PEGylated", "biologics", "on", "the", "market", "today.", "<tag2>", "Patients", "receiving", "the", "combination", "of", "Fovista", "(1.5", "mg)", "and", "Lucentis", "gained", "a", "mean", "of", "10.6", "letters", "of", "vision", "at", "24", "weeks", "on", "the", "Early", "Treatment", "Diabetic", "Retinopathy", "Study", "standardized", "eye", "chart,", "compared", "to", "6.5", "letters", "for", "patients", "receiving", "Lucentis", "monotherapy", "(p=0.019),", "representing", "a", "statistically", "significant", "62%", "additional", "benefit.", "<tag3>"], "wordsA": ["Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "enabled", "numerous", "successful", "PEGylated", "biologics", "on", "the", "market", "today."], "wordsB": ["Patients", "receiving", "the", "combination", "of", "Fovista", "(1.5", "mg)", "and", "Lucentis", "gained", "a", "mean", "of", "10.6", "letters", "of", "vision", "at", "24", "weeks", "on", "the", "Early", "Treatment", "Diabetic", "Retinopathy", "Study", "standardized", "eye", "chart,", "compared", "to", "6.5", "letters", "for", "patients", "receiving", "Lucentis", "monotherapy", "(p=0.019),", "representing", "a", "statistically", "significant", "62%", "additional", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p81_s1", "idA": "906709_13_item1_p24_s4", "sentA": "Our customized approaches with large molecule polymer conjugates have enabled numerous successful PEGylated biologics on the market today.", "sentB": "Gram-negative pneumonias carry a mortality risk that can exceed 50% in mechanically-ventilated patients and accounts for a substantial proportion of the pneumonias in intensive care units today.", "type": 1, "words": ["<tag1>", "Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "enabled", "numerous", "successful", "PEGylated", "biologics", "on", "the", "market", "today.", "<tag2>", "Gram-negative", "pneumonias", "carry", "a", "mortality", "risk", "that", "can", "exceed", "50%", "in", "mechanically-ventilated", "patients", "and", "accounts", "for", "a", "substantial", "proportion", "of", "the", "pneumonias", "in", "intensive", "care", "units", "today.", "<tag3>"], "wordsA": ["Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "enabled", "numerous", "successful", "PEGylated", "biologics", "on", "the", "market", "today."], "wordsB": ["Gram-negative", "pneumonias", "carry", "a", "mortality", "risk", "that", "can", "exceed", "50%", "in", "mechanically-ventilated", "patients", "and", "accounts", "for", "a", "substantial", "proportion", "of", "the", "pneumonias", "in", "intensive", "care", "units", "today."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p93_s4", "idA": "906709_13_item1_p25_s1", "sentA": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, which is currently being evaluated in Phase 3 clinical development in collaboration with Baxter for the treatment of hemophilia A. Antibody Fragment Polymer Conjugates This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "sentB": "The study also utilized a Williams Square cross-over design, which uses a series of randomized sequences for each individual subject.", "type": 1, "words": ["<tag1>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "3", "clinical", "development", "in", "collaboration", "with", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A.", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag2>", "The", "study", "also", "utilized", "a", "Williams", "Square", "cross-over", "design,", "which", "uses", "a", "series", "of", "randomized", "sequences", "for", "each", "individual", "subject.", "<tag3>"], "wordsA": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "3", "clinical", "development", "in", "collaboration", "with", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A.", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "wordsB": ["The", "study", "also", "utilized", "a", "Williams", "Square", "cross-over", "design,", "which", "uses", "a", "series", "of", "randomized", "sequences", "for", "each", "individual", "subject."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p126_s2", "idA": "906709_13_item1_p26_s0", "sentA": "There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease in the U.S. and rheumatoid arthritis in the U.S. and E.U.", "sentB": "However, we retained our economic interest in the future potential net sales royalties if Cipro DPI is approved by health authorities and is successfully commercialized by Bayer.", "type": 1, "words": ["<tag1>", "There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U.", "<tag2>", "However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer.", "<tag3>"], "wordsA": ["There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U."], "wordsB": ["However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s3", "idA": "906709_13_item1_p28_s2", "sentA": "A key component of our development strategy is to potentially reduce the risks and time associated with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic targets and drugs directed to those targets.", "sentB": "Therefore, the data may change based on future additional data as well as verification and audit procedures that will be performed on the final completed study data.", "type": 1, "words": ["<tag1>", "A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets.", "<tag2>", "Therefore,", "the", "data", "may", "change", "based", "on", "future", "additional", "data", "as", "well", "as", "verification", "and", "audit", "procedures", "that", "will", "be", "performed", "on", "the", "final", "completed", "study", "data.", "<tag3>"], "wordsA": ["A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets."], "wordsB": ["Therefore,", "the", "data", "may", "change", "based", "on", "future", "additional", "data", "as", "well", "as", "verification", "and", "audit", "procedures", "that", "will", "be", "performed", "on", "the", "final", "completed", "study", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p115_s2", "idA": "906709_13_item1_p29_s1", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies.", "sentB": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of BAX 855 was approximately 1.5-fold higher compared to ADVATE.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies.", "<tag2>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies."], "wordsB": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p125_s2", "idA": "906709_13_item1_p29_s1", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies.", "sentB": "The principal secondary endpoint is safety compared to bivalrudin as measured by major bleeding events through day three.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies.", "<tag2>", "The", "principal", "secondary", "endpoint", "is", "safety", "compared", "to", "bivalrudin", "as", "measured", "by", "major", "bleeding", "events", "through", "day", "three.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies."], "wordsB": ["The", "principal", "secondary", "endpoint", "is", "safety", "compared", "to", "bivalrudin", "as", "measured", "by", "major", "bleeding", "events", "through", "day", "three."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s1", "idA": "906709_13_item1_p29_s1", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies.", "sentB": "Patients who qualified during the baseline period entered a titration phase, during which they were titrated on NKTR-181 tablets administered orally twice-daily until a dose was reached that provided a reduction of at least 20% in the patient s pain score as compared to the patient s own baseline.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies.", "<tag2>", "Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "reduction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies."], "wordsB": ["Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "reduction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p94_s0", "idA": "906709_13_item1_p29_s1", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies.", "sentB": "On the bipolar VAS scale (0-100), a score of 50 indicates that the subject neither likes nor dislikes the drug.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies.", "<tag2>", "On", "the", "bipolar", "VAS", "scale", "(0-100),", "a", "score", "of", "50", "indicates", "that", "the", "subject", "neither", "likes", "nor", "dislikes", "the", "drug.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies."], "wordsB": ["On", "the", "bipolar", "VAS", "scale", "(0-100),", "a", "score", "of", "50", "indicates", "that", "the", "subject", "neither", "likes", "nor", "dislikes", "the", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p94_s3", "idA": "906709_13_item1_p29_s1", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies.", "sentB": "In the placebo arm, the maximum mean drug liking score was 50, indicating that the subjects neither liked nor disliked the effects.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies.", "<tag2>", "In", "the", "placebo", "arm,", "the", "maximum", "mean", "drug", "liking", "score", "was", "50,", "indicating", "that", "the", "subjects", "neither", "liked", "nor", "disliked", "the", "effects.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies."], "wordsB": ["In", "the", "placebo", "arm,", "the", "maximum", "mean", "drug", "liking", "score", "was", "50,", "indicating", "that", "the", "subjects", "neither", "liked", "nor", "disliked", "the", "effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p133_s2", "idA": "906709_13_item1_p2_s1", "sentA": "Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer chemistry technology and expertise.", "sentB": "This supply arrangement is on a non-exclusive basis (other than the use of the manufacturing suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other third party and Amgen is free to procure the Polymer Materials from any other third party.", "type": 1, "words": ["<tag1>", "Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise.", "<tag2>", "This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party.", "<tag3>"], "wordsA": ["Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise."], "wordsB": ["This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p80_s1", "idA": "906709_13_item1_p2_s1", "sentA": "Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer chemistry technology and expertise.", "sentB": "We share a portion of these royalties with the Research Foundation of the State University of New York under a license agreement.", "type": 1, "words": ["<tag1>", "Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise.", "<tag2>", "We", "share", "a", "portion", "of", "these", "royalties", "with", "the", "Research", "Foundation", "of", "the", "State", "University", "of", "New", "York", "under", "a", "license", "agreement.", "<tag3>"], "wordsA": ["Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise."], "wordsB": ["We", "share", "a", "portion", "of", "these", "royalties", "with", "the", "Research", "Foundation", "of", "the", "State", "University", "of", "New", "York", "under", "a", "license", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p119_s2", "idA": "906709_13_item1_p31_s0", "sentA": "We are committed to continuing to build on our intellectual property position in the field of PEGylation and polymer conjugate chemistry.", "sentB": "We are the exclusive supplier of all of Ophthotech s clinical and commercial requirements of our proprietary PEGylation reagent used in the manufacture of Fovista .", "type": 1, "words": ["<tag1>", "We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "PEGylation", "and", "polymer", "conjugate", "chemistry.", "<tag2>", "We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Ophthotech", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", ".", "<tag3>"], "wordsA": ["We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "PEGylation", "and", "polymer", "conjugate", "chemistry."], "wordsB": ["We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Ophthotech", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s7", "idA": "906709_13_item1_p31_s0", "sentA": "We are committed to continuing to build on our intellectual property position in the field of PEGylation and polymer conjugate chemistry.", "sentB": "We are the exclusive supplier of all of Regado s clinical and commercial requirements of our proprietary PEGylation reagent used in the manufacture of REG1.", "type": 1, "words": ["<tag1>", "We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "PEGylation", "and", "polymer", "conjugate", "chemistry.", "<tag2>", "We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Regado", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "REG1.", "<tag3>"], "wordsA": ["We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "PEGylation", "and", "polymer", "conjugate", "chemistry."], "wordsB": ["We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Regado", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "REG1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s6", "idA": "906709_13_item1_p31_s2", "sentA": "The following table summarizes our proprietary drug candidates that are being developed by us or in collaboration with other pharmaceutical companies.", "sentB": "Roche may terminate the toll-manufacturing agreement due to an uncured material default by us or for convenience under certain circumstances and subject to certain financial obligations.", "type": 1, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies.", "<tag2>", "Roche", "may", "terminate", "the", "toll-manufacturing", "agreement", "due", "to", "an", "uncured", "material", "default", "by", "us", "or", "for", "convenience", "under", "certain", "circumstances", "and", "subject", "to", "certain", "financial", "obligations.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies."], "wordsB": ["Roche", "may", "terminate", "the", "toll-manufacturing", "agreement", "due", "to", "an", "uncured", "material", "default", "by", "us", "or", "for", "convenience", "under", "certain", "circumstances", "and", "subject", "to", "certain", "financial", "obligations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p79_s3", "idA": "906709_13_item1_p31_s3", "sentA": "The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.", "sentB": "We have engaged third party contract manufacturers to perform our device manufacturing obligations for this program.", "type": 1, "words": ["<tag1>", "The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program.", "<tag2>", "We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "obligations", "for", "this", "program.", "<tag3>"], "wordsA": ["The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program."], "wordsB": ["We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "obligations", "for", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p9_s4", "idA": "906709_13_item1_p34_s0", "sentA": "Phase 2 a drug candidate in clinical trials to establish dosing and efficacy in patients.", "sentB": "However, patients who were randomized to the placebo arm following a drug titration phase did not show the expected increase in pain scores observed in similar enriched enrollment, randomized withdrawal studies.", "type": 1, "words": ["<tag1>", "Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag2>", "However,", "patients", "who", "were", "randomized", "to", "the", "placebo", "arm", "following", "a", "drug", "titration", "phase", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies.", "<tag3>"], "wordsA": ["Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "wordsB": ["However,", "patients", "who", "were", "randomized", "to", "the", "placebo", "arm", "following", "a", "drug", "titration", "phase", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s8", "idA": "906709_13_item1_p35_s1", "sentA": "As part of that transaction, we retained an exclusive license to this technology for the development and commercialization of this drug candidate originally developed by us.", "sentB": "In addition, UCB may terminate the agreement should it cease the development and marketing of CIMZIA and either party may terminate for cause under certain conditions.", "type": 1, "words": ["<tag1>", "As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us.", "<tag2>", "In", "addition,", "UCB", "may", "terminate", "the", "agreement", "should", "it", "cease", "the", "development", "and", "marketing", "of", "CIMZIA", "and", "either", "party", "may", "terminate", "for", "cause", "under", "certain", "conditions.", "<tag3>"], "wordsA": ["As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us."], "wordsB": ["In", "addition,", "UCB", "may", "terminate", "the", "agreement", "should", "it", "cease", "the", "development", "and", "marketing", "of", "CIMZIA", "and", "either", "party", "may", "terminate", "for", "cause", "under", "certain", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p138_s1", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "We currently manufacture our proprietary PEGylation reagent for Pfizer, Inc. on a price per gram basis.", "type": 1, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "reagent", "for", "Pfizer,", "Inc.", "on", "a", "price", "per", "gram", "basis.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "reagent", "for", "Pfizer,", "Inc.", "on", "a", "price", "per", "gram", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s0", "idA": "906709_13_item1_p37_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "In February 2014, we decided to close enrollment in this study after 80 patients were randomized due to challenges in recruiting new patients because the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the U.S. or E.U. Based on preliminary data we have collected to date from this study, etirinotecan pegol resulted in numerically improved overall survival, progression-free survival, objective response rate, and duration of response compared to that observed in the irinotecan comparator arm.", "type": 1, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U.", "Based", "on", "preliminary", "data", "we", "have", "collected", "to", "date", "from", "this", "study,", "etirinotecan", "pegol", "resulted", "in", "numerically", "improved", "overall", "survival,", "progression-free", "survival,", "objective", "response", "rate,", "and", "duration", "of", "response", "compared", "to", "that", "observed", "in", "the", "irinotecan", "comparator", "arm.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U.", "Based", "on", "preliminary", "data", "we", "have", "collected", "to", "date", "from", "this", "study,", "etirinotecan", "pegol", "resulted", "in", "numerically", "improved", "overall", "survival,", "progression-free", "survival,", "objective", "response", "rate,", "and", "duration", "of", "response", "compared", "to", "that", "observed", "in", "the", "irinotecan", "comparator", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p56_s2", "idA": "906709_13_item1_p39_s0", "sentA": "Filed an application for approval and marketing has been filed with the applicable government health authority.", "sentB": "If AstraZeneca elects to terminate the license agreement in its entirety due to a CV Safety Study, we would be required to repay them the $70.0 million payment noted above plus accrued interest at 4.5% compounded annually in four installments in accordance with the following payment schedule: $10.0 million plus accrued interest on January 15, 2015, $10.0 million plus accrued interest on January 15, 2016, $20.0 million plus accrued interest on January 15, 2017 and $30.0 million plus accrued interest on January 15, 2018.", "type": 1, "words": ["<tag1>", "Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority.", "<tag2>", "If", "AstraZeneca", "elects", "to", "terminate", "the", "license", "agreement", "in", "its", "entirety", "due", "to", "a", "CV", "Safety", "Study,", "we", "would", "be", "required", "to", "repay", "them", "the", "$70.0", "million", "payment", "noted", "above", "plus", "accrued", "interest", "at", "4.5%", "compounded", "annually", "in", "four", "installments", "in", "accordance", "with", "the", "following", "payment", "schedule:", "$10.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2015,", "$10.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2016,", "$20.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2017", "and", "$30.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2018.", "<tag3>"], "wordsA": ["Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority."], "wordsB": ["If", "AstraZeneca", "elects", "to", "terminate", "the", "license", "agreement", "in", "its", "entirety", "due", "to", "a", "CV", "Safety", "Study,", "we", "would", "be", "required", "to", "repay", "them", "the", "$70.0", "million", "payment", "noted", "above", "plus", "accrued", "interest", "at", "4.5%", "compounded", "annually", "in", "four", "installments", "in", "accordance", "with", "the", "following", "payment", "schedule:", "$10.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2015,", "$10.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2016,", "$20.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2017", "and", "$30.0", "million", "plus", "accrued", "interest", "on", "January", "15,", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p94_s2", "idA": "906709_13_item1_p41_s0", "sentA": "Phase 2 a drug candidate in clinical trials to establish dosing and efficacy in patients.", "sentB": "The oxycodone liking score was significantly different from placebo as early as 15 minutes after dosing and peaked at 60 minutes.", "type": 1, "words": ["<tag1>", "Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag2>", "The", "oxycodone", "liking", "score", "was", "significantly", "different", "from", "placebo", "as", "early", "as", "15", "minutes", "after", "dosing", "and", "peaked", "at", "60", "minutes.", "<tag3>"], "wordsA": ["Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "wordsB": ["The", "oxycodone", "liking", "score", "was", "significantly", "different", "from", "placebo", "as", "early", "as", "15", "minutes", "after", "dosing", "and", "peaked", "at", "60", "minutes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p83_s1", "idA": "906709_13_item1_p44_s0", "sentA": "This drug candidate was developed using our proprietary pulmonary delivery technology that was transferred by us to Novartis in an asset sale transaction that closed on December 31, 2008.", "sentB": "This drug candidate can be integrated with conventional mechanical ventilators or used as a hand-held off-vent device for patients no longer requiring breathing assistance.", "type": 1, "words": ["<tag1>", "This", "drug", "candidate", "was", "developed", "using", "our", "proprietary", "pulmonary", "delivery", "technology", "that", "was", "transferred", "by", "us", "to", "Novartis", "in", "an", "asset", "sale", "transaction", "that", "closed", "on", "December", "31,", "2008.", "<tag2>", "This", "drug", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance.", "<tag3>"], "wordsA": ["This", "drug", "candidate", "was", "developed", "using", "our", "proprietary", "pulmonary", "delivery", "technology", "that", "was", "transferred", "by", "us", "to", "Novartis", "in", "an", "asset", "sale", "transaction", "that", "closed", "on", "December", "31,", "2008."], "wordsB": ["This", "drug", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p109_s3", "idA": "906709_13_item1_p46_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "On March 1, 2013, Allergan, Inc. completed a merger and acquisition transaction with MAP pursuant to which MAP become a wholly-owned subsidiary of Allergan.", "type": 1, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "On", "March", "1,", "2013,", "Allergan,", "Inc.", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["On", "March", "1,", "2013,", "Allergan,", "Inc.", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p133_s3", "idA": "906709_13_item1_p46_s1", "sentA": "Under the terms of this agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for naloxegol and naloxegol fixed-dose combination products.", "sentB": "Under the terms of the 2010 Agreement, we received a $50.0 million upfront payment in return for guaranteeing supply of certain quantities of Polymer Materials to Amgen and the Additional Rights described below, and Amgen will pay manufacturing fees calculated based on fixed and variable components applicable to the Polymer Materials ordered by Amgen and delivered by us.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "received", "a", "$50.0", "million", "upfront", "payment", "in", "return", "for", "guaranteeing", "supply", "of", "certain", "quantities", "of", "Polymer", "Materials", "to", "Amgen", "and", "the", "Additional", "Rights", "described", "below,", "and", "Amgen", "will", "pay", "manufacturing", "fees", "calculated", "based", "on", "fixed", "and", "variable", "components", "applicable", "to", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "and", "delivered", "by", "us.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "received", "a", "$50.0", "million", "upfront", "payment", "in", "return", "for", "guaranteeing", "supply", "of", "certain", "quantities", "of", "Polymer", "Materials", "to", "Amgen", "and", "the", "Additional", "Rights", "described", "below,", "and", "Amgen", "will", "pay", "manufacturing", "fees", "calculated", "based", "on", "fixed", "and", "variable", "components", "applicable", "to", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "and", "delivered", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p115_s3", "idA": "906709_13_item1_p49_s1", "sentA": "When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur.", "sentB": "A longer half-life was achieved in all patients in the study using BAX 855, no patients developed inhibitors to either base molecule, BAX 855 or PEG, and no patients had allergic reactions.", "type": 1, "words": ["<tag1>", "When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur.", "<tag2>", "A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "BAX", "855,", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "BAX", "855", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions.", "<tag3>"], "wordsA": ["When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur."], "wordsB": ["A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "BAX", "855,", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "BAX", "855", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p138_s3", "idA": "906709_13_item1_p49_s1", "sentA": "When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur.", "sentB": "In addition, Pfizer, Inc. may terminate the agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and either party may terminate for cause if certain conditions are met.", "type": 1, "words": ["<tag1>", "When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur.", "<tag2>", "In", "addition,", "Pfizer,", "Inc.", "may", "terminate", "the", "agreement", "if", "marketing", "authorization", "is", "withdrawn", "or", "marketing", "is", "no", "longer", "feasible", "due", "to", "certain", "circumstances,", "and", "either", "party", "may", "terminate", "for", "cause", "if", "certain", "conditions", "are", "met.", "<tag3>"], "wordsA": ["When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur."], "wordsB": ["In", "addition,", "Pfizer,", "Inc.", "may", "terminate", "the", "agreement", "if", "marketing", "authorization", "is", "withdrawn", "or", "marketing", "is", "no", "longer", "feasible", "due", "to", "certain", "circumstances,", "and", "either", "party", "may", "terminate", "for", "cause", "if", "certain", "conditions", "are", "met."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p143_s3", "idA": "906709_13_item1_p49_s1", "sentA": "When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur.", "sentB": "In addition, Valeant may terminate the agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and either party may terminate for cause if certain conditions are met.", "type": 1, "words": ["<tag1>", "When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur.", "<tag2>", "In", "addition,", "Valeant", "may", "terminate", "the", "agreement", "if", "marketing", "authorization", "is", "withdrawn", "or", "marketing", "is", "no", "longer", "feasible", "due", "to", "certain", "circumstances,", "and", "either", "party", "may", "terminate", "for", "cause", "if", "certain", "conditions", "are", "met.", "<tag3>"], "wordsA": ["When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur."], "wordsB": ["In", "addition,", "Valeant", "may", "terminate", "the", "agreement", "if", "marketing", "authorization", "is", "withdrawn", "or", "marketing", "is", "no", "longer", "feasible", "due", "to", "certain", "circumstances,", "and", "either", "party", "may", "terminate", "for", "cause", "if", "certain", "conditions", "are", "met."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p93_s2", "idA": "906709_13_item1_p49_s1", "sentA": "When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur.", "sentB": "Study participants were 42 healthy adults who were not currently physically opioid-dependent but had used opioids to attain non-medical effects on at least 10 occasions during the past year and at least once in the 12 weeks before the study.", "type": 1, "words": ["<tag1>", "When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur.", "<tag2>", "Study", "participants", "were", "42", "healthy", "adults", "who", "were", "not", "currently", "physically", "opioid-dependent", "but", "had", "used", "opioids", "to", "attain", "non-medical", "effects", "on", "at", "least", "10", "occasions", "during", "the", "past", "year", "and", "at", "least", "once", "in", "the", "12", "weeks", "before", "the", "study.", "<tag3>"], "wordsA": ["When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur."], "wordsB": ["Study", "participants", "were", "42", "healthy", "adults", "who", "were", "not", "currently", "physically", "opioid-dependent", "but", "had", "used", "opioids", "to", "attain", "non-medical", "effects", "on", "at", "least", "10", "occasions", "during", "the", "past", "year", "and", "at", "least", "once", "in", "the", "12", "weeks", "before", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p107_s0", "idA": "906709_13_item1_p4_s1", "sentA": "OIC is a common side effect of prescription opioids when used for chronic pain management.", "sentB": "LEVADEX is a self-administered formulation of DHE using an inhaler device.", "type": 1, "words": ["<tag1>", "OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management.", "<tag2>", "LEVADEX", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device.", "<tag3>"], "wordsA": ["OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management."], "wordsB": ["LEVADEX", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p72_s0", "idA": "906709_13_item1_p4_s1", "sentA": "OIC is a common side effect of prescription opioids when used for chronic pain management.", "sentB": "Ovarian cancer is a significant health problem for women worldwide.", "type": 1, "words": ["<tag1>", "OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management.", "<tag2>", "Ovarian", "cancer", "is", "a", "significant", "health", "problem", "for", "women", "worldwide.", "<tag3>"], "wordsA": ["OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management."], "wordsB": ["Ovarian", "cancer", "is", "a", "significant", "health", "problem", "for", "women", "worldwide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p98_s1", "idA": "906709_13_item1_p4_s1", "sentA": "OIC is a common side effect of prescription opioids when used for chronic pain management.", "sentB": "A 2010 report from the Center for Disease Control and Prevention notes that emergency room visits tied to the abuse of prescription painkillers was at an all-time high at that point, having increased 111 percent over the preceding five-year period.", "type": 1, "words": ["<tag1>", "OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management.", "<tag2>", "A", "2010", "report", "from", "the", "Center", "for", "Disease", "Control", "and", "Prevention", "notes", "that", "emergency", "room", "visits", "tied", "to", "the", "abuse", "of", "prescription", "painkillers", "was", "at", "an", "all-time", "high", "at", "that", "point,", "having", "increased", "111", "percent", "over", "the", "preceding", "five-year", "period.", "<tag3>"], "wordsA": ["OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management."], "wordsB": ["A", "2010", "report", "from", "the", "Center", "for", "Disease", "Control", "and", "Prevention", "notes", "that", "emergency", "room", "visits", "tied", "to", "the", "abuse", "of", "prescription", "painkillers", "was", "at", "an", "all-time", "high", "at", "that", "point,", "having", "increased", "111", "percent", "over", "the", "preceding", "five-year", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p89_s2", "idA": "906709_13_item1_p52_s0", "sentA": "AstraZeneca has completed a Phase 3 clinical program for naloxegol AstraZeneca calls the KODIAC studies.", "sentB": "NKTR-181 was also well-tolerated at all doses evaluated in both studies.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies.", "<tag2>", "NKTR-181", "was", "also", "well-tolerated", "at", "all", "doses", "evaluated", "in", "both", "studies.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies."], "wordsB": ["NKTR-181", "was", "also", "well-tolerated", "at", "all", "doses", "evaluated", "in", "both", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s11", "idA": "906709_13_item1_p52_s0", "sentA": "AstraZeneca has completed a Phase 3 clinical program for naloxegol AstraZeneca calls the KODIAC studies.", "sentB": "However, patients who were randomized to placebo did not show the expected increase in pain scores observed in similar enriched enrollment, randomized withdrawal studies.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies.", "<tag2>", "However,", "patients", "who", "were", "randomized", "to", "placebo", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies."], "wordsB": ["However,", "patients", "who", "were", "randomized", "to", "placebo", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p93_s1", "idA": "906709_13_item1_p53_s0", "sentA": "KODIAC-07 was a three-month safety extension of KODIAC-04.", "sentB": "The HAL study was a randomized, double-blind, placebo- and active-controlled, 5-way crossover trial, that compared the effects of three doses of NKTR-181 oral solution (100 mg, 200 mg, and 400 mg), to the effects of 40 mg of oxycodone oral solution and placebo.", "type": 1, "words": ["<tag1>", "KODIAC-07", "was", "a", "three-month", "safety", "extension", "of", "KODIAC-04.", "<tag2>", "The", "HAL", "study", "was", "a", "randomized,", "double-blind,", "placebo-", "and", "active-controlled,", "5-way", "crossover", "trial,", "that", "compared", "the", "effects", "of", "three", "doses", "of", "NKTR-181", "oral", "solution", "(100", "mg,", "200", "mg,", "and", "400", "mg),", "to", "the", "effects", "of", "40", "mg", "of", "oxycodone", "oral", "solution", "and", "placebo.", "<tag3>"], "wordsA": ["KODIAC-07", "was", "a", "three-month", "safety", "extension", "of", "KODIAC-04."], "wordsB": ["The", "HAL", "study", "was", "a", "randomized,", "double-blind,", "placebo-", "and", "active-controlled,", "5-way", "crossover", "trial,", "that", "compared", "the", "effects", "of", "three", "doses", "of", "NKTR-181", "oral", "solution", "(100", "mg,", "200", "mg,", "and", "400", "mg),", "to", "the", "effects", "of", "40", "mg", "of", "oxycodone", "oral", "solution", "and", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p128_s0", "idA": "906709_13_item1_p53_s1", "sentA": "All three studies were conducted in patients with non-cancer pain and documented OIC, who required daily opioid therapy.", "sentB": "In patients with bronchiectasis, the bronchial tubes are enlarged, allowing mucus to pool and making the area prone to infection.", "type": 1, "words": ["<tag1>", "All", "three", "studies", "were", "conducted", "in", "patients", "with", "non-cancer", "pain", "and", "documented", "OIC,", "who", "required", "daily", "opioid", "therapy.", "<tag2>", "In", "patients", "with", "bronchiectasis,", "the", "bronchial", "tubes", "are", "enlarged,", "allowing", "mucus", "to", "pool", "and", "making", "the", "area", "prone", "to", "infection.", "<tag3>"], "wordsA": ["All", "three", "studies", "were", "conducted", "in", "patients", "with", "non-cancer", "pain", "and", "documented", "OIC,", "who", "required", "daily", "opioid", "therapy."], "wordsB": ["In", "patients", "with", "bronchiectasis,", "the", "bronchial", "tubes", "are", "enlarged,", "allowing", "mucus", "to", "pool", "and", "making", "the", "area", "prone", "to", "infection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p132_s0", "idA": "906709_13_item1_p53_s3", "sentA": "For both KODIAC-04 and -05, the 25 mg dose of naloxegol demonstrated statistically significant results for the primary endpoint.", "sentB": "Neulasta selectively stimulates the production of neutrophils that are depleted by cytotoxic chemotherapy, a condition called neutropenia that makes it more difficult for the body to fight infections.", "type": 1, "words": ["<tag1>", "For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint.", "<tag2>", "Neulasta", "selectively", "stimulates", "the", "production", "of", "neutrophils", "that", "are", "depleted", "by", "cytotoxic", "chemotherapy,", "a", "condition", "called", "neutropenia", "that", "makes", "it", "more", "difficult", "for", "the", "body", "to", "fight", "infections.", "<tag3>"], "wordsA": ["For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint."], "wordsB": ["Neulasta", "selectively", "stimulates", "the", "production", "of", "neutrophils", "that", "are", "depleted", "by", "cytotoxic", "chemotherapy,", "a", "condition", "called", "neutropenia", "that", "makes", "it", "more", "difficult", "for", "the", "body", "to", "fight", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p134_s0", "idA": "906709_13_item1_p53_s3", "sentA": "For both KODIAC-04 and -05, the 25 mg dose of naloxegol demonstrated statistically significant results for the primary endpoint.", "sentB": "the manufacturing facility to operate the manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights).", "type": 1, "words": ["<tag1>", "For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint.", "<tag2>", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights).", "<tag3>"], "wordsA": ["For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint."], "wordsB": ["the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p94_s1", "idA": "906709_13_item1_p53_s3", "sentA": "For both KODIAC-04 and -05, the 25 mg dose of naloxegol demonstrated statistically significant results for the primary endpoint.", "sentB": "In the study, 40 mg of oxycodone oral solution resulted in a maximum mean drug liking score of 85, indicating a strong liking for the effects of oxycodone.", "type": 1, "words": ["<tag1>", "For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint.", "<tag2>", "In", "the", "study,", "40", "mg", "of", "oxycodone", "oral", "solution", "resulted", "in", "a", "maximum", "mean", "drug", "liking", "score", "of", "85,", "indicating", "a", "strong", "liking", "for", "the", "effects", "of", "oxycodone.", "<tag3>"], "wordsA": ["For", "both", "KODIAC-04", "and", "-05,", "the", "25", "mg", "dose", "of", "naloxegol", "demonstrated", "statistically", "significant", "results", "for", "the", "primary", "endpoint."], "wordsB": ["In", "the", "study,", "40", "mg", "of", "oxycodone", "oral", "solution", "resulted", "in", "a", "maximum", "mean", "drug", "liking", "score", "of", "85,", "indicating", "a", "strong", "liking", "for", "the", "effects", "of", "oxycodone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p115_s4", "idA": "906709_13_item1_p53_s6", "sentA": "The most common adverse events (AEs) in the naloxegol treatment arms in both trials were abdominal pain, diarrhea and nausea.", "sentB": "Eleven adverse events were reported in eight patients across both treatment arms, but none was serious, treatment-related or resulted in withdrawal from the study.", "type": 1, "words": ["<tag1>", "The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea.", "<tag2>", "Eleven", "adverse", "events", "were", "reported", "in", "eight", "patients", "across", "both", "treatment", "arms,", "but", "none", "was", "serious,", "treatment-related", "or", "resulted", "in", "withdrawal", "from", "the", "study.", "<tag3>"], "wordsA": ["The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea."], "wordsB": ["Eleven", "adverse", "events", "were", "reported", "in", "eight", "patients", "across", "both", "treatment", "arms,", "but", "none", "was", "serious,", "treatment-related", "or", "resulted", "in", "withdrawal", "from", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p72_s2", "idA": "906709_13_item1_p53_s6", "sentA": "The most common adverse events (AEs) in the naloxegol treatment arms in both trials were abdominal pain, diarrhea and nausea.", "sentB": "Ovarian cancer is the ninth most common cancer among women, excluding non-melanoma skin cancers.", "type": 1, "words": ["<tag1>", "The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea.", "<tag2>", "Ovarian", "cancer", "is", "the", "ninth", "most", "common", "cancer", "among", "women,", "excluding", "non-melanoma", "skin", "cancers.", "<tag3>"], "wordsA": ["The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea."], "wordsB": ["Ovarian", "cancer", "is", "the", "ninth", "most", "common", "cancer", "among", "women,", "excluding", "non-melanoma", "skin", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p94_s4", "idA": "906709_13_item1_p54_s1", "sentA": "This trial was designed to evaluate the long-term safety and adverse event profile of naloxegol in patients taking 25 mg of naloxegol once daily, as compared to UC.", "sentB": "In this study, NKTR-181 was rated similar to placebo in drug liking and feeling high scores and had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "type": 1, "words": ["<tag1>", "This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC.", "<tag2>", "In", "this", "study,", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag3>"], "wordsA": ["This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC."], "wordsB": ["In", "this", "study,", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p9_s1", "idA": "906709_13_item1_p54_s1", "sentA": "This trial was designed to evaluate the long-term safety and adverse event profile of naloxegol in patients taking 25 mg of naloxegol once daily, as compared to UC.", "sentB": "On June 19, 2013, we announced results from that HAL study demonstrated that NKTR-181 was rated similar to placebo in drug liking and feeling high scores and had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "type": 1, "words": ["<tag1>", "This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC.", "<tag2>", "On", "June", "19,", "2013,", "we", "announced", "results", "from", "that", "HAL", "study", "demonstrated", "that", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag3>"], "wordsA": ["This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC."], "wordsB": ["On", "June", "19,", "2013,", "we", "announced", "results", "from", "that", "HAL", "study", "demonstrated", "that", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p88_s3", "idA": "906709_13_item1_p54_s2", "sentA": "In the trial, a total of 534 patients received naloxegol once daily for up to 52 weeks, while 270 patients received UC for OIC during the same treatment period.", "sentB": "The study enrolled a total of 60 healthy subjects over an eight-day treatment period, and included a placebo arm (n=3) for each dose cohort.", "type": 1, "words": ["<tag1>", "In", "the", "trial,", "a", "total", "of", "534", "patients", "received", "naloxegol", "once", "daily", "for", "up", "to", "52", "weeks,", "while", "270", "patients", "received", "UC", "for", "OIC", "during", "the", "same", "treatment", "period.", "<tag2>", "The", "study", "enrolled", "a", "total", "of", "60", "healthy", "subjects", "over", "an", "eight-day", "treatment", "period,", "and", "included", "a", "placebo", "arm", "(n=3)", "for", "each", "dose", "cohort.", "<tag3>"], "wordsA": ["In", "the", "trial,", "a", "total", "of", "534", "patients", "received", "naloxegol", "once", "daily", "for", "up", "to", "52", "weeks,", "while", "270", "patients", "received", "UC", "for", "OIC", "during", "the", "same", "treatment", "period."], "wordsB": ["The", "study", "enrolled", "a", "total", "of", "60", "healthy", "subjects", "over", "an", "eight-day", "treatment", "period,", "and", "included", "a", "placebo", "arm", "(n=3)", "for", "each", "dose", "cohort."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p103_s1", "idA": "906709_13_item1_p55_s4", "sentA": "Additionally, there were no reports of opioid withdrawal AEs which could be attributed to naloxegol.", "sentB": "However, at the highest doses tested in the study, there were several subjects who had elevated liver enzymes.", "type": 1, "words": ["<tag1>", "Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol.", "<tag2>", "However,", "at", "the", "highest", "doses", "tested", "in", "the", "study,", "there", "were", "several", "subjects", "who", "had", "elevated", "liver", "enzymes.", "<tag3>"], "wordsA": ["Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol."], "wordsB": ["However,", "at", "the", "highest", "doses", "tested", "in", "the", "study,", "there", "were", "several", "subjects", "who", "had", "elevated", "liver", "enzymes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p4_s3", "idA": "906709_13_item1_p55_s4", "sentA": "Additionally, there were no reports of opioid withdrawal AEs which could be attributed to naloxegol.", "sentB": "The FDA is currently planning to hold an advisory committee meeting to review the cardiovascular safety and potential additional safety study requirements for peripheral mu-opioid receptor antagonist class of drugs, including naloxegol.", "type": 1, "words": ["<tag1>", "Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol.", "<tag2>", "The", "FDA", "is", "currently", "planning", "to", "hold", "an", "advisory", "committee", "meeting", "to", "review", "the", "cardiovascular", "safety", "and", "potential", "additional", "safety", "study", "requirements", "for", "peripheral", "mu-opioid", "receptor", "antagonist", "class", "of", "drugs,", "including", "naloxegol.", "<tag3>"], "wordsA": ["Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol."], "wordsB": ["The", "FDA", "is", "currently", "planning", "to", "hold", "an", "advisory", "committee", "meeting", "to", "review", "the", "cardiovascular", "safety", "and", "potential", "additional", "safety", "study", "requirements", "for", "peripheral", "mu-opioid", "receptor", "antagonist", "class", "of", "drugs,", "including", "naloxegol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p109_s0", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "On May 26, 2011, MAP submitted an NDA to the FDA for LEVADEX .", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", ".", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p134_s2", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "Either party may terminate the 2010 Agreement in the event of insolvency or bankruptcy of the other party.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p136_s4", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "In August 2013, we agreed to deliver additional quantities of PEGylation materials used by Roche to produce PEGASYS and MIRCERA , all of which were delivered in the last quarter of 2013, for total consideration of approximately $18.6 million.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s5", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "In August 2013, we agreed to deliver additional quantities of PEGylation materials used by Roche to produce PEGASYS and MIRCERA , all of which were delivered in the last quarter of 2013, for total consideration of approximately $18.6 million.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p88_s4", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "Measurements in the study included plasma concentrations-time profiles, reductions in pupil diameter, and a cold pressor test, a model of pain used in healthy subjects to measure central analgesic activity.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "Measurements", "in", "the", "study", "included", "plasma", "concentrations-time", "profiles,", "reductions", "in", "pupil", "diameter,", "and", "a", "cold", "pressor", "test,", "a", "model", "of", "pain", "used", "in", "healthy", "subjects", "to", "measure", "central", "analgesic", "activity.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["Measurements", "in", "the", "study", "included", "plasma", "concentrations-time", "profiles,", "reductions", "in", "pupil", "diameter,", "and", "a", "cold", "pressor", "test,", "a", "model", "of", "pain", "used", "in", "healthy", "subjects", "to", "measure", "central", "analgesic", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p66_s0", "idA": "906709_13_item1_p57_s2", "sentA": "A petition for the decontrol of naloxegol was submitted to the DEA in March 2012 and subsequently accepted for review.", "sentB": "According to the American Cancer Society and World Health Organization, more than 1.4 million women worldwide are diagnosed with breast cancer globally every year.", "type": 1, "words": ["<tag1>", "A", "petition", "for", "the", "decontrol", "of", "naloxegol", "was", "submitted", "to", "the", "DEA", "in", "March", "2012", "and", "subsequently", "accepted", "for", "review.", "<tag2>", "According", "to", "the", "American", "Cancer", "Society", "and", "World", "Health", "Organization,", "more", "than", "1.4", "million", "women", "worldwide", "are", "diagnosed", "with", "breast", "cancer", "globally", "every", "year.", "<tag3>"], "wordsA": ["A", "petition", "for", "the", "decontrol", "of", "naloxegol", "was", "submitted", "to", "the", "DEA", "in", "March", "2012", "and", "subsequently", "accepted", "for", "review."], "wordsB": ["According", "to", "the", "American", "Cancer", "Society", "and", "World", "Health", "Organization,", "more", "than", "1.4", "million", "women", "worldwide", "are", "diagnosed", "with", "breast", "cancer", "globally", "every", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p133_s0", "idA": "906709_13_item1_p5_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products.", "sentB": "On October 29, 2010, we amended and restated the 1995 Agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and an amended and restated license agreement with Amgen Inc. and Amgen Manufacturing, Limited (together referred to as Amgen).", "type": 1, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "On", "October", "29,", "2010,", "we", "amended", "and", "restated", "the", "1995", "Agreement", "by", "entering", "into", "a", "supply,", "dedicated", "suite", "and", "manufacturing", "guarantee", "agreement", "(the", "2010", "Agreement)", "and", "an", "amended", "and", "restated", "license", "agreement", "with", "Amgen", "Inc.", "and", "Amgen", "Manufacturing,", "Limited", "(together", "referred", "to", "as", "Amgen).", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["On", "October", "29,", "2010,", "we", "amended", "and", "restated", "the", "1995", "Agreement", "by", "entering", "into", "a", "supply,", "dedicated", "suite", "and", "manufacturing", "guarantee", "agreement", "(the", "2010", "Agreement)", "and", "an", "amended", "and", "restated", "license", "agreement", "with", "Amgen", "Inc.", "and", "Amgen", "Manufacturing,", "Limited", "(together", "referred", "to", "as", "Amgen)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p56_s1", "idA": "906709_13_item1_p5_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products.", "sentB": "If the FDA does require a CV Safety Study, AstraZeneca may terminate the license agreement with us in its entirety or only with respect to its rights in the United States.", "type": 1, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "If", "the", "FDA", "does", "require", "a", "CV", "Safety", "Study,", "AstraZeneca", "may", "terminate", "the", "license", "agreement", "with", "us", "in", "its", "entirety", "or", "only", "with", "respect", "to", "its", "rights", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["If", "the", "FDA", "does", "require", "a", "CV", "Safety", "Study,", "AstraZeneca", "may", "terminate", "the", "license", "agreement", "with", "us", "in", "its", "entirety", "or", "only", "with", "respect", "to", "its", "rights", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p9_s3", "idA": "906709_13_item1_p5_s1", "sentA": "On November 12, 2012, AstraZeneca announced positive top-line results for naloxegol from two Phase 3 clinical studies and one safety extension study.", "sentB": "In this study, NKTR-181 performed as expected as an opioid analgesic throughout the study.", "type": 1, "words": ["<tag1>", "On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study.", "<tag2>", "In", "this", "study,", "NKTR-181", "performed", "as", "expected", "as", "an", "opioid", "analgesic", "throughout", "the", "study.", "<tag3>"], "wordsA": ["On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study."], "wordsB": ["In", "this", "study,", "NKTR-181", "performed", "as", "expected", "as", "an", "opioid", "analgesic", "throughout", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p102_s1", "idA": "906709_13_item1_p5_s2", "sentA": "On February 26, 2013, AstraZeneca announced positive top-line results from the long-term safety clinical study of naloxegol in patients with OIC.", "sentB": "In January 2014, we announced data from the multiple ascending dose study for an oral formulation of NKTR-192.", "type": 1, "words": ["<tag1>", "On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "the", "long-term", "safety", "clinical", "study", "of", "naloxegol", "in", "patients", "with", "OIC.", "<tag2>", "In", "January", "2014,", "we", "announced", "data", "from", "the", "multiple", "ascending", "dose", "study", "for", "an", "oral", "formulation", "of", "NKTR-192.", "<tag3>"], "wordsA": ["On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "the", "long-term", "safety", "clinical", "study", "of", "naloxegol", "in", "patients", "with", "OIC."], "wordsB": ["In", "January", "2014,", "we", "announced", "data", "from", "the", "multiple", "ascending", "dose", "study", "for", "an", "oral", "formulation", "of", "NKTR-192."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p68_s1", "idA": "906709_13_item1_p6_s0", "sentA": "The naloxegol fixed-dose combination program, formerly known as the NKTR-119 program, is an early stage research and development program that is designed to combine various opioids with naloxegol.", "sentB": "Anthracyclines and taxanes are the among the most active and widely used chemotherapeutic agents for breast cancer, but the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease.", "type": 1, "words": ["<tag1>", "The", "naloxegol", "fixed-dose", "combination", "program,", "formerly", "known", "as", "the", "NKTR-119", "program,", "is", "an", "early", "stage", "research", "and", "development", "program", "that", "is", "designed", "to", "combine", "various", "opioids", "with", "naloxegol.", "<tag2>", "Anthracyclines", "and", "taxanes", "are", "the", "among", "the", "most", "active", "and", "widely", "used", "chemotherapeutic", "agents", "for", "breast", "cancer,", "but", "the", "increased", "use", "of", "these", "agents", "at", "an", "early", "stage", "of", "disease", "often", "renders", "tumors", "resistant", "to", "these", "drugs", "by", "the", "time", "the", "disease", "recurs,", "thereby", "reducing", "the", "number", "of", "treatment", "options", "for", "metastatic", "disease.", "<tag3>"], "wordsA": ["The", "naloxegol", "fixed-dose", "combination", "program,", "formerly", "known", "as", "the", "NKTR-119", "program,", "is", "an", "early", "stage", "research", "and", "development", "program", "that", "is", "designed", "to", "combine", "various", "opioids", "with", "naloxegol."], "wordsB": ["Anthracyclines", "and", "taxanes", "are", "the", "among", "the", "most", "active", "and", "widely", "used", "chemotherapeutic", "agents", "for", "breast", "cancer,", "but", "the", "increased", "use", "of", "these", "agents", "at", "an", "early", "stage", "of", "disease", "often", "renders", "tumors", "resistant", "to", "these", "drugs", "by", "the", "time", "the", "disease", "recurs,", "thereby", "reducing", "the", "number", "of", "treatment", "options", "for", "metastatic", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p58_s2", "idA": "906709_13_item1_p7_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "sentB": "Unlike irinotecan, which is a first generation topo I inhibitor that exhibits a high initial peak concentration and short half-life, etirinotecan pegol s pro-drug design results in a lower initial peak concentration of active topo I inhibitor in the blood.", "type": 1, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "etirinotecan", "pegol", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood.", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "etirinotecan", "pegol", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p120_s1", "idA": "906709_13_item1_p7_s4", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "Fovista met the pre-specified primary efficacy endpoint of mean vision gain.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "Fovista", "met", "the", "pre-specified", "primary", "efficacy", "endpoint", "of", "mean", "vision", "gain.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["Fovista", "met", "the", "pre-specified", "primary", "efficacy", "endpoint", "of", "mean", "vision", "gain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p4_s0", "idA": "906709_13_item1_p8_s0", "sentA": "In November 2012, the U.S. Food and Drug Administration (FDA) designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "sentB": "In November 2013, we reported that our collaboration partner AstraZeneca PLC announced that the United States Food and Drug Administration, or FDA, accepted the New Drug Application, or NDA, for naloxegol, with a Prescription Drug User Fee Act, or PDUFA, date of September 16, 2014.", "type": 1, "words": ["<tag1>", "In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag2>", "In", "November", "2013,", "we", "reported", "that", "our", "collaboration", "partner", "AstraZeneca", "PLC", "announced", "that", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "accepted", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "naloxegol,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act,", "or", "PDUFA,", "date", "of", "September", "16,", "2014.", "<tag3>"], "wordsA": ["In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "wordsB": ["In", "November", "2013,", "we", "reported", "that", "our", "collaboration", "partner", "AstraZeneca", "PLC", "announced", "that", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "accepted", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "naloxegol,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act,", "or", "PDUFA,", "date", "of", "September", "16,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p76_s3", "idA": "906709_13_item1_p8_s3", "sentA": "A Phase 1 study to evaluate etirinotecan pegol in combination with 5-Fluorouracil/leucovorin in refractory solid tumor cancers has also been completed, and a Phase 2 clinical trial evaluating etirinotecan pegol as a single agent in patients with metastatic colorectal cancer is enrolling patients.", "sentB": "Most metastatic colorectal cancer patients have recurrence within two years and require retreatment with chemotherapy regimens.", "type": 1, "words": ["<tag1>", "A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients.", "<tag2>", "Most", "metastatic", "colorectal", "cancer", "patients", "have", "recurrence", "within", "two", "years", "and", "require", "retreatment", "with", "chemotherapy", "regimens.", "<tag3>"], "wordsA": ["A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients."], "wordsB": ["Most", "metastatic", "colorectal", "cancer", "patients", "have", "recurrence", "within", "two", "years", "and", "require", "retreatment", "with", "chemotherapy", "regimens."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p61_s0", "idA": "906709_13_item1_p9_s0", "sentA": "investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "Clinical studies have shown that etirinotecan pegol has an extended pharmacokinetic profile and remains in circulation throughout the entire chemotherapy cycle, providing sustained exposure to topo I inhibition.", "type": 1, "words": ["<tag1>", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "Clinical", "studies", "have", "shown", "that", "etirinotecan", "pegol", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition.", "<tag3>"], "wordsA": ["investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["Clinical", "studies", "have", "shown", "that", "etirinotecan", "pegol", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p77_s2", "idA": "906709_13_item1_p9_s0", "sentA": "investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "In May 2013, the study completed enrollment of 20 patients with high-grade glioma who had received a median of three prior lines of therapy before enrolling in the study.", "type": 1, "words": ["<tag1>", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "In", "May", "2013,", "the", "study", "completed", "enrollment", "of", "20", "patients", "with", "high-grade", "glioma", "who", "had", "received", "a", "median", "of", "three", "prior", "lines", "of", "therapy", "before", "enrolling", "in", "the", "study.", "<tag3>"], "wordsA": ["investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["In", "May", "2013,", "the", "study", "completed", "enrollment", "of", "20", "patients", "with", "high-grade", "glioma", "who", "had", "received", "a", "median", "of", "three", "prior", "lines", "of", "therapy", "before", "enrolling", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p98_s0", "idA": "906709_13_item1_p9_s0", "sentA": "investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "The FDA has cited prescription opioid analgesics as being at the center of a major public health crisis of addiction, misuse, abuse, overdose and death.", "type": 1, "words": ["<tag1>", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death.", "<tag3>"], "wordsA": ["investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p139_s3", "idA": "906709_13_item1_p9_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "In December 2010, the parties amended the manufacturing and supply agreement to provide for a transition plan to an alternative manufacturer and extension of the term through the successful manufacturing transition or December 31, 2018 at the latest.", "type": 1, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "In", "December", "2010,", "the", "parties", "amended", "the", "manufacturing", "and", "supply", "agreement", "to", "provide", "for", "a", "transition", "plan", "to", "an", "alternative", "manufacturer", "and", "extension", "of", "the", "term", "through", "the", "successful", "manufacturing", "transition", "or", "December", "31,", "2018", "at", "the", "latest.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["In", "December", "2010,", "the", "parties", "amended", "the", "manufacturing", "and", "supply", "agreement", "to", "provide", "for", "a", "transition", "plan", "to", "an", "alternative", "manufacturer", "and", "extension", "of", "the", "term", "through", "the", "successful", "manufacturing", "transition", "or", "December", "31,", "2018", "at", "the", "latest."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p95_s0", "idA": "906709_13_item1_p9_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "On June 19, 2013, we presented data from the HAL study at the 2013 Annual Meeting of The College on Problems of Drug Dependence in San Diego, California.", "type": 1, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "On", "June", "19,", "2013,", "we", "presented", "data", "from", "the", "HAL", "study", "at", "the", "2013", "Annual", "Meeting", "of", "The", "College", "on", "Problems", "of", "Drug", "Dependence", "in", "San", "Diego,", "California.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["On", "June", "19,", "2013,", "we", "presented", "data", "from", "the", "HAL", "study", "at", "the", "2013", "Annual", "Meeting", "of", "The", "College", "on", "Problems", "of", "Drug", "Dependence", "in", "San", "Diego,", "California."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s9", "idA": "906709_13_item1_p9_s3", "sentA": "Enrollment in this study is ongoing with a design to enroll approximately 200 patients in a randomized controlled study to receive either NKTR-181 or placebo.", "sentB": "Following the titration period, patients were randomized 1:1 to either continue to receive their analgesic dose of NKTR-181 or to receive placebo for 21 days.", "type": 1, "words": ["<tag1>", "Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag2>", "Following", "the", "titration", "period,", "patients", "were", "randomized", "1:1", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "21", "days.", "<tag3>"], "wordsA": ["Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo."], "wordsB": ["Following", "the", "titration", "period,", "patients", "were", "randomized", "1:1", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "21", "days."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p93_s3", "idA": "906709_13_item1_p9_s3", "sentA": "Enrollment in this study is ongoing with a design to enroll approximately 200 patients in a randomized controlled study to receive either NKTR-181 or placebo.", "sentB": "The study participants sequentially received the five treatments, administered in a randomized, double-blinded fashion, with each treatment separated by a washout period.", "type": 1, "words": ["<tag1>", "Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag2>", "The", "study", "participants", "sequentially", "received", "the", "five", "treatments,", "administered", "in", "a", "randomized,", "double-blinded", "fashion,", "with", "each", "treatment", "separated", "by", "a", "washout", "period.", "<tag3>"], "wordsA": ["Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo."], "wordsB": ["The", "study", "participants", "sequentially", "received", "the", "five", "treatments,", "administered", "in", "a", "randomized,", "double-blinded", "fashion,", "with", "each", "treatment", "separated", "by", "a", "washout", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p144_s1", "idA": "906709_14_item1_p101_s2", "sentA": "NKTR-192 is also designed to have slow entry into the CNS.", "sentB": "Where CDRH is determined to have primary jurisdiction over a product, 510(k) clearance or PMA approval is required.", "type": 1, "words": ["<tag1>", "NKTR-192", "is", "also", "designed", "to", "have", "slow", "entry", "into", "the", "CNS.", "<tag2>", "Where", "CDRH", "is", "determined", "to", "have", "primary", "jurisdiction", "over", "a", "product,", "510(k)", "clearance", "or", "PMA", "approval", "is", "required.", "<tag3>"], "wordsA": ["NKTR-192", "is", "also", "designed", "to", "have", "slow", "entry", "into", "the", "CNS."], "wordsB": ["Where", "CDRH", "is", "determined", "to", "have", "primary", "jurisdiction", "over", "a", "product,", "510(k)", "clearance", "or", "PMA", "approval", "is", "required."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p157_s2", "idA": "906709_14_item1_p105_s2", "sentA": "In certain cases, we also manufacture and supply our proprietary PEGylation materials to our partners.", "sentB": "We could incur substantial costs in defending ourselves and our partners against any such claims.", "type": 1, "words": ["<tag1>", "In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners.", "<tag2>", "We", "could", "incur", "substantial", "costs", "in", "defending", "ourselves", "and", "our", "partners", "against", "any", "such", "claims.", "<tag3>"], "wordsA": ["In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners."], "wordsB": ["We", "could", "incur", "substantial", "costs", "in", "defending", "ourselves", "and", "our", "partners", "against", "any", "such", "claims."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p108_s0", "idA": "906709_14_item1_p106_s2", "sentA": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of LEVADEX .", "sentB": "On January 23, 2015, we filed a breach of contract action against Allergan and MAP in California Superior Court in San Mateo County seeking monetary damages related to MAP s failure to pay us a certain specified percentage of $80 million in upfront and milestone payments received to date from Allergan under the 2011 Collaboration Agreement which we believe we were entitled to receive under the terms of our license agreement with MAP.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", ".", "<tag2>", "On", "January", "23,", "2015,", "we", "filed", "a", "breach", "of", "contract", "action", "against", "Allergan", "and", "MAP", "in", "California", "Superior", "Court", "in", "San", "Mateo", "County", "seeking", "monetary", "damages", "related", "to", "MAP", "s", "failure", "to", "pay", "us", "a", "certain", "specified", "percentage", "of", "$80", "million", "in", "upfront", "and", "milestone", "payments", "received", "to", "date", "from", "Allergan", "under", "the", "2011", "Collaboration", "Agreement", "which", "we", "believe", "we", "were", "entitled", "to", "receive", "under", "the", "terms", "of", "our", "license", "agreement", "with", "MAP.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", "."], "wordsB": ["On", "January", "23,", "2015,", "we", "filed", "a", "breach", "of", "contract", "action", "against", "Allergan", "and", "MAP", "in", "California", "Superior", "Court", "in", "San", "Mateo", "County", "seeking", "monetary", "damages", "related", "to", "MAP", "s", "failure", "to", "pay", "us", "a", "certain", "specified", "percentage", "of", "$80", "million", "in", "upfront", "and", "milestone", "payments", "received", "to", "date", "from", "Allergan", "under", "the", "2011", "Collaboration", "Agreement", "which", "we", "believe", "we", "were", "entitled", "to", "receive", "under", "the", "terms", "of", "our", "license", "agreement", "with", "MAP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p145_s1", "idA": "906709_14_item1_p109_s0", "sentA": "On May 26, 2011, MAP submitted an NDA to the FDA for LEVADEX .", "sentB": "Devices deemed to pose lower risks are placed in either Class I or II, which requires the manufacturer to submit to the FDA a Premarket Notification requesting permission to commercially distribute the device.", "type": 1, "words": ["<tag1>", "On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", ".", "<tag2>", "Devices", "deemed", "to", "pose", "lower", "risks", "are", "placed", "in", "either", "Class", "I", "or", "II,", "which", "requires", "the", "manufacturer", "to", "submit", "to", "the", "FDA", "a", "Premarket", "Notification", "requesting", "permission", "to", "commercially", "distribute", "the", "device.", "<tag3>"], "wordsA": ["On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", "."], "wordsB": ["Devices", "deemed", "to", "pose", "lower", "risks", "are", "placed", "in", "either", "Class", "I", "or", "II,", "which", "requires", "the", "manufacturer", "to", "submit", "to", "the", "FDA", "a", "Premarket", "Notification", "requesting", "permission", "to", "commercially", "distribute", "the", "device."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p132_s0", "idA": "906709_14_item1_p109_s2", "sentA": "In December 2012, MAP announced that its NDA resubmission for LEVADEX was accepted for filing by the FDA.", "sentB": "The research and development, clinical testing, manufacture and marketing of products using our technologies are subject to regulation by the FDA and by comparable regulatory agencies in other countries.", "type": 1, "words": ["<tag1>", "In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA.", "<tag2>", "The", "research", "and", "development,", "clinical", "testing,", "manufacture", "and", "marketing", "of", "products", "using", "our", "technologies", "are", "subject", "to", "regulation", "by", "the", "FDA", "and", "by", "comparable", "regulatory", "agencies", "in", "other", "countries.", "<tag3>"], "wordsA": ["In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA."], "wordsB": ["The", "research", "and", "development,", "clinical", "testing,", "manufacture", "and", "marketing", "of", "products", "using", "our", "technologies", "are", "subject", "to", "regulation", "by", "the", "FDA", "and", "by", "comparable", "regulatory", "agencies", "in", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p145_s4", "idA": "906709_14_item1_p109_s2", "sentA": "In December 2012, MAP announced that its NDA resubmission for LEVADEX was accepted for filing by the FDA.", "sentB": "Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device are placed in Class III, requiring PMA approval.", "type": 1, "words": ["<tag1>", "In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA.", "<tag2>", "Devices", "deemed", "by", "the", "FDA", "to", "pose", "the", "greatest", "risk,", "such", "as", "life-sustaining,", "life-supporting", "or", "implantable", "devices,", "or", "devices", "deemed", "not", "substantially", "equivalent", "to", "a", "previously", "cleared", "510(k)", "device", "are", "placed", "in", "Class", "III,", "requiring", "PMA", "approval.", "<tag3>"], "wordsA": ["In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA."], "wordsB": ["Devices", "deemed", "by", "the", "FDA", "to", "pose", "the", "greatest", "risk,", "such", "as", "life-sustaining,", "life-supporting", "or", "implantable", "devices,", "or", "devices", "deemed", "not", "substantially", "equivalent", "to", "a", "previously", "cleared", "510(k)", "device", "are", "placed", "in", "Class", "III,", "requiring", "PMA", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s1", "idA": "906709_14_item1_p10_s2", "sentA": "We also have additional proprietary preclinical and clinical drug candidates being developed for pain relief.", "sentB": "We also rely on trade secret protection for our confidential and proprietary information.", "type": 1, "words": ["<tag1>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief.", "<tag2>", "We", "also", "rely", "on", "trade", "secret", "protection", "for", "our", "confidential", "and", "proprietary", "information.", "<tag3>"], "wordsA": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief."], "wordsB": ["We", "also", "rely", "on", "trade", "secret", "protection", "for", "our", "confidential", "and", "proprietary", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s5", "idA": "906709_14_item1_p114_s1", "sentA": "Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country.", "sentB": "Product approvals, once obtained, may be withdrawn if compliance with regulatory standards is not maintained or if safety concerns arise after the product reaches the market.", "type": 1, "words": ["<tag1>", "Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country.", "<tag2>", "Product", "approvals,", "once", "obtained,", "may", "be", "withdrawn", "if", "compliance", "with", "regulatory", "standards", "is", "not", "maintained", "or", "if", "safety", "concerns", "arise", "after", "the", "product", "reaches", "the", "market.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country."], "wordsB": ["Product", "approvals,", "once", "obtained,", "may", "be", "withdrawn", "if", "compliance", "with", "regulatory", "standards", "is", "not", "maintained", "or", "if", "safety", "concerns", "arise", "after", "the", "product", "reaches", "the", "market."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p141_s1", "idA": "906709_14_item1_p11_s5", "sentA": "In addition, we are also advancing other acute pain drug candidates in preclinical development.", "sentB": "Such inspections are also held periodically after the commercialization.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "are", "also", "advancing", "other", "acute", "pain", "drug", "candidates", "in", "preclinical", "development.", "<tag2>", "Such", "inspections", "are", "also", "held", "periodically", "after", "the", "commercialization.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "also", "advancing", "other", "acute", "pain", "drug", "candidates", "in", "preclinical", "development."], "wordsB": ["Such", "inspections", "are", "also", "held", "periodically", "after", "the", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p127_s1", "idA": "906709_14_item1_p133_s4", "sentA": "Amgen has no minimum purchase commitments.", "sentB": "It is the only ESA that is peptide-based and its building blocks (amino acids) are arranged in a different order than erythropoietin (i.e., it has no sequence homology to endogenous erythropoietin).", "type": 1, "words": ["<tag1>", "Amgen", "has", "no", "minimum", "purchase", "commitments.", "<tag2>", "It", "is", "the", "only", "ESA", "that", "is", "peptide-based", "and", "its", "building", "blocks", "(amino", "acids)", "are", "arranged", "in", "a", "different", "order", "than", "erythropoietin", "(i.e.,", "it", "has", "no", "sequence", "homology", "to", "endogenous", "erythropoietin).", "<tag3>"], "wordsA": ["Amgen", "has", "no", "minimum", "purchase", "commitments."], "wordsB": ["It", "is", "the", "only", "ESA", "that", "is", "peptide-based", "and", "its", "building", "blocks", "(amino", "acids)", "are", "arranged", "in", "a", "different", "order", "than", "erythropoietin", "(i.e.,", "it", "has", "no", "sequence", "homology", "to", "endogenous", "erythropoietin)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p157_s0", "idA": "906709_14_item1_p136_s0", "sentA": "PEGASYS is approved in the U.S., E.U. and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "sentB": "U.S. and foreign patent rights and other proprietary rights exist that are owned by third parties and relate to pharmaceutical compositions and reagents, medical devices and equipment and methods for preparation, packaging and delivery of pharmaceutical compositions.", "type": 1, "words": ["<tag1>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag2>", "U.S.", "and", "foreign", "patent", "rights", "and", "other", "proprietary", "rights", "exist", "that", "are", "owned", "by", "third", "parties", "and", "relate", "to", "pharmaceutical", "compositions", "and", "reagents,", "medical", "devices", "and", "equipment", "and", "methods", "for", "preparation,", "packaging", "and", "delivery", "of", "pharmaceutical", "compositions.", "<tag3>"], "wordsA": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "wordsB": ["U.S.", "and", "foreign", "patent", "rights", "and", "other", "proprietary", "rights", "exist", "that", "are", "owned", "by", "third", "parties", "and", "relate", "to", "pharmaceutical", "compositions", "and", "reagents,", "medical", "devices", "and", "equipment", "and", "methods", "for", "preparation,", "packaging", "and", "delivery", "of", "pharmaceutical", "compositions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p152_s5", "idA": "906709_14_item1_p138_s2", "sentA": "The agreement expires on the later of ten years from the grant of first marketing authorization in the designated territory, which occurred in March 2003, or the expiration of our last relevant patent containing a valid claim.", "sentB": "Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid).", "type": 1, "words": ["<tag1>", "The", "agreement", "expires", "on", "the", "later", "of", "ten", "years", "from", "the", "grant", "of", "first", "marketing", "authorization", "in", "the", "designated", "territory,", "which", "occurred", "in", "March", "2003,", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid).", "<tag3>"], "wordsA": ["The", "agreement", "expires", "on", "the", "later", "of", "ten", "years", "from", "the", "grant", "of", "first", "marketing", "authorization", "in", "the", "designated", "territory,", "which", "occurred", "in", "March", "2003,", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p149_s0", "idA": "906709_14_item1_p143_s0", "sentA": "Under the terms of the agreement, we will receive royalties on net product sales in any particular country for the longer of ten years from the date of the first commercial sale of the product in that country or the duration of patent coverage.", "sentB": "Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication may be approved during the exclusivity period only if the second product is shown to be clinically superior to the original orphan drug in that it is more effective, safer or otherwise makes a major contribution to patient care or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "will", "receive", "royalties", "on", "net", "product", "sales", "in", "any", "particular", "country", "for", "the", "longer", "of", "ten", "years", "from", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "duration", "of", "patent", "coverage.", "<tag2>", "Once", "a", "product", "receives", "orphan", "drug", "exclusivity,", "a", "second", "product", "that", "is", "considered", "to", "be", "the", "same", "drug", "for", "the", "same", "indication", "may", "be", "approved", "during", "the", "exclusivity", "period", "only", "if", "the", "second", "product", "is", "shown", "to", "be", "clinically", "superior", "to", "the", "original", "orphan", "drug", "in", "that", "it", "is", "more", "effective,", "safer", "or", "otherwise", "makes", "a", "major", "contribution", "to", "patient", "care", "or", "the", "holder", "of", "exclusive", "approval", "cannot", "assure", "the", "availability", "of", "sufficient", "quantities", "of", "the", "orphan", "drug", "to", "meet", "the", "needs", "of", "patients", "with", "the", "disease", "or", "condition", "for", "which", "the", "drug", "was", "designated.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "will", "receive", "royalties", "on", "net", "product", "sales", "in", "any", "particular", "country", "for", "the", "longer", "of", "ten", "years", "from", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "duration", "of", "patent", "coverage."], "wordsB": ["Once", "a", "product", "receives", "orphan", "drug", "exclusivity,", "a", "second", "product", "that", "is", "considered", "to", "be", "the", "same", "drug", "for", "the", "same", "indication", "may", "be", "approved", "during", "the", "exclusivity", "period", "only", "if", "the", "second", "product", "is", "shown", "to", "be", "clinically", "superior", "to", "the", "original", "orphan", "drug", "in", "that", "it", "is", "more", "effective,", "safer", "or", "otherwise", "makes", "a", "major", "contribution", "to", "patient", "care", "or", "the", "holder", "of", "exclusive", "approval", "cannot", "assure", "the", "availability", "of", "sufficient", "quantities", "of", "the", "orphan", "drug", "to", "meet", "the", "needs", "of", "patients", "with", "the", "disease", "or", "condition", "for", "which", "the", "drug", "was", "designated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p134_s1", "idA": "906709_14_item1_p144_s3", "sentA": "We were also entitled to receive royalties on net sales of the CIMZIA product for the longer of ten years from the first commercial sale of the product anywhere in the world or the expiration of patent rights in a particular country.", "sentB": "If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests relating to systemic toxicity normally required for the IND and NDA or BLA may not be necessary if the company has a right of reference to such data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section 505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.", "type": 1, "words": ["<tag1>", "We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "CIMZIA", "product", "for", "the", "longer", "of", "ten", "years", "from", "the", "first", "commercial", "sale", "of", "the", "product", "anywhere", "in", "the", "world", "or", "the", "expiration", "of", "patent", "rights", "in", "a", "particular", "country.", "<tag2>", "If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "such", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act.", "<tag3>"], "wordsA": ["We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "CIMZIA", "product", "for", "the", "longer", "of", "ten", "years", "from", "the", "first", "commercial", "sale", "of", "the", "product", "anywhere", "in", "the", "world", "or", "the", "expiration", "of", "patent", "rights", "in", "a", "particular", "country."], "wordsB": ["If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "such", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p154_s2", "idA": "906709_14_item1_p145_s1", "sentA": "Pursuant to the agreement, we license our intellectual property related to our proprietary PEGylation materials for the manufacture and commercialization of Roche s MIRCERA product.", "sentB": "Pursuant to the exclusive license agreement, Novartis Pharma AG grants back to us an exclusive, irrevocable, perpetual, royalty-free and worldwide license under certain specific patent rights and other related intellectual property rights acquired by Novartis from us in the Novartis Pulmonary Asset Sale, as well as certain improvements or modifications thereto that are made by Novartis.", "type": 1, "words": ["<tag1>", "Pursuant", "to", "the", "agreement,", "we", "license", "our", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "materials", "for", "the", "manufacture", "and", "commercialization", "of", "Roche", "s", "MIRCERA", "product.", "<tag2>", "Pursuant", "to", "the", "exclusive", "license", "agreement,", "Novartis", "Pharma", "AG", "grants", "back", "to", "us", "an", "exclusive,", "irrevocable,", "perpetual,", "royalty-free", "and", "worldwide", "license", "under", "certain", "specific", "patent", "rights", "and", "other", "related", "intellectual", "property", "rights", "acquired", "by", "Novartis", "from", "us", "in", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "well", "as", "certain", "improvements", "or", "modifications", "thereto", "that", "are", "made", "by", "Novartis.", "<tag3>"], "wordsA": ["Pursuant", "to", "the", "agreement,", "we", "license", "our", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "materials", "for", "the", "manufacture", "and", "commercialization", "of", "Roche", "s", "MIRCERA", "product."], "wordsB": ["Pursuant", "to", "the", "exclusive", "license", "agreement,", "Novartis", "Pharma", "AG", "grants", "back", "to", "us", "an", "exclusive,", "irrevocable,", "perpetual,", "royalty-free", "and", "worldwide", "license", "under", "certain", "specific", "patent", "rights", "and", "other", "related", "intellectual", "property", "rights", "acquired", "by", "Novartis", "from", "us", "in", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "well", "as", "certain", "improvements", "or", "modifications", "thereto", "that", "are", "made", "by", "Novartis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p127_s0", "idA": "906709_14_item1_p146_s0", "sentA": "MIRCERA is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis.", "sentB": "OMONTYS is a synthetic PEGylated peptidic compound that binds to and stimulates the erythropoietin receptor and thus acts as an erythropoietin stimulating agent (ESA).", "type": 1, "words": ["<tag1>", "MIRCERA", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis.", "<tag2>", "OMONTYS", "is", "a", "synthetic", "PEGylated", "peptidic", "compound", "that", "binds", "to", "and", "stimulates", "the", "erythropoietin", "receptor", "and", "thus", "acts", "as", "an", "erythropoietin", "stimulating", "agent", "(ESA).", "<tag3>"], "wordsA": ["MIRCERA", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis."], "wordsB": ["OMONTYS", "is", "a", "synthetic", "PEGylated", "peptidic", "compound", "that", "binds", "to", "and", "stimulates", "the", "erythropoietin", "receptor", "and", "thus", "acts", "as", "an", "erythropoietin", "stimulating", "agent", "(ESA)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p134_s4", "idA": "906709_14_item1_p147_s4", "sentA": "Roche would also pay us additional consideration for any future orders of the PEGylation materials for MIRCERA beyond the initial quantities ordered as part of the initial arrangement.", "sentB": "The results of the preclinical tests for drugs, biological products and combination products subject to the primary jurisdiction of the FDA s Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) are submitted to the FDA as part of the IND and are reviewed by the FDA before clinical trials can begin.", "type": 1, "words": ["<tag1>", "Roche", "would", "also", "pay", "us", "additional", "consideration", "for", "any", "future", "orders", "of", "the", "PEGylation", "materials", "for", "MIRCERA", "beyond", "the", "initial", "quantities", "ordered", "as", "part", "of", "the", "initial", "arrangement.", "<tag2>", "The", "results", "of", "the", "preclinical", "tests", "for", "drugs,", "biological", "products", "and", "combination", "products", "subject", "to", "the", "primary", "jurisdiction", "of", "the", "FDA", "s", "Center", "for", "Drug", "Evaluation", "and", "Research", "(CDER)", "or", "Center", "for", "Biologics", "Evaluation", "and", "Research", "(CBER)", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "the", "IND", "and", "are", "reviewed", "by", "the", "FDA", "before", "clinical", "trials", "can", "begin.", "<tag3>"], "wordsA": ["Roche", "would", "also", "pay", "us", "additional", "consideration", "for", "any", "future", "orders", "of", "the", "PEGylation", "materials", "for", "MIRCERA", "beyond", "the", "initial", "quantities", "ordered", "as", "part", "of", "the", "initial", "arrangement."], "wordsB": ["The", "results", "of", "the", "preclinical", "tests", "for", "drugs,", "biological", "products", "and", "combination", "products", "subject", "to", "the", "primary", "jurisdiction", "of", "the", "FDA", "s", "Center", "for", "Drug", "Evaluation", "and", "Research", "(CDER)", "or", "Center", "for", "Biologics", "Evaluation", "and", "Research", "(CBER)", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "the", "IND", "and", "are", "reviewed", "by", "the", "FDA", "before", "clinical", "trials", "can", "begin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s3", "idA": "906709_14_item1_p147_s7", "sentA": "We were also entitled to receive royalties on net sales of the MIRCERA product.", "sentB": "Additionally, the approved labeling may narrowly limit the conditions of use of the product, including the intended uses, or impose warnings, precautions or contraindications which could significantly limit the potential market for the product.", "type": 1, "words": ["<tag1>", "We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "MIRCERA", "product.", "<tag2>", "Additionally,", "the", "approved", "labeling", "may", "narrowly", "limit", "the", "conditions", "of", "use", "of", "the", "product,", "including", "the", "intended", "uses,", "or", "impose", "warnings,", "precautions", "or", "contraindications", "which", "could", "significantly", "limit", "the", "potential", "market", "for", "the", "product.", "<tag3>"], "wordsA": ["We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "MIRCERA", "product."], "wordsB": ["Additionally,", "the", "approved", "labeling", "may", "narrowly", "limit", "the", "conditions", "of", "use", "of", "the", "product,", "including", "the", "intended", "uses,", "or", "impose", "warnings,", "precautions", "or", "contraindications", "which", "could", "significantly", "limit", "the", "potential", "market", "for", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p158_s1", "idA": "906709_14_item1_p15_s3", "sentA": "The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in, this Annual Report.", "sentB": "There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternative technology.", "type": 1, "words": ["<tag1>", "The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report.", "<tag2>", "There", "can", "be", "no", "assurance", "that", "we", "can", "obtain", "a", "license", "to", "any", "technology", "that", "we", "determine", "we", "need", "on", "reasonable", "terms,", "if", "at", "all,", "or", "that", "we", "could", "develop", "or", "otherwise", "obtain", "alternative", "technology.", "<tag3>"], "wordsA": ["The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report."], "wordsB": ["There", "can", "be", "no", "assurance", "that", "we", "can", "obtain", "a", "license", "to", "any", "technology", "that", "we", "determine", "we", "need", "on", "reasonable", "terms,", "if", "at", "all,", "or", "that", "we", "could", "develop", "or", "otherwise", "obtain", "alternative", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p130_s0", "idA": "906709_14_item1_p17_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body.", "sentB": "On February 23, 2013, Affymax and Takeda announced a voluntary recall of all lots of OMONTYS drug product to the user level as a result of new post-marketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal.", "type": 1, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body.", "<tag2>", "On", "February", "23,", "2013,", "Affymax", "and", "Takeda", "announced", "a", "voluntary", "recall", "of", "all", "lots", "of", "OMONTYS", "drug", "product", "to", "the", "user", "level", "as", "a", "result", "of", "new", "post-marketing", "reports", "regarding", "serious", "hypersensitivity", "reactions,", "including", "anaphylaxis,", "which", "can", "be", "life-threatening", "or", "fatal.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body."], "wordsB": ["On", "February", "23,", "2013,", "Affymax", "and", "Takeda", "announced", "a", "voluntary", "recall", "of", "all", "lots", "of", "OMONTYS", "drug", "product", "to", "the", "user", "level", "as", "a", "result", "of", "new", "post-marketing", "reports", "regarding", "serious", "hypersensitivity", "reactions,", "including", "anaphylaxis,", "which", "can", "be", "life-threatening", "or", "fatal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s3", "idA": "906709_14_item1_p18_s0", "sentA": "With our expertise and proprietary technology in PEGylation, we have created the next generation of PEGylation technology.", "sentB": "Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to, or disclose, our trade secrets.", "type": 1, "words": ["<tag1>", "With", "our", "expertise", "and", "proprietary", "technology", "in", "PEGylation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology.", "<tag2>", "Others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to,", "or", "disclose,", "our", "trade", "secrets.", "<tag3>"], "wordsA": ["With", "our", "expertise", "and", "proprietary", "technology", "in", "PEGylation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology."], "wordsB": ["Others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to,", "or", "disclose,", "our", "trade", "secrets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p152_s6", "idA": "906709_14_item1_p23_s3", "sentA": "Based on our knowledge of the technology and biologics, our scientists have designed novel hydrolyzable linkers that in many cases can be used to optimize bioactivity.", "sentB": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "type": 1, "words": ["<tag1>", "Based", "on", "our", "knowledge", "of", "the", "technology", "and", "biologics,", "our", "scientists", "have", "designed", "novel", "hydrolyzable", "linkers", "that", "in", "many", "cases", "can", "be", "used", "to", "optimize", "bioactivity.", "<tag2>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag3>"], "wordsA": ["Based", "on", "our", "knowledge", "of", "the", "technology", "and", "biologics,", "our", "scientists", "have", "designed", "novel", "hydrolyzable", "linkers", "that", "in", "many", "cases", "can", "be", "used", "to", "optimize", "bioactivity."], "wordsB": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s2", "idA": "906709_14_item1_p23_s4", "sentA": "Through rational drug design, a protein or peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "sentB": "No assurance can be given that we can meaningfully protect our trade secrets.", "type": 1, "words": ["<tag1>", "Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag2>", "No", "assurance", "can", "be", "given", "that", "we", "can", "meaningfully", "protect", "our", "trade", "secrets.", "<tag3>"], "wordsA": ["Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "wordsB": ["No", "assurance", "can", "be", "given", "that", "we", "can", "meaningfully", "protect", "our", "trade", "secrets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p145_s0", "idA": "906709_14_item1_p26_s2", "sentA": "A key component of our development strategy is to potentially reduce the risks and time associated with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic targets and drugs directed to those targets.", "sentB": "Medical devices are classified into one of three classes Class I, Class II, or Class III depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness.", "type": 1, "words": ["<tag1>", "A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets.", "<tag2>", "Medical", "devices", "are", "classified", "into", "one", "of", "three", "classes", "Class", "I,", "Class", "II,", "or", "Class", "III", "depending", "on", "the", "degree", "of", "risk", "associated", "with", "each", "medical", "device", "and", "the", "extent", "of", "control", "needed", "to", "ensure", "safety", "and", "effectiveness.", "<tag3>"], "wordsA": ["A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets."], "wordsB": ["Medical", "devices", "are", "classified", "into", "one", "of", "three", "classes", "Class", "I,", "Class", "II,", "or", "Class", "III", "depending", "on", "the", "degree", "of", "risk", "associated", "with", "each", "medical", "device", "and", "the", "extent", "of", "control", "needed", "to", "ensure", "safety", "and", "effectiveness."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p78_s1", "idA": "906709_14_item1_p26_s2", "sentA": "A key component of our development strategy is to potentially reduce the risks and time associated with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic targets and drugs directed to those targets.", "sentB": "However, opioids cause significant problems for physicians and patients because of their serious side effects such as respiratory depression and sedation, as well as the risks they pose for addiction, abuse, misuse, and diversion.", "type": 1, "words": ["<tag1>", "A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets.", "<tag2>", "However,", "opioids", "cause", "significant", "problems", "for", "physicians", "and", "patients", "because", "of", "their", "serious", "side", "effects", "such", "as", "respiratory", "depression", "and", "sedation,", "as", "well", "as", "the", "risks", "they", "pose", "for", "addiction,", "abuse,", "misuse,", "and", "diversion.", "<tag3>"], "wordsA": ["A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets."], "wordsB": ["However,", "opioids", "cause", "significant", "problems", "for", "physicians", "and", "patients", "because", "of", "their", "serious", "side", "effects", "such", "as", "respiratory", "depression", "and", "sedation,", "as", "well", "as", "the", "risks", "they", "pose", "for", "addiction,", "abuse,", "misuse,", "and", "diversion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s0", "idA": "906709_14_item1_p28_s2", "sentA": "When we determine to seek a partner, our strategy is to enter into collaborations with leading pharmaceutical and biotechnology companies to fund further clinical development, manage the global regulatory filing process, and market and sell drugs in one or more geographies.", "sentB": "The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues.", "type": 1, "words": ["<tag1>", "When", "we", "determine", "to", "seek", "a", "partner,", "our", "strategy", "is", "to", "enter", "into", "collaborations", "with", "leading", "pharmaceutical", "and", "biotechnology", "companies", "to", "fund", "further", "clinical", "development,", "manage", "the", "global", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies.", "<tag2>", "The", "patent", "positions", "of", "pharmaceutical", "and", "biotechnology", "companies,", "such", "as", "ours,", "are", "uncertain", "and", "involve", "complex", "legal", "and", "factual", "issues.", "<tag3>"], "wordsA": ["When", "we", "determine", "to", "seek", "a", "partner,", "our", "strategy", "is", "to", "enter", "into", "collaborations", "with", "leading", "pharmaceutical", "and", "biotechnology", "companies", "to", "fund", "further", "clinical", "development,", "manage", "the", "global", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies."], "wordsB": ["The", "patent", "positions", "of", "pharmaceutical", "and", "biotechnology", "companies,", "such", "as", "ours,", "are", "uncertain", "and", "involve", "complex", "legal", "and", "factual", "issues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p148_s1", "idA": "906709_14_item1_p33_s1", "sentA": "As part of that transaction, we retained an exclusive license to this technology for the development and commercialization of this drug candidate originally developed by us.", "sentB": "The company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years.", "type": 1, "words": ["<tag1>", "As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us.", "<tag2>", "The", "company", "that", "obtains", "the", "first", "FDA", "approval", "for", "a", "designated", "orphan", "drug", "for", "a", "rare", "disease", "receives", "marketing", "exclusivity", "for", "use", "of", "that", "drug", "for", "the", "designated", "condition", "for", "a", "period", "of", "seven", "years.", "<tag3>"], "wordsA": ["As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us."], "wordsB": ["The", "company", "that", "obtains", "the", "first", "FDA", "approval", "for", "a", "designated", "orphan", "drug", "for", "a", "rare", "disease", "receives", "marketing", "exclusivity", "for", "use", "of", "that", "drug", "for", "the", "designated", "condition", "for", "a", "period", "of", "seven", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s5", "idA": "906709_14_item1_p33_s1", "sentA": "As part of that transaction, we retained an exclusive license to this technology for the development and commercialization of this drug candidate originally developed by us.", "sentB": "Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products encompassed by our patent.", "type": 1, "words": ["<tag1>", "As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us.", "<tag2>", "Even", "if", "a", "patent", "is", "issued", "and", "enforceable,", "because", "development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays,", "patents", "may", "expire", "early", "and", "provide", "only", "a", "short", "period", "of", "protection,", "if", "any,", "following", "the", "commercialization", "of", "products", "encompassed", "by", "our", "patent.", "<tag3>"], "wordsA": ["As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us."], "wordsB": ["Even", "if", "a", "patent", "is", "issued", "and", "enforceable,", "because", "development", "and", "commercialization", "of", "pharmaceutical", "products", "can", "be", "subject", "to", "substantial", "delays,", "patents", "may", "expire", "early", "and", "provide", "only", "a", "short", "period", "of", "protection,", "if", "any,", "following", "the", "commercialization", "of", "products", "encompassed", "by", "our", "patent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s5", "idA": "906709_14_item1_p35_s2", "sentA": "These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products.", "sentB": "In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs.", "type": 1, "words": ["<tag1>", "These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products.", "<tag2>", "In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs.", "<tag3>"], "wordsA": ["These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products."], "wordsB": ["In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p151_s0", "idA": "906709_14_item1_p36_s0", "sentA": "(1) Status definitions are: Approved regulatory approval to market and sell product obtained in one or more of the U.S., E.U. or other countries.", "sentB": "In the U.S., the FDA may grant Fast Track or Breakthrough designation to a product candidate, which allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.", "type": 1, "words": ["<tag1>", "(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries.", "<tag2>", "In", "the", "U.S.,", "the", "FDA", "may", "grant", "Fast", "Track", "or", "Breakthrough", "designation", "to", "a", "product", "candidate,", "which", "allows", "the", "FDA", "to", "expedite", "the", "review", "of", "new", "drugs", "that", "are", "intended", "for", "serious", "or", "life-threatening", "conditions", "and", "that", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs.", "<tag3>"], "wordsA": ["(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries."], "wordsB": ["In", "the", "U.S.,", "the", "FDA", "may", "grant", "Fast", "Track", "or", "Breakthrough", "designation", "to", "a", "product", "candidate,", "which", "allows", "the", "FDA", "to", "expedite", "the", "review", "of", "new", "drugs", "that", "are", "intended", "for", "serious", "or", "life-threatening", "conditions", "and", "that", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s4", "idA": "906709_14_item1_p42_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "Further, our competitors may be able to circumvent and otherwise design around our patents.", "type": 1, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "Further,", "our", "competitors", "may", "be", "able", "to", "circumvent", "and", "otherwise", "design", "around", "our", "patents.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["Further,", "our", "competitors", "may", "be", "able", "to", "circumvent", "and", "otherwise", "design", "around", "our", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p83_s2", "idA": "906709_14_item1_p47_s4", "sentA": "The studies enrolled approximately 630 patients each.", "sentB": "The studies also compared NKTR-214 single agent and combination dosing regimens with single agent and combination dosing regimens of anti-PD-1 and anti-CTLA-4 therapies.", "type": 1, "words": ["<tag1>", "The", "studies", "enrolled", "approximately", "630", "patients", "each.", "<tag2>", "The", "studies", "also", "compared", "NKTR-214", "single", "agent", "and", "combination", "dosing", "regimens", "with", "single", "agent", "and", "combination", "dosing", "regimens", "of", "anti-PD-1", "and", "anti-CTLA-4", "therapies.", "<tag3>"], "wordsA": ["The", "studies", "enrolled", "approximately", "630", "patients", "each."], "wordsB": ["The", "studies", "also", "compared", "NKTR-214", "single", "agent", "and", "combination", "dosing", "regimens", "with", "single", "agent", "and", "combination", "dosing", "regimens", "of", "anti-PD-1", "and", "anti-CTLA-4", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p138_s0", "idA": "906709_14_item1_p49_s0", "sentA": "On November 12, 2012, AstraZeneca reported top-line efficacy and safety results from KODIAC-04, -05 and -07.", "sentB": "identify possible adverse effects and safety risks.", "type": 1, "words": ["<tag1>", "On", "November", "12,", "2012,", "AstraZeneca", "reported", "top-line", "efficacy", "and", "safety", "results", "from", "KODIAC-04,", "-05", "and", "-07.", "<tag2>", "identify", "possible", "adverse", "effects", "and", "safety", "risks.", "<tag3>"], "wordsA": ["On", "November", "12,", "2012,", "AstraZeneca", "reported", "top-line", "efficacy", "and", "safety", "results", "from", "KODIAC-04,", "-05", "and", "-07."], "wordsB": ["identify", "possible", "adverse", "effects", "and", "safety", "risks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s9", "idA": "906709_14_item1_p4_s2", "sentA": "AstraZeneca has also filed marketing applications for naloxegol with health authorities in the European Union (E.U.) and Canada.", "sentB": "The EC s approval applies to all 28 European Union member countries plus Iceland and Norway.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "also", "filed", "marketing", "applications", "for", "naloxegol", "with", "health", "authorities", "in", "the", "European", "Union", "(E.U.)", "and", "Canada.", "<tag2>", "The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "also", "filed", "marketing", "applications", "for", "naloxegol", "with", "health", "authorities", "in", "the", "European", "Union", "(E.U.)", "and", "Canada."], "wordsB": ["The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p50_s2", "idA": "906709_14_item1_p4_s2", "sentA": "AstraZeneca has also filed marketing applications for naloxegol with health authorities in the European Union (E.U.) and Canada.", "sentB": "The EC s approval applies to all 28 European Union member countries plus Iceland and Norway.", "type": 1, "words": ["<tag1>", "AstraZeneca", "has", "also", "filed", "marketing", "applications", "for", "naloxegol", "with", "health", "authorities", "in", "the", "European", "Union", "(E.U.)", "and", "Canada.", "<tag2>", "The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "also", "filed", "marketing", "applications", "for", "naloxegol", "with", "health", "authorities", "in", "the", "European", "Union", "(E.U.)", "and", "Canada."], "wordsB": ["The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s1", "idA": "906709_14_item1_p4_s4", "sentA": "The FDA advisory committee meeting, which had been originally scheduled for March 10-11, 2014, is being rescheduled due to scheduling conflicts.", "sentB": "The FDA may deny approval if applicable regulatory criteria are not satisfied or may require additional clinical or pharmaceutical testing or requirements.", "type": 1, "words": ["<tag1>", "The", "FDA", "advisory", "committee", "meeting,", "which", "had", "been", "originally", "scheduled", "for", "March", "10-11,", "2014,", "is", "being", "rescheduled", "due", "to", "scheduling", "conflicts.", "<tag2>", "The", "FDA", "may", "deny", "approval", "if", "applicable", "regulatory", "criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "pharmaceutical", "testing", "or", "requirements.", "<tag3>"], "wordsA": ["The", "FDA", "advisory", "committee", "meeting,", "which", "had", "been", "originally", "scheduled", "for", "March", "10-11,", "2014,", "is", "being", "rescheduled", "due", "to", "scheduling", "conflicts."], "wordsB": ["The", "FDA", "may", "deny", "approval", "if", "applicable", "regulatory", "criteria", "are", "not", "satisfied", "or", "may", "require", "additional", "clinical", "or", "pharmaceutical", "testing", "or", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s5", "idA": "906709_14_item1_p51_s2", "sentA": "In addition, there were a low number of major adverse cardiovascular events, as adjudicated by an independent external committee, and there was no imbalance of these events across naloxegol and UC arms.", "sentB": "The study design also includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring committee.", "type": 1, "words": ["<tag1>", "In", "addition,", "there", "were", "a", "low", "number", "of", "major", "adverse", "cardiovascular", "events,", "as", "adjudicated", "by", "an", "independent", "external", "committee,", "and", "there", "was", "no", "imbalance", "of", "these", "events", "across", "naloxegol", "and", "UC", "arms.", "<tag2>", "The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee.", "<tag3>"], "wordsA": ["In", "addition,", "there", "were", "a", "low", "number", "of", "major", "adverse", "cardiovascular", "events,", "as", "adjudicated", "by", "an", "independent", "external", "committee,", "and", "there", "was", "no", "imbalance", "of", "these", "events", "across", "naloxegol", "and", "UC", "arms."], "wordsB": ["The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s17", "idA": "906709_14_item1_p51_s2", "sentA": "In addition, there were a low number of major adverse cardiovascular events, as adjudicated by an independent external committee, and there was no imbalance of these events across naloxegol and UC arms.", "sentB": "The study design also includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring committee.", "type": 1, "words": ["<tag1>", "In", "addition,", "there", "were", "a", "low", "number", "of", "major", "adverse", "cardiovascular", "events,", "as", "adjudicated", "by", "an", "independent", "external", "committee,", "and", "there", "was", "no", "imbalance", "of", "these", "events", "across", "naloxegol", "and", "UC", "arms.", "<tag2>", "The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee.", "<tag3>"], "wordsA": ["In", "addition,", "there", "were", "a", "low", "number", "of", "major", "adverse", "cardiovascular", "events,", "as", "adjudicated", "by", "an", "independent", "external", "committee,", "and", "there", "was", "no", "imbalance", "of", "these", "events", "across", "naloxegol", "and", "UC", "arms."], "wordsB": ["The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s1", "idA": "906709_14_item1_p53_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "There can be no assurance that patents that have issued will be held valid and enforceable in a court of law.", "type": 1, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p157_s1", "idA": "906709_14_item1_p53_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "We cannot predict with any certainty which, if any, of these rights will be considered relevant to our technology by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties.", "type": 1, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "We", "cannot", "predict", "with", "any", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "be", "considered", "relevant", "to", "our", "technology", "by", "authorities", "in", "the", "various", "jurisdictions", "where", "such", "rights", "exist,", "nor", "can", "we", "predict", "with", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "or", "may", "be", "asserted", "against", "us", "by", "third", "parties.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["We", "cannot", "predict", "with", "any", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "be", "considered", "relevant", "to", "our", "technology", "by", "authorities", "in", "the", "various", "jurisdictions", "where", "such", "rights", "exist,", "nor", "can", "we", "predict", "with", "certainty", "which,", "if", "any,", "of", "these", "rights", "will", "or", "may", "be", "asserted", "against", "us", "by", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p139_s0", "idA": "906709_14_item1_p56_s0", "sentA": "If the FDA does not require a future clinical trial or other significant studies to assess the cardiovascular safety (CV Safety Study) of naloxegol prior to an approval decision, AstraZeneca is required to pay us a $35.0 million milestone.", "sentB": "The FDA, the clinical trial sponsor, the investigators or the IRB may suspend clinical trials at any time if any one of them believes that study participants are being subjected to an unacceptable health risk.", "type": 1, "words": ["<tag1>", "If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(CV", "Safety", "Study)", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "required", "to", "pay", "us", "a", "$35.0", "million", "milestone.", "<tag2>", "The", "FDA,", "the", "clinical", "trial", "sponsor,", "the", "investigators", "or", "the", "IRB", "may", "suspend", "clinical", "trials", "at", "any", "time", "if", "any", "one", "of", "them", "believes", "that", "study", "participants", "are", "being", "subjected", "to", "an", "unacceptable", "health", "risk.", "<tag3>"], "wordsA": ["If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(CV", "Safety", "Study)", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "required", "to", "pay", "us", "a", "$35.0", "million", "milestone."], "wordsB": ["The", "FDA,", "the", "clinical", "trial", "sponsor,", "the", "investigators", "or", "the", "IRB", "may", "suspend", "clinical", "trials", "at", "any", "time", "if", "any", "one", "of", "them", "believes", "that", "study", "participants", "are", "being", "subjected", "to", "an", "unacceptable", "health", "risk."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p145_s2", "idA": "906709_14_item1_p58_s0", "sentA": "We are developing etirinotecan pegol (also known as NKTR-102), a next generation topoisomerase I (topo I) inhibitor which was designed using our PEGylation technology.", "sentB": "This process is known as 510(k) clearance.", "type": 1, "words": ["<tag1>", "We", "are", "developing", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology.", "<tag2>", "This", "process", "is", "known", "as", "510(k)", "clearance.", "<tag3>"], "wordsA": ["We", "are", "developing", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology."], "wordsB": ["This", "process", "is", "known", "as", "510(k)", "clearance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p83_s4", "idA": "906709_14_item1_p60_s0", "sentA": "In preclinical models, etirinotecan pegol achieved a 300-fold increase in tumor concentration as compared to irinotecan.", "sentB": "In the aggressive EMT6 breast tumor model where activity with single-agent anti-PD-1 therapy or single-agent anti-CTLA-4 therapy was not observed, pre-dosing of NKTR-214 followed by anti-PD-1 demonstrated better efficacy (tumor growth inhibition of 74%) as compared to a concomitant dosing regimen of anti-CTLA-4 and anti-PD-1 therapies (tumor growth inhibition of 23%).", "type": 1, "words": ["<tag1>", "In", "preclinical", "models,", "etirinotecan", "pegol", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan.", "<tag2>", "In", "the", "aggressive", "EMT6", "breast", "tumor", "model", "where", "activity", "with", "single-agent", "anti-PD-1", "therapy", "or", "single-agent", "anti-CTLA-4", "therapy", "was", "not", "observed,", "pre-dosing", "of", "NKTR-214", "followed", "by", "anti-PD-1", "demonstrated", "better", "efficacy", "(tumor", "growth", "inhibition", "of", "74%)", "as", "compared", "to", "a", "concomitant", "dosing", "regimen", "of", "anti-CTLA-4", "and", "anti-PD-1", "therapies", "(tumor", "growth", "inhibition", "of", "23%).", "<tag3>"], "wordsA": ["In", "preclinical", "models,", "etirinotecan", "pegol", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan."], "wordsB": ["In", "the", "aggressive", "EMT6", "breast", "tumor", "model", "where", "activity", "with", "single-agent", "anti-PD-1", "therapy", "or", "single-agent", "anti-CTLA-4", "therapy", "was", "not", "observed,", "pre-dosing", "of", "NKTR-214", "followed", "by", "anti-PD-1", "demonstrated", "better", "efficacy", "(tumor", "growth", "inhibition", "of", "74%)", "as", "compared", "to", "a", "concomitant", "dosing", "regimen", "of", "anti-CTLA-4", "and", "anti-PD-1", "therapies", "(tumor", "growth", "inhibition", "of", "23%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p83_s3", "idA": "906709_14_item1_p68_s0", "sentA": "Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.", "sentB": "In both the breast and colon tumor models, the combination dosing regimens of NKTR-214 therapy with anti-PD-1 therapy or anti-CTLA-4 therapy resulted in significant tumor growth inhibition.", "type": 1, "words": ["<tag1>", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body.", "<tag2>", "In", "both", "the", "breast", "and", "colon", "tumor", "models,", "the", "combination", "dosing", "regimens", "of", "NKTR-214", "therapy", "with", "anti-PD-1", "therapy", "or", "anti-CTLA-4", "therapy", "resulted", "in", "significant", "tumor", "growth", "inhibition.", "<tag3>"], "wordsA": ["Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body."], "wordsB": ["In", "both", "the", "breast", "and", "colon", "tumor", "models,", "the", "combination", "dosing", "regimens", "of", "NKTR-214", "therapy", "with", "anti-PD-1", "therapy", "or", "anti-CTLA-4", "therapy", "resulted", "in", "significant", "tumor", "growth", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p134_s3", "idA": "906709_14_item1_p77_s0", "sentA": "In addition to the clinical studies being conducted by us, there are also three investigator-initiated Phase 2 studies being conducted for etirinotecan pegol.", "sentB": "Preclinical safety tests must be conducted by laboratories that comply with FDA good laboratory practices (GLP) regulations.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "studies", "being", "conducted", "by", "us,", "there", "are", "also", "three", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol.", "<tag2>", "Preclinical", "safety", "tests", "must", "be", "conducted", "by", "laboratories", "that", "comply", "with", "FDA", "good", "laboratory", "practices", "(GLP)", "regulations.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "studies", "being", "conducted", "by", "us,", "there", "are", "also", "three", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol."], "wordsB": ["Preclinical", "safety", "tests", "must", "be", "conducted", "by", "laboratories", "that", "comply", "with", "FDA", "good", "laboratory", "practices", "(GLP)", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p145_s5", "idA": "906709_14_item1_p79_s2", "sentA": "We are responsible for all future development, manufacturing and supply of the nebulizer device for clinical and commercial use.", "sentB": "To date, our partners have generally been responsible for clinical and regulatory approval procedures, but we may participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for the inhaler device, PEGylation materials or drug.", "type": 1, "words": ["<tag1>", "We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use.", "<tag2>", "To", "date,", "our", "partners", "have", "generally", "been", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug.", "<tag3>"], "wordsA": ["We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use."], "wordsB": ["To", "date,", "our", "partners", "have", "generally", "been", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p147_s1", "idA": "906709_14_item1_p80_s2", "sentA": "The agreement expires in relation to a particular country upon the expiration of all royalty and payment obligations between the parties related to such country.", "sentB": "Such requirements vary widely from country to country.", "type": 1, "words": ["<tag1>", "The", "agreement", "expires", "in", "relation", "to", "a", "particular", "country", "upon", "the", "expiration", "of", "all", "royalty", "and", "payment", "obligations", "between", "the", "parties", "related", "to", "such", "country.", "<tag2>", "Such", "requirements", "vary", "widely", "from", "country", "to", "country.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "in", "relation", "to", "a", "particular", "country", "upon", "the", "expiration", "of", "all", "royalty", "and", "payment", "obligations", "between", "the", "parties", "related", "to", "such", "country."], "wordsB": ["Such", "requirements", "vary", "widely", "from", "country", "to", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p148_s2", "idA": "906709_14_item1_p80_s4", "sentA": "In addition, the agreement may also be terminated by either party for certain product safety concerns, the product s failure to meet certain minimum commercial profile requirements or uncured material breaches by the other party.", "sentB": "In addition, the Orphan Drug Act provides for protocol assistance, tax credits, research grants, and exclusions from user fees for sponsors of orphan products.", "type": 1, "words": ["<tag1>", "In", "addition,", "the", "agreement", "may", "also", "be", "terminated", "by", "either", "party", "for", "certain", "product", "safety", "concerns,", "the", "product", "s", "failure", "to", "meet", "certain", "minimum", "commercial", "profile", "requirements", "or", "uncured", "material", "breaches", "by", "the", "other", "party.", "<tag2>", "In", "addition,", "the", "Orphan", "Drug", "Act", "provides", "for", "protocol", "assistance,", "tax", "credits,", "research", "grants,", "and", "exclusions", "from", "user", "fees", "for", "sponsors", "of", "orphan", "products.", "<tag3>"], "wordsA": ["In", "addition,", "the", "agreement", "may", "also", "be", "terminated", "by", "either", "party", "for", "certain", "product", "safety", "concerns,", "the", "product", "s", "failure", "to", "meet", "certain", "minimum", "commercial", "profile", "requirements", "or", "uncured", "material", "breaches", "by", "the", "other", "party."], "wordsB": ["In", "addition,", "the", "Orphan", "Drug", "Act", "provides", "for", "protocol", "assistance,", "tax", "credits,", "research", "grants,", "and", "exclusions", "from", "user", "fees", "for", "sponsors", "of", "orphan", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p101_s1", "idA": "906709_14_item1_p81_s0", "sentA": "Gram-negative pneumonias are often the result of complications of other patient conditions or surgeries.", "sentB": "Halozyme s FDA-approved, HYLENEX recombinant human hyaluronidase, rHuPH20, is administered subcutaneously and temporarily and reversibly degrades HA to facilitate the absorption and dispersion of other injected drugs or fluids and for subcutaneous fluid administration.", "type": 1, "words": ["<tag1>", "Gram-negative", "pneumonias", "are", "often", "the", "result", "of", "complications", "of", "other", "patient", "conditions", "or", "surgeries.", "<tag2>", "Halozyme", "s", "FDA-approved,", "HYLENEX", "recombinant", "human", "hyaluronidase,", "rHuPH20,", "is", "administered", "subcutaneously", "and", "temporarily", "and", "reversibly", "degrades", "HA", "to", "facilitate", "the", "absorption", "and", "dispersion", "of", "other", "injected", "drugs", "or", "fluids", "and", "for", "subcutaneous", "fluid", "administration.", "<tag3>"], "wordsA": ["Gram-negative", "pneumonias", "are", "often", "the", "result", "of", "complications", "of", "other", "patient", "conditions", "or", "surgeries."], "wordsB": ["Halozyme", "s", "FDA-approved,", "HYLENEX", "recombinant", "human", "hyaluronidase,", "rHuPH20,", "is", "administered", "subcutaneously", "and", "temporarily", "and", "reversibly", "degrades", "HA", "to", "facilitate", "the", "absorption", "and", "dispersion", "of", "other", "injected", "drugs", "or", "fluids", "and", "for", "subcutaneous", "fluid", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p143_s0", "idA": "906709_14_item1_p83_s0", "sentA": "The aerosol generator within the nebulizer for Amikacin Inhale delivers a fine aerosol of the antimicrobial agent directly to the site of infection in the lungs.", "sentB": "The FDA will make a determination as to the most appropriate center and division within the agency that will assume primary responsibility for the review of the applicable applications, which would consist of an IND and an NDA or BLA where CDER or CBER are determined to have primary jurisdiction or an investigational device exemption application and PMA or 510(k) where the Center for Devices and Radiological Health (CDRH) is determined to have primary jurisdiction.", "type": 1, "words": ["<tag1>", "The", "aerosol", "generator", "within", "the", "nebulizer", "for", "Amikacin", "Inhale", "delivers", "a", "fine", "aerosol", "of", "the", "antimicrobial", "agent", "directly", "to", "the", "site", "of", "infection", "in", "the", "lungs.", "<tag2>", "The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBER", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction.", "<tag3>"], "wordsA": ["The", "aerosol", "generator", "within", "the", "nebulizer", "for", "Amikacin", "Inhale", "delivers", "a", "fine", "aerosol", "of", "the", "antimicrobial", "agent", "directly", "to", "the", "site", "of", "infection", "in", "the", "lungs."], "wordsB": ["The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBER", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s7", "idA": "906709_14_item1_p85_s1", "sentA": "NKTR-181 is designed with the objective to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies.", "sentB": "After approval, there are ongoing reporting obligations concerning adverse reactions associated with the product, including expedited reports for serious and unexpected adverse events.", "type": 1, "words": ["<tag1>", "NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag2>", "After", "approval,", "there", "are", "ongoing", "reporting", "obligations", "concerning", "adverse", "reactions", "associated", "with", "the", "product,", "including", "expedited", "reports", "for", "serious", "and", "unexpected", "adverse", "events.", "<tag3>"], "wordsA": ["NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "wordsB": ["After", "approval,", "there", "are", "ongoing", "reporting", "obligations", "concerning", "adverse", "reactions", "associated", "with", "the", "product,", "including", "expedited", "reports", "for", "serious", "and", "unexpected", "adverse", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p151_s1", "idA": "906709_14_item1_p87_s0", "sentA": "In May 2012, the FDA granted Fast Track designation for the NKTR-181 development program.", "sentB": "Important features of Fast Track or Breakthrough designation include a potentially reduced clinical program and close, early communication between the FDA and the sponsor company to improve the efficiency of product development.", "type": 1, "words": ["<tag1>", "In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program.", "<tag2>", "Important", "features", "of", "Fast", "Track", "or", "Breakthrough", "designation", "include", "a", "potentially", "reduced", "clinical", "program", "and", "close,", "early", "communication", "between", "the", "FDA", "and", "the", "sponsor", "company", "to", "improve", "the", "efficiency", "of", "product", "development.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program."], "wordsB": ["Important", "features", "of", "Fast", "Track", "or", "Breakthrough", "designation", "include", "a", "potentially", "reduced", "clinical", "program", "and", "close,", "early", "communication", "between", "the", "FDA", "and", "the", "sponsor", "company", "to", "improve", "the", "efficiency", "of", "product", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s2", "idA": "906709_14_item1_p89_s1", "sentA": "Pupillometry data from the study demonstrated that NKTR-181 s centrally-mediated opioid effects are dose-dependent and indicates that the molecule enters the brain slowly, which has the potential to reduce the euphoria and other CNS side effects that are associated with current opioids.", "sentB": "Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.", "type": 1, "words": ["<tag1>", "Pupillometry", "data", "from", "the", "study", "demonstrated", "that", "NKTR-181", "s", "centrally-mediated", "opioid", "effects", "are", "dose-dependent", "and", "indicates", "that", "the", "molecule", "enters", "the", "brain", "slowly,", "which", "has", "the", "potential", "to", "reduce", "the", "euphoria", "and", "other", "CNS", "side", "effects", "that", "are", "associated", "with", "current", "opioids.", "<tag2>", "Even", "for", "patents", "that", "are", "held", "valid", "and", "enforceable,", "the", "legal", "process", "associated", "with", "obtaining", "such", "a", "judgment", "is", "time", "consuming", "and", "costly.", "<tag3>"], "wordsA": ["Pupillometry", "data", "from", "the", "study", "demonstrated", "that", "NKTR-181", "s", "centrally-mediated", "opioid", "effects", "are", "dose-dependent", "and", "indicates", "that", "the", "molecule", "enters", "the", "brain", "slowly,", "which", "has", "the", "potential", "to", "reduce", "the", "euphoria", "and", "other", "CNS", "side", "effects", "that", "are", "associated", "with", "current", "opioids."], "wordsB": ["Even", "for", "patents", "that", "are", "held", "valid", "and", "enforceable,", "the", "legal", "process", "associated", "with", "obtaining", "such", "a", "judgment", "is", "time", "consuming", "and", "costly."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s6", "idA": "906709_14_item1_p92_s0", "sentA": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 study design.", "sentB": "The FDA may require additional post-marketing clinical testing and pharmacovigilance programs to monitor the effect of drug products that have been commercialized and has the power to prevent or limit future marketing of the product based on the results of such programs.", "type": 1, "words": ["<tag1>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design.", "<tag2>", "The", "FDA", "may", "require", "additional", "post-marketing", "clinical", "testing", "and", "pharmacovigilance", "programs", "to", "monitor", "the", "effect", "of", "drug", "products", "that", "have", "been", "commercialized", "and", "has", "the", "power", "to", "prevent", "or", "limit", "future", "marketing", "of", "the", "product", "based", "on", "the", "results", "of", "such", "programs.", "<tag3>"], "wordsA": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design."], "wordsB": ["The", "FDA", "may", "require", "additional", "post-marketing", "clinical", "testing", "and", "pharmacovigilance", "programs", "to", "monitor", "the", "effect", "of", "drug", "products", "that", "have", "been", "commercialized", "and", "has", "the", "power", "to", "prevent", "or", "limit", "future", "marketing", "of", "the", "product", "based", "on", "the", "results", "of", "such", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p130_s2", "idA": "906709_14_item1_p94_s2", "sentA": "The oxycodone liking score was significantly different from placebo as early as 15 minutes after dosing and peaked at 60 minutes.", "sentB": "The reported serious hypersensitivity reactions have occurred within 30 minutes after such administration of OMONTYS .", "type": 1, "words": ["<tag1>", "The", "oxycodone", "liking", "score", "was", "significantly", "different", "from", "placebo", "as", "early", "as", "15", "minutes", "after", "dosing", "and", "peaked", "at", "60", "minutes.", "<tag2>", "The", "reported", "serious", "hypersensitivity", "reactions", "have", "occurred", "within", "30", "minutes", "after", "such", "administration", "of", "OMONTYS", ".", "<tag3>"], "wordsA": ["The", "oxycodone", "liking", "score", "was", "significantly", "different", "from", "placebo", "as", "early", "as", "15", "minutes", "after", "dosing", "and", "peaked", "at", "60", "minutes."], "wordsB": ["The", "reported", "serious", "hypersensitivity", "reactions", "have", "occurred", "within", "30", "minutes", "after", "such", "administration", "of", "OMONTYS", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p71_s4", "idA": "906709_14_item1_p99_s1", "sentA": "NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "sentB": "Antimicrobial drugs designed to treat serious and life-threatening infections, designated as QIDP, are eligible for fast-track designation, priority review by FDA and a five-year extension of market exclusivity.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag2>", "Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "designation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "wordsB": ["Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "designation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p95_s1", "idA": "906709_14_item1_p99_s1", "sentA": "NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "sentB": "Antimicrobial drugs designed to treat serious and life-threatening infections, designated as QIDP, are eligible for fast-track designation, priority review by FDA and a five-year extension of market exclusivity.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag2>", "Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "designation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "wordsB": ["Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "designation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p135_s5", "idA": "906709_14_item1_p9_s5", "sentA": "This lack of a placebo rebound in the maintenance phase of the trial caused the Phase 2 study to miss the primary endpoint, which was the average change in a patient s pain score from baseline to the end of the double-blind, randomized treatment period.", "sentB": "The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted.", "type": 1, "words": ["<tag1>", "This", "lack", "of", "a", "placebo", "rebound", "in", "the", "maintenance", "phase", "of", "the", "trial", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint,", "which", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period.", "<tag2>", "The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted.", "<tag3>"], "wordsA": ["This", "lack", "of", "a", "placebo", "rebound", "in", "the", "maintenance", "phase", "of", "the", "trial", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint,", "which", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period."], "wordsB": ["The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p179_s0", "idA": "906709_15_item1_p107_s0", "sentA": "SEMPRANA is a self-administered formulation of DHE using an inhaler device that is currently under review by the FDA.", "sentB": "From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex.", "type": 1, "words": ["<tag1>", "SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA.", "<tag2>", "From", "1991", "to", "2001,", "Mr.", "Robin", "was", "Corporate", "Vice", "President", "and", "General", "Manager", "at", "Berlex", "Laboratories,", "Inc.", "(Berlex),", "a", "pharmaceutical", "products", "company", "that", "is", "a", "subsidiary", "of", "Schering,", "AG,", "and", "from", "1987", "to", "1991", "he", "served", "as", "Vice", "President", "of", "Finance", "and", "Business", "Development", "and", "Chief", "Financial", "Officer", "of", "Berlex.", "<tag3>"], "wordsA": ["SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA."], "wordsB": ["From", "1991", "to", "2001,", "Mr.", "Robin", "was", "Corporate", "Vice", "President", "and", "General", "Manager", "at", "Berlex", "Laboratories,", "Inc.", "(Berlex),", "a", "pharmaceutical", "products", "company", "that", "is", "a", "subsidiary", "of", "Schering,", "AG,", "and", "from", "1987", "to", "1991", "he", "served", "as", "Vice", "President", "of", "Finance", "and", "Business", "Development", "and", "Chief", "Financial", "Officer", "of", "Berlex."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p185_s3", "idA": "906709_15_item1_p107_s4", "sentA": "In June 2014, Allergan announced that it had received a third complete response letter from the FDA related to specifications around content uniformity on the improved canister filling process and on standards for device actuation.", "sentB": "Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine and received a B.S. in Chemical Engineering from the University of Delaware.", "type": 1, "words": ["<tag1>", "In", "June", "2014,", "Allergan", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation.", "<tag2>", "Dr.", "Doberstein", "received", "his", "Ph.D.", "in", "Biochemistry,", "Cell", "and", "Molecular", "Biology", "from", "the", "Johns", "Hopkins", "University", "School", "of", "Medicine", "and", "received", "a", "B.S.", "in", "Chemical", "Engineering", "from", "the", "University", "of", "Delaware.", "<tag3>"], "wordsA": ["In", "June", "2014,", "Allergan", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation."], "wordsB": ["Dr.", "Doberstein", "received", "his", "Ph.D.", "in", "Biochemistry,", "Cell", "and", "Molecular", "Biology", "from", "the", "Johns", "Hopkins", "University", "School", "of", "Medicine", "and", "received", "a", "B.S.", "in", "Chemical", "Engineering", "from", "the", "University", "of", "Delaware."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p112_s3", "idA": "906709_15_item1_p107_s5", "sentA": "Allergan has responded to the FDA s latest complete response letter and has stated that it expects a response from the FDA on the NDA for SEMPRANA in the second half of 2015.", "sentB": "Exploratory analyses from the same study showed greater improvement in clinical measures of disease activity in the dapriolizumab pegol group versus placebo.", "type": 1, "words": ["<tag1>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "SEMPRANA", "in", "the", "second", "half", "of", "2015.", "<tag2>", "Exploratory", "analyses", "from", "the", "same", "study", "showed", "greater", "improvement", "in", "clinical", "measures", "of", "disease", "activity", "in", "the", "dapriolizumab", "pegol", "group", "versus", "placebo.", "<tag3>"], "wordsA": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "SEMPRANA", "in", "the", "second", "half", "of", "2015."], "wordsB": ["Exploratory", "analyses", "from", "the", "same", "study", "showed", "greater", "improvement", "in", "clinical", "measures", "of", "disease", "activity", "in", "the", "dapriolizumab", "pegol", "group", "versus", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p160_s1", "idA": "906709_15_item1_p107_s7", "sentA": "On March 1, 2013, Allergan, Inc. completed a merger and acquisition transaction with MAP pursuant to which MAP become a wholly-owned subsidiary of Allergan.", "sentB": "Inventory is produced and sales are made pursuant to customer purchase orders for delivery.", "type": 1, "words": ["<tag1>", "On", "March", "1,", "2013,", "Allergan,", "Inc.", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan.", "<tag2>", "Inventory", "is", "produced", "and", "sales", "are", "made", "pursuant", "to", "customer", "purchase", "orders", "for", "delivery.", "<tag3>"], "wordsA": ["On", "March", "1,", "2013,", "Allergan,", "Inc.", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan."], "wordsB": ["Inventory", "is", "produced", "and", "sales", "are", "made", "pursuant", "to", "customer", "purchase", "orders", "for", "delivery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s3", "idA": "906709_15_item1_p112_s1", "sentA": "Under the terms of the 2010 Agreement, we guarantee the manufacture and supply of our proprietary PEGylation materials (Polymer Materials) to Amgen in an existing manufacturing suite to be used exclusively for the manufacture of Polymer Materials for Amgen in our manufacturing facility in Huntsville, Alabama.", "sentB": "For the drug starting materials necessary for our proprietary drug candidate development, we have agreements for the supply of such drug components with drug manufacturers or suppliers that we believe have sufficient capacity to meet our demands.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "guarantee", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "(Polymer", "Materials)", "to", "Amgen", "in", "an", "existing", "manufacturing", "suite", "to", "be", "used", "exclusively", "for", "the", "manufacture", "of", "Polymer", "Materials", "for", "Amgen", "in", "our", "manufacturing", "facility", "in", "Huntsville,", "Alabama.", "<tag2>", "For", "the", "drug", "starting", "materials", "necessary", "for", "our", "proprietary", "drug", "candidate", "development,", "we", "have", "agreements", "for", "the", "supply", "of", "such", "drug", "components", "with", "drug", "manufacturers", "or", "suppliers", "that", "we", "believe", "have", "sufficient", "capacity", "to", "meet", "our", "demands.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "guarantee", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "(Polymer", "Materials)", "to", "Amgen", "in", "an", "existing", "manufacturing", "suite", "to", "be", "used", "exclusively", "for", "the", "manufacture", "of", "Polymer", "Materials", "for", "Amgen", "in", "our", "manufacturing", "facility", "in", "Huntsville,", "Alabama."], "wordsB": ["For", "the", "drug", "starting", "materials", "necessary", "for", "our", "proprietary", "drug", "candidate", "development,", "we", "have", "agreements", "for", "the", "supply", "of", "such", "drug", "components", "with", "drug", "manufacturers", "or", "suppliers", "that", "we", "believe", "have", "sufficient", "capacity", "to", "meet", "our", "demands."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s9", "idA": "906709_15_item1_p113_s4", "sentA": "The term of the 2010 Agreement runs through October 29, 2020.", "sentB": "Prior to that, Dr. Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute.", "type": 1, "words": ["<tag1>", "The", "term", "of", "the", "2010", "Agreement", "runs", "through", "October", "29,", "2020.", "<tag2>", "Prior", "to", "that,", "Dr.", "Gergel", "served", "as", "Vice", "President", "and", "Chief", "Medical", "Officer", "at", "Forest", "and", "Executive", "Vice", "President", "of", "the", "Forest", "Research", "Institute.", "<tag3>"], "wordsA": ["The", "term", "of", "the", "2010", "Agreement", "runs", "through", "October", "29,", "2020."], "wordsB": ["Prior", "to", "that,", "Dr.", "Gergel", "served", "as", "Vice", "President", "and", "Chief", "Medical", "Officer", "at", "Forest", "and", "Executive", "Vice", "President", "of", "the", "Forest", "Research", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s1", "idA": "906709_15_item1_p115_s2", "sentA": "In connection with Roche s exercise of the license extension option in December 2009, we received a payment of $31.0 million.", "sentB": "Mr. Nicholson joined the Company as Senior Vice President of Corporate Development and Business Operations in October 2007 and was appointed Senior Vice President and Chief Financial Officer in December 2007.", "type": 1, "words": ["<tag1>", "In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million.", "<tag2>", "Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007.", "<tag3>"], "wordsA": ["In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million."], "wordsB": ["Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s4", "idA": "906709_15_item1_p118_s1", "sentA": "PEG-Intron is a treatment for patients with Hepatitis C. Schering was acquired by, and became a wholly-owned subsidiary of, Merck Co., Inc.", "sentB": "From 2001 to September 2007, he concurrently served as President of Schering Berlin Insurance Co., and from February 2007 through September 2007, he also concurrently served as President of Bayer Pharma Chemicals and Schering Berlin Capital Corp.", "type": 1, "words": ["<tag1>", "PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc.", "<tag2>", "From", "2001", "to", "September", "2007,", "he", "concurrently", "served", "as", "President", "of", "Schering", "Berlin", "Insurance", "Co.,", "and", "from", "February", "2007", "through", "September", "2007,", "he", "also", "concurrently", "served", "as", "President", "of", "Bayer", "Pharma", "Chemicals", "and", "Schering", "Berlin", "Capital", "Corp.", "<tag3>"], "wordsA": ["PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc."], "wordsB": ["From", "2001", "to", "September", "2007,", "he", "concurrently", "served", "as", "President", "of", "Schering", "Berlin", "Insurance", "Co.,", "and", "from", "February", "2007", "through", "September", "2007,", "he", "also", "concurrently", "served", "as", "President", "of", "Bayer", "Pharma", "Chemicals", "and", "Schering", "Berlin", "Capital", "Corp."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s11", "idA": "906709_15_item1_p119_s0", "sentA": "Macugen , Agreement with Valeant Pharmaceuticals International, Inc.", "sentB": "Dr. Gergel is a member of the Board of Directors of Corium International, Inc., a commercial-stage biopharmaceutical company.", "type": 1, "words": ["<tag1>", "Macugen", ",", "Agreement", "with", "Valeant", "Pharmaceuticals", "International,", "Inc.", "<tag2>", "Dr.", "Gergel", "is", "a", "member", "of", "the", "Board", "of", "Directors", "of", "Corium", "International,", "Inc.,", "a", "commercial-stage", "biopharmaceutical", "company.", "<tag3>"], "wordsA": ["Macugen", ",", "Agreement", "with", "Valeant", "Pharmaceuticals", "International,", "Inc."], "wordsB": ["Dr.", "Gergel", "is", "a", "member", "of", "the", "Board", "of", "Directors", "of", "Corium", "International,", "Inc.,", "a", "commercial-stage", "biopharmaceutical", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p185_s0", "idA": "906709_15_item1_p11_s3", "sentA": "In this first efficacy study, we plan to randomize approximately 416 chronic low back pain patients in a clinical study that utilizes an enriched enrollment randomized withdrawal design.", "sentB": "From September 2001 until July 2004, D r. Doberstein was Vice President, Research at privately held Xencor, Inc., a clinical stage biotechnology company.", "type": 1, "words": ["<tag1>", "In", "this", "first", "efficacy", "study,", "we", "plan", "to", "randomize", "approximately", "416", "chronic", "low", "back", "pain", "patients", "in", "a", "clinical", "study", "that", "utilizes", "an", "enriched", "enrollment", "randomized", "withdrawal", "design.", "<tag2>", "From", "September", "2001", "until", "July", "2004,", "D", "r.", "Doberstein", "was", "Vice", "President,", "Research", "at", "privately", "held", "Xencor,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company.", "<tag3>"], "wordsA": ["In", "this", "first", "efficacy", "study,", "we", "plan", "to", "randomize", "approximately", "416", "chronic", "low", "back", "pain", "patients", "in", "a", "clinical", "study", "that", "utilizes", "an", "enriched", "enrollment", "randomized", "withdrawal", "design."], "wordsB": ["From", "September", "2001", "until", "July", "2004,", "D", "r.", "Doberstein", "was", "Vice", "President,", "Research", "at", "privately", "held", "Xencor,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p159_s2", "idA": "906709_15_item1_p11_s5", "sentA": "The study design also includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring committee.", "sentB": "The agreements provide that all inventions conceived by an employee shall be our property.", "type": 1, "words": ["<tag1>", "The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee.", "<tag2>", "The", "agreements", "provide", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property.", "<tag3>"], "wordsA": ["The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee."], "wordsB": ["The", "agreements", "provide", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p189_s2", "idA": "906709_15_item1_p121_s0", "sentA": "CIMZIA , Agreement with UCB Pharma In December 2000, we entered into a license, manufacturing and supply agreement covering our proprietary PEGylation materials for use in CIMZIA (certolizumab pegol) with Celltech Chiroscience Ltd., which was acquired by UCB Pharma (UCB) in 2004.", "sentB": "From July 2006 to July 2010, he held various executive positions most recently as Vice President, Product and Quality Operations at Facet Biotech Corporation (now Abbvie Biotherapeutics), a clinical stage biotechnology company, which was acquired in 2010 by Abbvie Biotherapeutics (formerly Abbot).", "type": 1, "words": ["<tag1>", "CIMZIA", ",", "Agreement", "with", "UCB", "Pharma", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "covering", "our", "proprietary", "PEGylation", "materials", "for", "use", "in", "CIMZIA", "(certolizumab", "pegol)", "with", "Celltech", "Chiroscience", "Ltd.,", "which", "was", "acquired", "by", "UCB", "Pharma", "(UCB)", "in", "2004.", "<tag2>", "From", "July", "2006", "to", "July", "2010,", "he", "held", "various", "executive", "positions", "most", "recently", "as", "Vice", "President,", "Product", "and", "Quality", "Operations", "at", "Facet", "Biotech", "Corporation", "(now", "Abbvie", "Biotherapeutics),", "a", "clinical", "stage", "biotechnology", "company,", "which", "was", "acquired", "in", "2010", "by", "Abbvie", "Biotherapeutics", "(formerly", "Abbot).", "<tag3>"], "wordsA": ["CIMZIA", ",", "Agreement", "with", "UCB", "Pharma", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "covering", "our", "proprietary", "PEGylation", "materials", "for", "use", "in", "CIMZIA", "(certolizumab", "pegol)", "with", "Celltech", "Chiroscience", "Ltd.,", "which", "was", "acquired", "by", "UCB", "Pharma", "(UCB)", "in", "2004."], "wordsB": ["From", "July", "2006", "to", "July", "2010,", "he", "held", "various", "executive", "positions", "most", "recently", "as", "Vice", "President,", "Product", "and", "Quality", "Operations", "at", "Facet", "Biotech", "Corporation", "(now", "Abbvie", "Biotherapeutics),", "a", "clinical", "stage", "biotechnology", "company,", "which", "was", "acquired", "in", "2010", "by", "Abbvie", "Biotherapeutics", "(formerly", "Abbot)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p187_s1", "idA": "906709_15_item1_p121_s1", "sentA": "Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses.", "sentB": "While at E2open, Mr. Labrucherie was responsible for global corporate alliances and merger and acquisitions.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses.", "<tag2>", "While", "at", "E2open,", "Mr.", "Labrucherie", "was", "responsible", "for", "global", "corporate", "alliances", "and", "merger", "and", "acquisitions.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses."], "wordsB": ["While", "at", "E2open,", "Mr.", "Labrucherie", "was", "responsible", "for", "global", "corporate", "alliances", "and", "merger", "and", "acquisitions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p187_s2", "idA": "906709_15_item1_p121_s1", "sentA": "Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses.", "sentB": "Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses.", "<tag2>", "Prior", "to", "E2open,", "he", "was", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses."], "wordsB": ["Prior", "to", "E2open,", "he", "was", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p184_s1", "idA": "906709_15_item1_p125_s0", "sentA": "a secondary back-up source on a non-exclusive basis through December 31, 2016.", "sentB": "From October 2008 through December 2009, Dr. Doberstein served as Vice President, Research at Xoma (US) LLC, a publicly traded clinical stage biotechnology company.", "type": 1, "words": ["<tag1>", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016.", "<tag2>", "From", "October", "2008", "through", "December", "2009,", "Dr.", "Doberstein", "served", "as", "Vice", "President,", "Research", "at", "Xoma", "(US)", "LLC,", "a", "publicly", "traded", "clinical", "stage", "biotechnology", "company.", "<tag3>"], "wordsA": ["a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016."], "wordsB": ["From", "October", "2008", "through", "December", "2009,", "Dr.", "Doberstein", "served", "as", "Vice", "President,", "Research", "at", "Xoma", "(US)", "LLC,", "a", "publicly", "traded", "clinical", "stage", "biotechnology", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p177_s0", "idA": "906709_15_item1_p125_s6", "sentA": "In February 2012, we sold all of our future rights to receive royalties on future worldwide net sales of MIRCERA effective as of January 1, 2012.", "sentB": "EXECUTIVE OFFICERS OF THE REGISTRANT The following table sets forth the names, ages and positions of our executive officers as of February 15, 2016:", "type": 1, "words": ["<tag1>", "In", "February", "2012,", "we", "sold", "all", "of", "our", "future", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012.", "<tag2>", "EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "15,", "2016:", "<tag3>"], "wordsA": ["In", "February", "2012,", "we", "sold", "all", "of", "our", "future", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012."], "wordsB": ["EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "15,", "2016:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p159_s0", "idA": "906709_15_item1_p131_s2", "sentA": "In July 2013, Affymax terminated the license, manufacturing and supply agreement with us.", "sentB": "It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us.", "type": 1, "words": ["<tag1>", "In", "July", "2013,", "Affymax", "terminated", "the", "license,", "manufacturing", "and", "supply", "agreement", "with", "us.", "<tag2>", "It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consultants,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us.", "<tag3>"], "wordsA": ["In", "July", "2013,", "Affymax", "terminated", "the", "license,", "manufacturing", "and", "supply", "agreement", "with", "us."], "wordsB": ["It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consultants,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p55_s1", "idA": "906709_15_item1_p133_s0", "sentA": "The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S. depends on whether the chemical composition of the product has previously been approved for use in other dosage forms.", "sentB": "7,199,223 and 8,247,536 provide composition of matter coverage through February 26, 2024, for this important drug (although extensions of patent term may be available under various regulatory mechanisms).", "type": 1, "words": ["<tag1>", "The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms.", "<tag2>", "7,199,223", "and", "8,247,536", "provide", "composition", "of", "matter", "coverage", "through", "February", "26,", "2024,", "for", "this", "important", "drug", "(although", "extensions", "of", "patent", "term", "may", "be", "available", "under", "various", "regulatory", "mechanisms).", "<tag3>"], "wordsA": ["The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms."], "wordsB": ["7,199,223", "and", "8,247,536", "provide", "composition", "of", "matter", "coverage", "through", "February", "26,", "2024,", "for", "this", "important", "drug", "(although", "extensions", "of", "patent", "term", "may", "be", "available", "under", "various", "regulatory", "mechanisms)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p170_s2", "idA": "906709_15_item1_p135_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "Potential competitors in the TIL and CAR-T space include Kite Pharma/NCI, Adaptimmune LLC, Celgene Corporation, Juno Therapeutics, and Novartis, Alkermes, Altor, and Armo in the cytokine-based therapies space, and Tesaro, Macrogenics, Merck, BMS, and Roche in the checkpoint inhibitor space.", "type": 1, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "Potential", "competitors", "in", "the", "TIL", "and", "CAR-T", "space", "include", "Kite", "Pharma/NCI,", "Adaptimmune", "LLC,", "Celgene", "Corporation,", "Juno", "Therapeutics,", "and", "Novartis,", "Alkermes,", "Altor,", "and", "Armo", "in", "the", "cytokine-based", "therapies", "space,", "and", "Tesaro,", "Macrogenics,", "Merck,", "BMS,", "and", "Roche", "in", "the", "checkpoint", "inhibitor", "space.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["Potential", "competitors", "in", "the", "TIL", "and", "CAR-T", "space", "include", "Kite", "Pharma/NCI,", "Adaptimmune", "LLC,", "Celgene", "Corporation,", "Juno", "Therapeutics,", "and", "Novartis,", "Alkermes,", "Altor,", "and", "Armo", "in", "the", "cytokine-based", "therapies", "space,", "and", "Tesaro,", "Macrogenics,", "Merck,", "BMS,", "and", "Roche", "in", "the", "checkpoint", "inhibitor", "space."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p53_s3", "idA": "906709_15_item1_p135_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "In 2014, according to the Evaluate Group, sales of FVIII replacement products exceeded $6 billion globally.", "type": 1, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6", "billion", "globally.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6", "billion", "globally."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p93_s0", "idA": "906709_15_item1_p135_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "In 2014, according to the Evaluate Group, sales of FVIII replacement products exceeded $6 billion globally.", "type": 1, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6", "billion", "globally.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6", "billion", "globally."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p159_s1", "idA": "906709_15_item1_p135_s4", "sentA": "Apart from the IND process described above, each clinical study must be reviewed by an independent Institutional Review Board (IRB) and the IRB must be kept current with respect to the status of the clinical study.", "sentB": "These agreements provide that all confidential information developed or made known to the individual during the course of the individual s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.", "type": 1, "words": ["<tag1>", "Apart", "from", "the", "IND", "process", "described", "above,", "each", "clinical", "study", "must", "be", "reviewed", "by", "an", "independent", "Institutional", "Review", "Board", "(IRB)", "and", "the", "IRB", "must", "be", "kept", "current", "with", "respect", "to", "the", "status", "of", "the", "clinical", "study.", "<tag2>", "These", "agreements", "provide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances.", "<tag3>"], "wordsA": ["Apart", "from", "the", "IND", "process", "described", "above,", "each", "clinical", "study", "must", "be", "reviewed", "by", "an", "independent", "Institutional", "Review", "Board", "(IRB)", "and", "the", "IRB", "must", "be", "kept", "current", "with", "respect", "to", "the", "status", "of", "the", "clinical", "study."], "wordsB": ["These", "agreements", "provide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p179_s2", "idA": "906709_15_item1_p139_s1", "sentA": "In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed prior to entering Phase 3 trials.", "sentB": "He was a Senior Associate with Arthur Andersen Co. prior to joining Berlex.", "type": 1, "words": ["<tag1>", "In", "some", "cases,", "the", "FDA", "and", "the", "drug", "sponsor", "may", "determine", "that", "Phase", "2", "trials", "are", "not", "needed", "prior", "to", "entering", "Phase", "3", "trials.", "<tag2>", "He", "was", "a", "Senior", "Associate", "with", "Arthur", "Andersen", "Co.", "prior", "to", "joining", "Berlex.", "<tag3>"], "wordsA": ["In", "some", "cases,", "the", "FDA", "and", "the", "drug", "sponsor", "may", "determine", "that", "Phase", "2", "trials", "are", "not", "needed", "prior", "to", "entering", "Phase", "3", "trials."], "wordsB": ["He", "was", "a", "Senior", "Associate", "with", "Arthur", "Andersen", "Co.", "prior", "to", "joining", "Berlex."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p168_s2", "idA": "906709_15_item1_p13_s4", "sentA": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Halozyme Therapeutics, Inc., Merck Co., Inc., Ophthotech Corporation, Pfizer, Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "sentB": "Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include Bristol-Meyers Squibb Company, Eisai, Inc., Roche Holding Group (including its Genentech subsidiary), GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly Co., Johnson Johnson, Sanofi Aventis S.A., and many others.", "type": 1, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag2>", "Major", "pharmaceutical", "or", "biotechnology", "companies", "with", "approved", "drugs", "or", "drugs", "in", "development", "for", "these", "cancers", "include", "Bristol-Meyers", "Squibb", "Company,", "Eisai,", "Inc.,", "Roche", "Holding", "Group", "(including", "its", "Genentech", "subsidiary),", "GlaxoSmithKline", "plc,", "Pfizer,", "Inc.,", "Eli", "Lilly", "Co.,", "Johnson", "Johnson,", "Sanofi", "Aventis", "S.A.,", "and", "many", "others.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "wordsB": ["Major", "pharmaceutical", "or", "biotechnology", "companies", "with", "approved", "drugs", "or", "drugs", "in", "development", "for", "these", "cancers", "include", "Bristol-Meyers", "Squibb", "Company,", "Eisai,", "Inc.,", "Roche", "Holding", "Group", "(including", "its", "Genentech", "subsidiary),", "GlaxoSmithKline", "plc,", "Pfizer,", "Inc.,", "Eli", "Lilly", "Co.,", "Johnson", "Johnson,", "Sanofi", "Aventis", "S.A.,", "and", "many", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p184_s2", "idA": "906709_15_item1_p13_s4", "sentA": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Halozyme Therapeutics, Inc., Merck Co., Inc., Ophthotech Corporation, Pfizer, Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "sentB": "From July 2004 until August 2008, he served as Vice President, Research at privately held Five Prime Therapeutics, Inc., a clinical stage biotechnology company.", "type": 1, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag2>", "From", "July", "2004", "until", "August", "2008,", "he", "served", "as", "Vice", "President,", "Research", "at", "privately", "held", "Five", "Prime", "Therapeutics,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "wordsB": ["From", "July", "2004", "until", "August", "2008,", "he", "served", "as", "Vice", "President,", "Research", "at", "privately", "held", "Five", "Prime", "Therapeutics,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p190_s1", "idA": "906709_15_item1_p141_s1", "sentA": "Such inspections are also held periodically after the commercialization.", "sentB": "Dr. Hora has also held positions at Wyeth Pharmaceuticals and GlaxoSmithKline plc prior to joining Chiron.", "type": 1, "words": ["<tag1>", "Such", "inspections", "are", "also", "held", "periodically", "after", "the", "commercialization.", "<tag2>", "Dr.", "Hora", "has", "also", "held", "positions", "at", "Wyeth", "Pharmaceuticals", "and", "GlaxoSmithKline", "plc", "prior", "to", "joining", "Chiron.", "<tag3>"], "wordsA": ["Such", "inspections", "are", "also", "held", "periodically", "after", "the", "commercialization."], "wordsB": ["Dr.", "Hora", "has", "also", "held", "positions", "at", "Wyeth", "Pharmaceuticals", "and", "GlaxoSmithKline", "plc", "prior", "to", "joining", "Chiron."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s2", "idA": "906709_15_item1_p141_s2", "sentA": "Establishments handling controlled substances must also be licensed by the U.S. Drug Enforcement Administration.", "sentB": "Before joining Nektar, Mr. Nicholson spent 18 years in various executive roles at Schering Berlin, Inc., the U.S. management holding company of Bayer Schering Pharma AG, a pharmaceutical company.", "type": 1, "words": ["<tag1>", "Establishments", "handling", "controlled", "substances", "must", "also", "be", "licensed", "by", "the", "U.S.", "Drug", "Enforcement", "Administration.", "<tag2>", "Before", "joining", "Nektar,", "Mr.", "Nicholson", "spent", "18", "years", "in", "various", "executive", "roles", "at", "Schering", "Berlin,", "Inc.,", "the", "U.S.", "management", "holding", "company", "of", "Bayer", "Schering", "Pharma", "AG,", "a", "pharmaceutical", "company.", "<tag3>"], "wordsA": ["Establishments", "handling", "controlled", "substances", "must", "also", "be", "licensed", "by", "the", "U.S.", "Drug", "Enforcement", "Administration."], "wordsB": ["Before", "joining", "Nektar,", "Mr.", "Nicholson", "spent", "18", "years", "in", "various", "executive", "roles", "at", "Schering", "Berlin,", "Inc.,", "the", "U.S.", "management", "holding", "company", "of", "Bayer", "Schering", "Pharma", "AG,", "a", "pharmaceutical", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p53_s2", "idA": "906709_15_item1_p144_s1", "sentA": "Where CDRH is determined to have primary jurisdiction over a product, 510(k) clearance or PMA approval is required.", "sentB": "A 2010 Datamonitor report calculates that there are approximately 78,000 patients reported to have Hemophilia A worldwide.", "type": 1, "words": ["<tag1>", "Where", "CDRH", "is", "determined", "to", "have", "primary", "jurisdiction", "over", "a", "product,", "510(k)", "clearance", "or", "PMA", "approval", "is", "required.", "<tag2>", "A", "2010", "Datamonitor", "report", "calculates", "that", "there", "are", "approximately", "78,000", "patients", "reported", "to", "have", "Hemophilia", "A", "worldwide.", "<tag3>"], "wordsA": ["Where", "CDRH", "is", "determined", "to", "have", "primary", "jurisdiction", "over", "a", "product,", "510(k)", "clearance", "or", "PMA", "approval", "is", "required."], "wordsB": ["A", "2010", "Datamonitor", "report", "calculates", "that", "there", "are", "approximately", "78,000", "patients", "reported", "to", "have", "Hemophilia", "A", "worldwide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p161_s2", "idA": "906709_15_item1_p146_s1", "sentA": "Our ability to manufacture and market products, whether developed by us or under collaboration agreements, ultimately depends upon the completion of satisfactory clinical trials and success in obtaining marketing approvals from the FDA and equivalent foreign health authorities.", "sentB": "We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies.", "type": 1, "words": ["<tag1>", "Our", "ability", "to", "manufacture", "and", "market", "products,", "whether", "developed", "by", "us", "or", "under", "collaboration", "agreements,", "ultimately", "depends", "upon", "the", "completion", "of", "satisfactory", "clinical", "trials", "and", "success", "in", "obtaining", "marketing", "approvals", "from", "the", "FDA", "and", "equivalent", "foreign", "health", "authorities.", "<tag2>", "We", "face", "competition", "from", "these", "companies", "not", "just", "in", "product", "development", "but", "also", "in", "areas", "such", "as", "recruiting", "employees,", "acquiring", "technologies", "that", "might", "enhance", "our", "ability", "to", "commercialize", "products,", "establishing", "relationships", "with", "certain", "research", "and", "academic", "institutions,", "enrolling", "patients", "in", "clinical", "trials", "and", "seeking", "program", "partnerships", "and", "collaborations", "with", "larger", "pharmaceutical", "companies.", "<tag3>"], "wordsA": ["Our", "ability", "to", "manufacture", "and", "market", "products,", "whether", "developed", "by", "us", "or", "under", "collaboration", "agreements,", "ultimately", "depends", "upon", "the", "completion", "of", "satisfactory", "clinical", "trials", "and", "success", "in", "obtaining", "marketing", "approvals", "from", "the", "FDA", "and", "equivalent", "foreign", "health", "authorities."], "wordsB": ["We", "face", "competition", "from", "these", "companies", "not", "just", "in", "product", "development", "but", "also", "in", "areas", "such", "as", "recruiting", "employees,", "acquiring", "technologies", "that", "might", "enhance", "our", "ability", "to", "commercialize", "products,", "establishing", "relationships", "with", "certain", "research", "and", "academic", "institutions,", "enrolling", "patients", "in", "clinical", "trials", "and", "seeking", "program", "partnerships", "and", "collaborations", "with", "larger", "pharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p180_s0", "idA": "906709_15_item1_p152_s4", "sentA": "Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world.", "sentB": "Mr. Robin serves as a director of the Biotechnology Industry Organization, the world s largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community.", "type": 1, "words": ["<tag1>", "Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world.", "<tag2>", "Mr.", "Robin", "serves", "as", "a", "director", "of", "the", "Biotechnology", "Industry", "Organization,", "the", "world", "s", "largest", "biotechnology", "industry", "trade", "organization,", "and", "also", "serves", "as", "a", "director", "of", "BayBio,", "a", "non-profit", "trade", "association", "serving", "the", "Northern", "California", "life", "sciences", "community.", "<tag3>"], "wordsA": ["Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world."], "wordsB": ["Mr.", "Robin", "serves", "as", "a", "director", "of", "the", "Biotechnology", "Industry", "Organization,", "the", "world", "s", "largest", "biotechnology", "industry", "trade", "organization,", "and", "also", "serves", "as", "a", "director", "of", "BayBio,", "a", "non-profit", "trade", "association", "serving", "the", "Northern", "California", "life", "sciences", "community."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p188_s0", "idA": "906709_15_item1_p152_s4", "sentA": "Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world.", "sentB": "Mr. Labrucherie serves on the General Counsel Committee of the Biotechnology Industry Organization, the world s largest biotechnology industry trade organization.", "type": 1, "words": ["<tag1>", "Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world.", "<tag2>", "Mr.", "Labrucherie", "serves", "on", "the", "General", "Counsel", "Committee", "of", "the", "Biotechnology", "Industry", "Organization,", "the", "world", "s", "largest", "biotechnology", "industry", "trade", "organization.", "<tag3>"], "wordsA": ["Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world."], "wordsB": ["Mr.", "Labrucherie", "serves", "on", "the", "General", "Counsel", "Committee", "of", "the", "Biotechnology", "Industry", "Organization,", "the", "world", "s", "largest", "biotechnology", "industry", "trade", "organization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p174_s1", "idA": "906709_15_item1_p152_s6", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "sentB": "We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations.", "type": 1, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "We", "have", "incurred,", "and", "may", "continue", "to", "incur,", "significant", "expenditures", "to", "ensure", "we", "are", "in", "compliance", "with", "these", "laws", "and", "regulations.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["We", "have", "incurred,", "and", "may", "continue", "to", "incur,", "significant", "expenditures", "to", "ensure", "we", "are", "in", "compliance", "with", "these", "laws", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p6_s1", "idA": "906709_15_item1_p152_s6", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "sentB": "The protocol of the NKTR-181 study defined only two possible outcomes for this pre-planned blinded interim sample size assessment: (1) if the conditional powering at the midpoint of the trial fell between 50-85%, the sample size was to be increased by about 200 patients; or (2) if the conditional powering fell below 50%, or above 85%, the sample size was not to be changed.", "type": 1, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "The", "protocol", "of", "the", "NKTR-181", "study", "defined", "only", "two", "possible", "outcomes", "for", "this", "pre-planned", "blinded", "interim", "sample", "size", "assessment:", "(1)", "if", "the", "conditional", "powering", "at", "the", "midpoint", "of", "the", "trial", "fell", "between", "50-85%,", "the", "sample", "size", "was", "to", "be", "increased", "by", "about", "200", "patients;", "or", "(2)", "if", "the", "conditional", "powering", "fell", "below", "50%,", "or", "above", "85%,", "the", "sample", "size", "was", "not", "to", "be", "changed.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["The", "protocol", "of", "the", "NKTR-181", "study", "defined", "only", "two", "possible", "outcomes", "for", "this", "pre-planned", "blinded", "interim", "sample", "size", "assessment:", "(1)", "if", "the", "conditional", "powering", "at", "the", "midpoint", "of", "the", "trial", "fell", "between", "50-85%,", "the", "sample", "size", "was", "to", "be", "increased", "by", "about", "200", "patients;", "or", "(2)", "if", "the", "conditional", "powering", "fell", "below", "50%,", "or", "above", "85%,", "the", "sample", "size", "was", "not", "to", "be", "changed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p190_s0", "idA": "906709_15_item1_p156_s0", "sentA": "The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues.", "sentB": "From 1986 to 2006, Dr. Hora held positions of increasing responsibility with Chiron Corporation (acquired in 2005 by Novartis), a pharmaceutical company, serving most recently at Chiron as Vice President of Process and Product Development.", "type": 1, "words": ["<tag1>", "The", "patent", "positions", "of", "pharmaceutical", "and", "biotechnology", "companies,", "such", "as", "ours,", "are", "uncertain", "and", "involve", "complex", "legal", "and", "factual", "issues.", "<tag2>", "From", "1986", "to", "2006,", "Dr.", "Hora", "held", "positions", "of", "increasing", "responsibility", "with", "Chiron", "Corporation", "(acquired", "in", "2005", "by", "Novartis),", "a", "pharmaceutical", "company,", "serving", "most", "recently", "at", "Chiron", "as", "Vice", "President", "of", "Process", "and", "Product", "Development.", "<tag3>"], "wordsA": ["The", "patent", "positions", "of", "pharmaceutical", "and", "biotechnology", "companies,", "such", "as", "ours,", "are", "uncertain", "and", "involve", "complex", "legal", "and", "factual", "issues."], "wordsB": ["From", "1986", "to", "2006,", "Dr.", "Hora", "held", "positions", "of", "increasing", "responsibility", "with", "Chiron", "Corporation", "(acquired", "in", "2005", "by", "Novartis),", "a", "pharmaceutical", "company,", "serving", "most", "recently", "at", "Chiron", "as", "Vice", "President", "of", "Process", "and", "Product", "Development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p51_s2", "idA": "906709_15_item1_p156_s6", "sentA": "We may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us.", "sentB": "Four patents (i.e., U.S. Patent Nos. 7,056,500, 7,662,365, 7,786,133 and 9,012,469) are composition of matter patents -- one of which has a patent expiry extending into 2032.", "type": 1, "words": ["<tag1>", "We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us.", "<tag2>", "Four", "patents", "(i.e.,", "U.S.", "Patent", "Nos.", "7,056,500,", "7,662,365,", "7,786,133", "and", "9,012,469)", "are", "composition", "of", "matter", "patents", "--", "one", "of", "which", "has", "a", "patent", "expiry", "extending", "into", "2032.", "<tag3>"], "wordsA": ["We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us."], "wordsB": ["Four", "patents", "(i.e.,", "U.S.", "Patent", "Nos.", "7,056,500,", "7,662,365,", "7,786,133", "and", "9,012,469)", "are", "composition", "of", "matter", "patents", "--", "one", "of", "which", "has", "a", "patent", "expiry", "extending", "into", "2032."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p51_s3", "idA": "906709_15_item1_p156_s6", "sentA": "We may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us.", "sentB": "In addition, two patents (i.e., U.S. Patent Nos. 8,067,431 and 8,617,530) are directed to methods of treatment .", "type": 1, "words": ["<tag1>", "We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us.", "<tag2>", "In", "addition,", "two", "patents", "(i.e.,", "U.S.", "Patent", "Nos.", "8,067,431", "and", "8,617,530)", "are", "directed", "to", "methods", "of", "treatment", ".", "<tag3>"], "wordsA": ["We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us."], "wordsB": ["In", "addition,", "two", "patents", "(i.e.,", "U.S.", "Patent", "Nos.", "8,067,431", "and", "8,617,530)", "are", "directed", "to", "methods", "of", "treatment", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p160_s5", "idA": "906709_15_item1_p157_s2", "sentA": "We could incur substantial costs in defending ourselves and our partners against any such claims.", "sentB": "In light of industry practice and our own experience, we do not believe that backlog as of any particular date is indicative of future results.", "type": 1, "words": ["<tag1>", "We", "could", "incur", "substantial", "costs", "in", "defending", "ourselves", "and", "our", "partners", "against", "any", "such", "claims.", "<tag2>", "In", "light", "of", "industry", "practice", "and", "our", "own", "experience,", "we", "do", "not", "believe", "that", "backlog", "as", "of", "any", "particular", "date", "is", "indicative", "of", "future", "results.", "<tag3>"], "wordsA": ["We", "could", "incur", "substantial", "costs", "in", "defending", "ourselves", "and", "our", "partners", "against", "any", "such", "claims."], "wordsB": ["In", "light", "of", "industry", "practice", "and", "our", "own", "experience,", "we", "do", "not", "believe", "that", "backlog", "as", "of", "any", "particular", "date", "is", "indicative", "of", "future", "results."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s10", "idA": "906709_15_item1_p17_s0", "sentA": "We were incorporated in California in 1990 and reincorporated in Delaware in 1998.", "sentB": "He joined Forest in 1998 as Executive Director of Clinical Research following nine years at SmithKline Beecham, and was named Vice President of Clinical Development and Clinical Affairs in 1999.", "type": 1, "words": ["<tag1>", "We", "were", "incorporated", "in", "California", "in", "1990", "and", "reincorporated", "in", "Delaware", "in", "1998.", "<tag2>", "He", "joined", "Forest", "in", "1998", "as", "Executive", "Director", "of", "Clinical", "Research", "following", "nine", "years", "at", "SmithKline", "Beecham,", "and", "was", "named", "Vice", "President", "of", "Clinical", "Development", "and", "Clinical", "Affairs", "in", "1999.", "<tag3>"], "wordsA": ["We", "were", "incorporated", "in", "California", "in", "1990", "and", "reincorporated", "in", "Delaware", "in", "1998."], "wordsB": ["He", "joined", "Forest", "in", "1998", "as", "Executive", "Director", "of", "Clinical", "Research", "following", "nine", "years", "at", "SmithKline", "Beecham,", "and", "was", "named", "Vice", "President", "of", "Clinical", "Development", "and", "Clinical", "Affairs", "in", "1999."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p176_s4", "idA": "906709_15_item1_p17_s2", "sentA": "Our website is located at www.nektar.com.", "sentB": "The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.", "type": 1, "words": ["<tag1>", "Our", "website", "is", "located", "at", "www.nektar.com.", "<tag2>", "The", "SEC", "maintains", "an", "Internet", "site", "that", "contains", "reports,", "proxy", "and", "information", "statements", "and", "other", "information", "regarding", "our", "filings", "at", "www.sec.gov.", "<tag3>"], "wordsA": ["Our", "website", "is", "located", "at", "www.nektar.com."], "wordsB": ["The", "SEC", "maintains", "an", "Internet", "site", "that", "contains", "reports,", "proxy", "and", "information", "statements", "and", "other", "information", "regarding", "our", "filings", "at", "www.sec.gov."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p8_s2", "idA": "906709_15_item1_p1_s1", "sentA": "Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates.", "sentB": "The immunologic effect of NKTR-214 on tumor-infiltrati ng lymphocytes and other immune infiltrating cells in both blood and tumor tissue will also be assessed.", "type": 1, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates.", "<tag2>", "The", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrati", "ng", "lymphocytes", "and", "other", "immune", "infiltrating", "cells", "in", "both", "blood", "and", "tumor", "tissue", "will", "also", "be", "assessed.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates."], "wordsB": ["The", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrati", "ng", "lymphocytes", "and", "other", "immune", "infiltrating", "cells", "in", "both", "blood", "and", "tumor", "tissue", "will", "also", "be", "assessed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p81_s1", "idA": "906709_15_item1_p21_s1", "sentA": "Our advanced polymer conjugate technology platform is designed to overcome the limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "sentB": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "type": 1, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag2>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "wordsB": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s6", "idA": "906709_15_item1_p25_s7", "sentA": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, for which Baxter filed a biologic license application with the United States Food and Drug Administration on December 1, 2014.", "sentB": "In Europe, we have met with the National Authorities in Sweden (MPA) and the United Kingdom (MHRA) to discuss the BEACON data.", "type": 1, "words": ["<tag1>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014.", "<tag2>", "In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data.", "<tag3>"], "wordsA": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014."], "wordsB": ["In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s8", "idA": "906709_15_item1_p25_s7", "sentA": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, for which Baxter filed a biologic license application with the United States Food and Drug Administration on December 1, 2014.", "sentB": "In Europe, we have met with the National Authorities in Sweden (MPA) and the United Kingdom (MHRA) to discuss the BEACON data.", "type": 1, "words": ["<tag1>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014.", "<tag2>", "In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data.", "<tag3>"], "wordsA": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014."], "wordsB": ["In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s4", "idA": "906709_15_item1_p25_s8", "sentA": "This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "sentB": "We constantly monitor scientific and medical developments in order to improve our current technologies, seek licensing opportunities where appropriate, and determine the best applications for our technology platforms.", "type": 1, "words": ["<tag1>", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag2>", "We", "constantly", "monitor", "scientific", "and", "medical", "developments", "in", "order", "to", "improve", "our", "current", "technologies,", "seek", "licensing", "opportunities", "where", "appropriate,", "and", "determine", "the", "best", "applications", "for", "our", "technology", "platforms.", "<tag3>"], "wordsA": ["This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "wordsB": ["We", "constantly", "monitor", "scientific", "and", "medical", "developments", "in", "order", "to", "improve", "our", "current", "technologies,", "seek", "licensing", "opportunities", "where", "appropriate,", "and", "determine", "the", "best", "applications", "for", "our", "technology", "platforms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p175_s3", "idA": "906709_15_item1_p27_s0", "sentA": "The key elements of our business strategy are described below:", "sentB": "None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages.", "type": 1, "words": ["<tag1>", "The", "key", "elements", "of", "our", "business", "strategy", "are", "described", "below:", "<tag2>", "None", "of", "our", "employees", "are", "covered", "by", "a", "collective", "bargaining", "agreement,", "and", "we", "have", "experienced", "no", "work", "stoppages.", "<tag3>"], "wordsA": ["The", "key", "elements", "of", "our", "business", "strategy", "are", "described", "below:"], "wordsB": ["None", "of", "our", "employees", "are", "covered", "by", "a", "collective", "bargaining", "agreement,", "and", "we", "have", "experienced", "no", "work", "stoppages."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p178_s0", "idA": "906709_15_item1_p27_s0", "sentA": "The key elements of our business strategy are described below:", "sentB": "Howard W. Robin has served as our President and Chief Executive Officer since January 2007 and has served as a member of our board of directors since February 2007.", "type": 1, "words": ["<tag1>", "The", "key", "elements", "of", "our", "business", "strategy", "are", "described", "below:", "<tag2>", "Howard", "W.", "Robin", "has", "served", "as", "our", "President", "and", "Chief", "Executive", "Officer", "since", "January", "2007", "and", "has", "served", "as", "a", "member", "of", "our", "board", "of", "directors", "since", "February", "2007.", "<tag3>"], "wordsA": ["The", "key", "elements", "of", "our", "business", "strategy", "are", "described", "below:"], "wordsB": ["Howard", "W.", "Robin", "has", "served", "as", "our", "President", "and", "Chief", "Executive", "Officer", "since", "January", "2007", "and", "has", "served", "as", "a", "member", "of", "our", "board", "of", "directors", "since", "February", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p83_s4", "idA": "906709_15_item1_p2_s1", "sentA": "Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer chemistry technology and expertise.", "sentB": "The combination of NKTR-214 plus anti-PD-1 or NKTR-214 plus anti-CTLA-4 produced complete tumor regressions in 40% and 70% of the animals, respectively.", "type": 1, "words": ["<tag1>", "Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise.", "<tag2>", "The", "combination", "of", "NKTR-214", "plus", "anti-PD-1", "or", "NKTR-214", "plus", "anti-CTLA-4", "produced", "complete", "tumor", "regressions", "in", "40%", "and", "70%", "of", "the", "animals,", "respectively.", "<tag3>"], "wordsA": ["Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise."], "wordsB": ["The", "combination", "of", "NKTR-214", "plus", "anti-PD-1", "or", "NKTR-214", "plus", "anti-CTLA-4", "produced", "complete", "tumor", "regressions", "in", "40%", "and", "70%", "of", "the", "animals,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s4", "idA": "906709_15_item1_p30_s0", "sentA": "Ensure Future Growth of our Proprietary Pipeline through Internal Research Efforts and Advancement of our Preclinical Drug Candidates into Clinical Trials We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business.", "sentB": "However, from time to time, we source critical raw materials and services from one or a limited number of suppliers and there is a risk that if such supply or services were interrupted, it would materially harm our business.", "type": 1, "words": ["<tag1>", "Ensure", "Future", "Growth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business.", "<tag2>", "However,", "from", "time", "to", "time,", "we", "source", "critical", "raw", "materials", "and", "services", "from", "one", "or", "a", "limited", "number", "of", "suppliers", "and", "there", "is", "a", "risk", "that", "if", "such", "supply", "or", "services", "were", "interrupted,", "it", "would", "materially", "harm", "our", "business.", "<tag3>"], "wordsA": ["Ensure", "Future", "Growth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business."], "wordsB": ["However,", "from", "time", "to", "time,", "we", "source", "critical", "raw", "materials", "and", "services", "from", "one", "or", "a", "limited", "number", "of", "suppliers", "and", "there", "is", "a", "risk", "that", "if", "such", "supply", "or", "services", "were", "interrupted,", "it", "would", "materially", "harm", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p166_s1", "idA": "906709_15_item1_p31_s3", "sentA": "The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.", "sentB": "Prior to its 2014 approval, the fusion protein in ELOCTATE was not used outside of the clinical trial setting for Hemophilia A patients.", "type": 1, "words": ["<tag1>", "The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program.", "<tag2>", "Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients.", "<tag3>"], "wordsA": ["The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program."], "wordsB": ["Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p176_s2", "idA": "906709_15_item1_p39_s1", "sentA": "Filed an application for approval and marketing has been filed with the applicable government health authority.", "sentB": "The public may read and copy any materials we file with the SEC at the SEC s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549.", "type": 1, "words": ["<tag1>", "Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority.", "<tag2>", "The", "public", "may", "read", "and", "copy", "any", "materials", "we", "file", "with", "the", "SEC", "at", "the", "SEC", "s", "Public", "Reference", "Room", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549.", "<tag3>"], "wordsA": ["Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority."], "wordsB": ["The", "public", "may", "read", "and", "copy", "any", "materials", "we", "file", "with", "the", "SEC", "at", "the", "SEC", "s", "Public", "Reference", "Room", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p178_s1", "idA": "906709_15_item1_p43_s0", "sentA": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd (Roche) and as a result of this legal ruling Roche was prevented from marketing MIRCERA in the U.S. until July 2014.", "sentB": "Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director.", "type": 1, "words": ["<tag1>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag2>", "Mr.", "Robin", "served", "as", "Chief", "Executive", "Officer,", "President", "and", "a", "director", "of", "Sirna", "Therapeutics,", "Inc.,", "a", "biotechnology", "company,", "from", "July", "2001", "to", "November", "2006", "and", "from", "January", "2001", "to", "June", "2001,", "served", "as", "their", "Chief", "Operating", "Officer,", "President", "and", "as", "a", "director.", "<tag3>"], "wordsA": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "wordsB": ["Mr.", "Robin", "served", "as", "Chief", "Executive", "Officer,", "President", "and", "a", "director", "of", "Sirna", "Therapeutics,", "Inc.,", "a", "biotechnology", "company,", "from", "July", "2001", "to", "November", "2006", "and", "from", "January", "2001", "to", "June", "2001,", "served", "as", "their", "Chief", "Operating", "Officer,", "President", "and", "as", "a", "director."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s6", "idA": "906709_15_item1_p43_s0", "sentA": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd (Roche) and as a result of this legal ruling Roche was prevented from marketing MIRCERA in the U.S. until July 2014.", "sentB": "Ivan P. Gergel, M.D. has served as our Senior Vice President, Drug Development and Chief Medical Officer since May 2014.", "type": 1, "words": ["<tag1>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag2>", "Ivan", "P.", "Gergel,", "M.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Drug", "Development", "and", "Chief", "Medical", "Officer", "since", "May", "2014.", "<tag3>"], "wordsA": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "wordsB": ["Ivan", "P.", "Gergel,", "M.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Drug", "Development", "and", "Chief", "Medical", "Officer", "since", "May", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p189_s0", "idA": "906709_15_item1_p51_s0", "sentA": "On January 23, 2015, the DEA published the final rule in the Federal Register, effective immediately on the date it was published, removing naloxegol and its salts from the schedules of the Controlled Substances Act.", "sentB": "Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich Rosati, P.C. Mr. Labrucherie received his J.D. from the Berkeley Law School and a B.A. from the University of California Davis.", "type": 1, "words": ["<tag1>", "On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act.", "<tag2>", "Mr.", "Labrucherie", "began", "his", "career", "as", "an", "associate", "in", "the", "corporate", "practice", "of", "the", "law", "firm", "of", "Wilson", "Sonsini", "Goodrich", "Rosati,", "P.C.", "Mr.", "Labrucherie", "received", "his", "J.D.", "from", "the", "Berkeley", "Law", "School", "and", "a", "B.A.", "from", "the", "University", "of", "California", "Davis.", "<tag3>"], "wordsA": ["On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act."], "wordsB": ["Mr.", "Labrucherie", "began", "his", "career", "as", "an", "associate", "in", "the", "corporate", "practice", "of", "the", "law", "firm", "of", "Wilson", "Sonsini", "Goodrich", "Rosati,", "P.C.", "Mr.", "Labrucherie", "received", "his", "J.D.", "from", "the", "Berkeley", "Law", "School", "and", "a", "B.A.", "from", "the", "University", "of", "California", "Davis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s9", "idA": "906709_15_item1_p52_s2", "sentA": "We received $70.0 million and $25.0 million upon the acceptance for review of MOVANTIK TM regulatory approval applications filed with the FDA and European Medicines Agency (EMA), respectively, in 2013.", "sentB": "We also met the European Medicines Agency to discuss filing a marketing authorization application (MAA).", "type": 1, "words": ["<tag1>", "We", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "MOVANTIK", "TM", "regulatory", "approval", "applications", "filed", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013.", "<tag2>", "We", "also", "met", "the", "European", "Medicines", "Agency", "to", "discuss", "filing", "a", "marketing", "authorization", "application", "(MAA).", "<tag3>"], "wordsA": ["We", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "MOVANTIK", "TM", "regulatory", "approval", "applications", "filed", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013."], "wordsB": ["We", "also", "met", "the", "European", "Medicines", "Agency", "to", "discuss", "filing", "a", "marketing", "authorization", "application", "(MAA)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p51_s1", "idA": "906709_15_item1_p52_s3", "sentA": "In 2014, we received an additional $35.0 million payment upon the FDA s approval of MOVANTIK TM .", "sentB": "The Orange Book currently lists six patents for Movantik TM .", "type": 1, "words": ["<tag1>", "In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", ".", "<tag2>", "The", "Orange", "Book", "currently", "lists", "six", "patents", "for", "Movantik", "TM", ".", "<tag3>"], "wordsA": ["In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "."], "wordsB": ["The", "Orange", "Book", "currently", "lists", "six", "patents", "for", "Movantik", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p170_s1", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "In", "particular,", "we", "expect", "to", "compete", "with", "therapies", "with", "tumor", "infiltrating", "lymphocytes,", "or", "TILS,", "chimeric", "antigen", "receptor-expressing", "T", "cells,", "or", "CAR-T,", "cytokine-based", "therapies,", "and", "checkpoint", "inhibitors.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["In", "particular,", "we", "expect", "to", "compete", "with", "therapies", "with", "tumor", "infiltrating", "lymphocytes,", "or", "TILS,", "chimeric", "antigen", "receptor-expressing", "T", "cells,", "or", "CAR-T,", "cytokine-based", "therapies,", "and", "checkpoint", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p179_s1", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "From", "1984", "to", "1987,", "Mr.", "Robin", "was", "Director", "of", "Business", "Planning", "and", "Development", "at", "Berlex.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["From", "1984", "to", "1987,", "Mr.", "Robin", "was", "Director", "of", "Business", "Planning", "and", "Development", "at", "Berlex."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s0", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "John Nicholson has served as our Senior Vice President and Chief Financial Officer since December 2007.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "December", "2007.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "December", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s3", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "From 1997 to September 2007, Mr. Nicholson served as Schering Berlin Inc. s Vice President of Corporate Development and Treasurer.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "From", "1997", "to", "September", "2007,", "Mr.", "Nicholson", "served", "as", "Schering", "Berlin", "Inc.", "s", "Vice", "President", "of", "Corporate", "Development", "and", "Treasurer.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["From", "1997", "to", "September", "2007,", "Mr.", "Nicholson", "served", "as", "Schering", "Berlin", "Inc.", "s", "Vice", "President", "of", "Corporate", "Development", "and", "Treasurer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s7", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "From April 2008 through March 2014, Dr. Gergel served as Executive Vice President, Research Development and Chief Scientific Officer of Endo Pharmaceuticals, a pharmaceutical company.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "From", "April", "2008", "through", "March", "2014,", "Dr.", "Gergel", "served", "as", "Executive", "Vice", "President,", "Research", "Development", "and", "Chief", "Scientific", "Officer", "of", "Endo", "Pharmaceuticals,", "a", "pharmaceutical", "company.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["From", "April", "2008", "through", "March", "2014,", "Dr.", "Gergel", "served", "as", "Executive", "Vice", "President,", "Research", "Development", "and", "Chief", "Scientific", "Officer", "of", "Endo", "Pharmaceuticals,", "a", "pharmaceutical", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p184_s0", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "Stephen K. Doberstein, Ph.D. has served as our Senior Vice President and Chief Scientific Officer since January 2010.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "Stephen", "K.", "Doberstein,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Scientific", "Officer", "since", "January", "2010.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["Stephen", "K.", "Doberstein,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Scientific", "Officer", "since", "January", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p185_s1", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "From 1997 to 2000, he held various pharmaceutical research positions at Exelixis, Inc. (Exelixis), a publicly traded clinical stage biotechno logy company.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "From", "1997", "to", "2000,", "he", "held", "various", "pharmaceutical", "research", "positions", "at", "Exelixis,", "Inc.", "(Exelixis),", "a", "publicly", "traded", "clinical", "stage", "biotechno", "logy", "company.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["From", "1997", "to", "2000,", "he", "held", "various", "pharmaceutical", "research", "positions", "at", "Exelixis,", "Inc.", "(Exelixis),", "a", "publicly", "traded", "clinical", "stage", "biotechno", "logy", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p186_s1", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "Mr.", "Labrucherie", "served", "as", "our", "Vice", "President,", "Corporate", "Legal", "from", "October", "2005", "through", "April", "2007.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["Mr.", "Labrucherie", "served", "as", "our", "Vice", "President,", "Corporate", "Legal", "from", "October", "2005", "through", "April", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p189_s1", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "Maninder Hora, Ph.D. has served as our Senior Vice President, Pharmaceutical Development and Manufacturing Operations since August 2010.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "Maninder", "Hora,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Pharmaceutical", "Development", "and", "Manufacturing", "Operations", "since", "August", "2010.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["Maninder", "Hora,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Pharmaceutical", "Development", "and", "Manufacturing", "Operations", "since", "August", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p193_s0", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "Jillian B. Thomsen has served as our Senior Vice President, Finance and Chief Accounting Officer since February 2010.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "Jillian", "B.", "Thomsen", "has", "served", "as", "our", "Senior", "Vice", "President,", "Finance", "and", "Chief", "Accounting", "Officer", "since", "February", "2010.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["Jillian", "B.", "Thomsen", "has", "served", "as", "our", "Senior", "Vice", "President,", "Finance", "and", "Chief", "Accounting", "Officer", "since", "February", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p193_s1", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "From March 2006 through March 2008, Ms. Thomsen served as our Vice President Finance and Corporate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "From", "March", "2006", "through", "March", "2008,", "Ms.", "Thomsen", "served", "as", "our", "Vice", "President", "Finance", "and", "Corporate", "Controller", "and", "from", "April", "2008", "through", "January", "2010", "she", "served", "as", "our", "Vice", "President", "Finance", "and", "Chief", "Accounting", "Officer.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["From", "March", "2006", "through", "March", "2008,", "Ms.", "Thomsen", "served", "as", "our", "Vice", "President", "Finance", "and", "Corporate", "Controller", "and", "from", "April", "2008", "through", "January", "2010", "she", "served", "as", "our", "Vice", "President", "Finance", "and", "Chief", "Accounting", "Officer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p193_s2", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "Before joining Nektar, Ms. Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "Before", "joining", "Nektar,", "Ms.", "Thomsen", "was", "Vice", "President", "Finance", "and", "Deputy", "Corporate", "Controller", "of", "Calpine", "Corporation", "from", "September", "2002", "to", "February", "2006.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["Before", "joining", "Nektar,", "Ms.", "Thomsen", "was", "Vice", "President", "Finance", "and", "Deputy", "Corporate", "Controller", "of", "Calpine", "Corporation", "from", "September", "2002", "to", "February", "2006."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s7", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "All participants received prophylactic ADYNOVATE TM treatment (median 1.9 infusions per week) and were followed for six months.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "All", "participants", "received", "prophylactic", "ADYNOVATE", "TM", "treatment", "(median", "1.9", "infusions", "per", "week)", "and", "were", "followed", "for", "six", "months.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["All", "participants", "received", "prophylactic", "ADYNOVATE", "TM", "treatment", "(median", "1.9", "infusions", "per", "week)", "and", "were", "followed", "for", "six", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p92_s3", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "All races and ethnic groups are affected.", "type": 1, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "All", "races", "and", "ethnic", "groups", "are", "affected.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["All", "races", "and", "ethnic", "groups", "are", "affected."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p92_s4", "idA": "906709_15_item1_p60_s0", "sentA": "In November 2012, the FDA designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "sentB": "Hemophilia A is four times as common as Hemophilia B while more than half of patients with Hemophilia A have the severe form of hemophilia.", "type": 1, "words": ["<tag1>", "In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag2>", "Hemophilia", "A", "is", "four", "times", "as", "common", "as", "Hemophilia", "B", "while", "more", "than", "half", "of", "patients", "with", "Hemophilia", "A", "have", "the", "severe", "form", "of", "hemophilia.", "<tag3>"], "wordsA": ["In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "wordsB": ["Hemophilia", "A", "is", "four", "times", "as", "common", "as", "Hemophilia", "B", "while", "more", "than", "half", "of", "patients", "with", "Hemophilia", "A", "have", "the", "severe", "form", "of", "hemophilia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p164_s0", "idA": "906709_15_item1_p65_s0", "sentA": "There are currently no FDA-approved topoisomerase I inhibitors indicated to treat breast cancer.", "sentB": "Other therapies used to treat OIC and OBD include over-the-counter laxatives and stool softeners, such as docusate sodium, senna, and milk of magnesia.", "type": 1, "words": ["<tag1>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag2>", "Other", "therapies", "used", "to", "treat", "OIC", "and", "OBD", "include", "over-the-counter", "laxatives", "and", "stool", "softeners,", "such", "as", "docusate", "sodium,", "senna,", "and", "milk", "of", "magnesia.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "wordsB": ["Other", "therapies", "used", "to", "treat", "OIC", "and", "OBD", "include", "over-the-counter", "laxatives", "and", "stool", "softeners,", "such", "as", "docusate", "sodium,", "senna,", "and", "milk", "of", "magnesia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p166_s2", "idA": "906709_15_item1_p65_s0", "sentA": "There are currently no FDA-approved topoisomerase I inhibitors indicated to treat breast cancer.", "sentB": "There are other long-acting Factor VIII programs in late-stage development for Hemophilia A patients.", "type": 1, "words": ["<tag1>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag2>", "There", "are", "other", "long-acting", "Factor", "VIII", "programs", "in", "late-stage", "development", "for", "Hemophilia", "A", "patients.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "wordsB": ["There", "are", "other", "long-acting", "Factor", "VIII", "programs", "in", "late-stage", "development", "for", "Hemophilia", "A", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s4", "idA": "906709_15_item1_p65_s3", "sentA": "We also initiated a Phase 2 clinical study of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "We also announced that we observed a significant overall survival benefit in two pre-specified subgroups patients with a history of brain metastases and patients with baseline liver metastases at study entry.", "type": 1, "words": ["<tag1>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroups", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry.", "<tag3>"], "wordsA": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroups", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s6", "idA": "906709_15_item1_p65_s3", "sentA": "We also initiated a Phase 2 clinical study of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "We also announced that we observed a significant overall survival benefit in two pre-specified subgroup populations patients with a history of brain metastases and patients with baseline liver metastases at study entry.", "type": 1, "words": ["<tag1>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroup", "populations", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry.", "<tag3>"], "wordsA": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroup", "populations", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p192_s0", "idA": "906709_15_item1_p66_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "Dr. Hora completed his Ph.D. in Bioengineering from the Indian Institute of Technology, Delhi, India, and was a Fulbright Scholar at the University of Washington, and received his B.S. in chemistry from the University of Jabalpur.", "type": 1, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "Dr.", "Hora", "completed", "his", "Ph.D.", "in", "Bioengineering", "from", "the", "Indian", "Institute", "of", "Technology,", "Delhi,", "India,", "and", "was", "a", "Fulbright", "Scholar", "at", "the", "University", "of", "Washington,", "and", "received", "his", "B.S.", "in", "chemistry", "from", "the", "University", "of", "Jabalpur.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["Dr.", "Hora", "completed", "his", "Ph.D.", "in", "Bioengineering", "from", "the", "Indian", "Institute", "of", "Technology,", "Delhi,", "India,", "and", "was", "a", "Fulbright", "Scholar", "at", "the", "University", "of", "Washington,", "and", "received", "his", "B.S.", "in", "chemistry", "from", "the", "University", "of", "Jabalpur."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p193_s4", "idA": "906709_15_item1_p66_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.", "type": 1, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "Ms.", "Thomsen", "holds", "a", "Masters", "of", "Accountancy", "from", "the", "University", "of", "Denver", "and", "a", "B.A.", "in", "Business", "Economics", "from", "Colorado", "College.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["Ms.", "Thomsen", "holds", "a", "Masters", "of", "Accountancy", "from", "the", "University", "of", "Denver", "and", "a", "B.A.", "in", "Business", "Economics", "from", "Colorado", "College."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p63_s4", "idA": "906709_15_item1_p67_s8", "sentA": "The agreement expires in relation to a particular country upon the expiration of all royalty and payment obligations between the parties related to such country.", "sentB": "This same report attributes 18,893 overdose deaths in 2015 were related to prescription pain relievers.", "type": 1, "words": ["<tag1>", "The", "agreement", "expires", "in", "relation", "to", "a", "particular", "country", "upon", "the", "expiration", "of", "all", "royalty", "and", "payment", "obligations", "between", "the", "parties", "related", "to", "such", "country.", "<tag2>", "This", "same", "report", "attributes", "18,893", "overdose", "deaths", "in", "2015", "were", "related", "to", "prescription", "pain", "relievers.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "in", "relation", "to", "a", "particular", "country", "upon", "the", "expiration", "of", "all", "royalty", "and", "payment", "obligations", "between", "the", "parties", "related", "to", "such", "country."], "wordsB": ["This", "same", "report", "attributes", "18,893", "overdose", "deaths", "in", "2015", "were", "related", "to", "prescription", "pain", "relievers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p167_s0", "idA": "906709_15_item1_p81_s3", "sentA": "NKTR-171 is designed to be a peripherally-restricted molecule which selectively blocks hyper-excitable sodium channels without causing the CNS side effects that limit usage of existing therapies.", "sentB": "There are numerous companies developing pain therapies designed to have less abuse potential primarily through formulation technologies and techniques applied to existing pain therapies.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "designed", "to", "be", "a", "peripherally-restricted", "molecule", "which", "selectively", "blocks", "hyper-excitable", "sodium", "channels", "without", "causing", "the", "CNS", "side", "effects", "that", "limit", "usage", "of", "existing", "therapies.", "<tag2>", "There", "are", "numerous", "companies", "developing", "pain", "therapies", "designed", "to", "have", "less", "abuse", "potential", "primarily", "through", "formulation", "technologies", "and", "techniques", "applied", "to", "existing", "pain", "therapies.", "<tag3>"], "wordsA": ["NKTR-171", "is", "designed", "to", "be", "a", "peripherally-restricted", "molecule", "which", "selectively", "blocks", "hyper-excitable", "sodium", "channels", "without", "causing", "the", "CNS", "side", "effects", "that", "limit", "usage", "of", "existing", "therapies."], "wordsB": ["There", "are", "numerous", "companies", "developing", "pain", "therapies", "designed", "to", "have", "less", "abuse", "potential", "primarily", "through", "formulation", "technologies", "and", "techniques", "applied", "to", "existing", "pain", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p187_s0", "idA": "906709_15_item1_p86_s0", "sentA": "In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation (Baxter) to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "sentB": "From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open.", "type": 1, "words": ["<tag1>", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "Baxter", "Healthcare", "SA", "and", "Baxter", "Healthcare", "Corporation", "(Baxter)", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag2>", "From", "October", "2000", "to", "September", "2005,", "Mr.", "Labrucherie", "was", "Vice", "President", "of", "Corporate", "Development", "at", "E2open.", "<tag3>"], "wordsA": ["In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "Baxter", "Healthcare", "SA", "and", "Baxter", "Healthcare", "Corporation", "(Baxter)", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "wordsB": ["From", "October", "2000", "to", "September", "2005,", "Mr.", "Labrucherie", "was", "Vice", "President", "of", "Corporate", "Development", "at", "E2open."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p61_s0", "idA": "906709_15_item1_p87_s0", "sentA": "BAX 855 is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "sentB": "As described above, on February 29, 2016 the independent analysis center ( IAC ) instructed us to increase the sample size by about 200 patients.", "type": 1, "words": ["<tag1>", "BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag2>", "As", "described", "above,", "on", "February", "29,", "2016", "the", "independent", "analysis", "center", "(", "IAC", ")", "instructed", "us", "to", "increase", "the", "sample", "size", "by", "about", "200", "patients.", "<tag3>"], "wordsA": ["BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "wordsB": ["As", "described", "above,", "on", "February", "29,", "2016", "the", "independent", "analysis", "center", "(", "IAC", ")", "instructed", "us", "to", "increase", "the", "sample", "size", "by", "about", "200", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s5", "idA": "906709_15_item1_p8_s0", "sentA": "and announce the top-line data from the BEACON Study in March 2015.", "sentB": "Mr. Nicholson holds a B.B.A. from the University of Toledo.", "type": 1, "words": ["<tag1>", "and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015.", "<tag2>", "Mr.", "Nicholson", "holds", "a", "B.B.A.", "from", "the", "University", "of", "Toledo.", "<tag3>"], "wordsA": ["and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015."], "wordsB": ["Mr.", "Nicholson", "holds", "a", "B.B.A.", "from", "the", "University", "of", "Toledo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p181_s0", "idA": "906709_15_item1_p90_s0", "sentA": "Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.", "type": 1, "words": ["<tag1>", "Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "He", "received", "his", "B.S.", "in", "Accounting", "and", "Finance", "from", "Fairleigh", "Dickinson", "University", "in", "1974.", "<tag3>"], "wordsA": ["Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["He", "received", "his", "B.S.", "in", "Accounting", "and", "Finance", "from", "Fairleigh", "Dickinson", "University", "in", "1974."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s1", "idA": "906709_15_item1_p98_s2", "sentA": "Patients receiving the combination of Fovista (1.5 mg) and Lucentis gained a mean of 10.6 letters of vision at 24 weeks on the Early Treatment Diabetic Retinopathy Study standardized eye chart, compared to 6.5 letters for patients receiving Lucentis monotherapy (p=0.019), representing a statistically significant 62% additional benefit.", "sentB": "In a topline analysis of 852 patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival (OS) over TPC (12.4 months for patients receiving NKTR-102 compared to 10.3 months for patients receiving TPC).", "type": 1, "words": ["<tag1>", "Patients", "receiving", "the", "combination", "of", "Fovista", "(1.5", "mg)", "and", "Lucentis", "gained", "a", "mean", "of", "10.6", "letters", "of", "vision", "at", "24", "weeks", "on", "the", "Early", "Treatment", "Diabetic", "Retinopathy", "Study", "standardized", "eye", "chart,", "compared", "to", "6.5", "letters", "for", "patients", "receiving", "Lucentis", "monotherapy", "(p=0.019),", "representing", "a", "statistically", "significant", "62%", "additional", "benefit.", "<tag2>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag3>"], "wordsA": ["Patients", "receiving", "the", "combination", "of", "Fovista", "(1.5", "mg)", "and", "Lucentis", "gained", "a", "mean", "of", "10.6", "letters", "of", "vision", "at", "24", "weeks", "on", "the", "Early", "Treatment", "Diabetic", "Retinopathy", "Study", "standardized", "eye", "chart,", "compared", "to", "6.5", "letters", "for", "patients", "receiving", "Lucentis", "monotherapy", "(p=0.019),", "representing", "a", "statistically", "significant", "62%", "additional", "benefit."], "wordsB": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s3", "idA": "906709_15_item1_p98_s2", "sentA": "Patients receiving the combination of Fovista (1.5 mg) and Lucentis gained a mean of 10.6 letters of vision at 24 weeks on the Early Treatment Diabetic Retinopathy Study standardized eye chart, compared to 6.5 letters for patients receiving Lucentis monotherapy (p=0.019), representing a statistically significant 62% additional benefit.", "sentB": "In a topline analysis of 852 patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival (OS) over TPC (12.4 months for patients receiving NKTR-102 compared to 10.3 months for patients receiving TPC).", "type": 1, "words": ["<tag1>", "Patients", "receiving", "the", "combination", "of", "Fovista", "(1.5", "mg)", "and", "Lucentis", "gained", "a", "mean", "of", "10.6", "letters", "of", "vision", "at", "24", "weeks", "on", "the", "Early", "Treatment", "Diabetic", "Retinopathy", "Study", "standardized", "eye", "chart,", "compared", "to", "6.5", "letters", "for", "patients", "receiving", "Lucentis", "monotherapy", "(p=0.019),", "representing", "a", "statistically", "significant", "62%", "additional", "benefit.", "<tag2>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag3>"], "wordsA": ["Patients", "receiving", "the", "combination", "of", "Fovista", "(1.5", "mg)", "and", "Lucentis", "gained", "a", "mean", "of", "10.6", "letters", "of", "vision", "at", "24", "weeks", "on", "the", "Early", "Treatment", "Diabetic", "Retinopathy", "Study", "standardized", "eye", "chart,", "compared", "to", "6.5", "letters", "for", "patients", "receiving", "Lucentis", "monotherapy", "(p=0.019),", "representing", "a", "statistically", "significant", "62%", "additional", "benefit."], "wordsB": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p193_s3", "idA": "906709_15_item1_p9_s0", "sentA": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions.", "sentB": "Ms. Thomsen is a certified public accountant and previously was a senior manager at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies.", "type": 1, "words": ["<tag1>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions.", "<tag2>", "Ms.", "Thomsen", "is", "a", "certified", "public", "accountant", "and", "previously", "was", "a", "senior", "manager", "at", "Arthur", "Andersen", "LLP,", "where", "she", "worked", "from", "1990", "to", "2002,", "and", "specialized", "in", "audits", "of", "multinational", "consumer", "products,", "life", "sciences,", "manufacturing", "and", "energy", "companies.", "<tag3>"], "wordsA": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions."], "wordsB": ["Ms.", "Thomsen", "is", "a", "certified", "public", "accountant", "and", "previously", "was", "a", "senior", "manager", "at", "Arthur", "Andersen", "LLP,", "where", "she", "worked", "from", "1990", "to", "2002,", "and", "specialized", "in", "audits", "of", "multinational", "consumer", "products,", "life", "sciences,", "manufacturing", "and", "energy", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p169_s2", "idA": "906709_15_item1_p9_s1", "sentA": "NKTR-181 has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such as sedation and respiratory depression, which are associated with standard opioid therapies.", "sentB": "These drugs include drugs that fall into the categories of antipseudomonal cephalosporins, antipseudomonal carbepenems, beta-lactam/beta-lactamase inhibitors, antipseudomonal fluoroquinolones, such as ciprofloxacin or levofloxacin, and aminoglycosides, such as amikacin, gentamycin or tobramycin.", "type": 1, "words": ["<tag1>", "NKTR-181", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "associated", "with", "standard", "opioid", "therapies.", "<tag2>", "These", "drugs", "include", "drugs", "that", "fall", "into", "the", "categories", "of", "antipseudomonal", "cephalosporins,", "antipseudomonal", "carbepenems,", "beta-lactam/beta-lactamase", "inhibitors,", "antipseudomonal", "fluoroquinolones,", "such", "as", "ciprofloxacin", "or", "levofloxacin,", "and", "aminoglycosides,", "such", "as", "amikacin,", "gentamycin", "or", "tobramycin.", "<tag3>"], "wordsA": ["NKTR-181", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "associated", "with", "standard", "opioid", "therapies."], "wordsB": ["These", "drugs", "include", "drugs", "that", "fall", "into", "the", "categories", "of", "antipseudomonal", "cephalosporins,", "antipseudomonal", "carbepenems,", "beta-lactam/beta-lactamase", "inhibitors,", "antipseudomonal", "fluoroquinolones,", "such", "as", "ciprofloxacin", "or", "levofloxacin,", "and", "aminoglycosides,", "such", "as", "amikacin,", "gentamycin", "or", "tobramycin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p107_s1", "idA": "906709_16_item1_p124_s3", "sentA": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc.", "sentB": "On November 10, 2016 Halozyme announced an agreement with Genentech, a amember of the Roche Group, to collaborate, beginning in 2017, on clinical studies evaluating PEGPH20 in up to eight different tumor types.", "type": 1, "words": ["<tag1>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "<tag2>", "On", "November", "10,", "2016", "Halozyme", "announced", "an", "agreement", "with", "Genentech,", "a", "amember", "of", "the", "Roche", "Group,", "to", "collaborate,", "beginning", "in", "2017,", "on", "clinical", "studies", "evaluating", "PEGPH20", "in", "up", "to", "eight", "different", "tumor", "types.", "<tag3>"], "wordsA": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc."], "wordsB": ["On", "November", "10,", "2016", "Halozyme", "announced", "an", "agreement", "with", "Genentech,", "a", "amember", "of", "the", "Roche", "Group,", "to", "collaborate,", "beginning", "in", "2017,", "on", "clinical", "studies", "evaluating", "PEGPH20", "in", "up", "to", "eight", "different", "tumor", "types."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p6_s0", "idA": "906709_16_item1_p135_s1", "sentA": "Phase 2 involves studies in a limited patient population to:", "sentB": "There is consistent evidence that suboptimal T regulatory cell numbers and their lack of activity play a significant role in a myriad of autoimmune diseases.", "type": 1, "words": ["<tag1>", "Phase", "2", "involves", "studies", "in", "a", "limited", "patient", "population", "to:", "<tag2>", "There", "is", "consistent", "evidence", "that", "suboptimal", "T", "regulatory", "cell", "numbers", "and", "their", "lack", "of", "activity", "play", "a", "significant", "role", "in", "a", "myriad", "of", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Phase", "2", "involves", "studies", "in", "a", "limited", "patient", "population", "to:"], "wordsB": ["There", "is", "consistent", "evidence", "that", "suboptimal", "T", "regulatory", "cell", "numbers", "and", "their", "lack", "of", "activity", "play", "a", "significant", "role", "in", "a", "myriad", "of", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p103_s3", "idA": "906709_16_item1_p156_s6", "sentA": "We may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us.", "sentB": "The addition of Fovista to a monthly Lucentis regimen did not result in benefit as measured by the mean change in visual acuity at the 12 month time point.", "type": 1, "words": ["<tag1>", "We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us.", "<tag2>", "The", "addition", "of", "Fovista", "to", "a", "monthly", "Lucentis", "regimen", "did", "not", "result", "in", "benefit", "as", "measured", "by", "the", "mean", "change", "in", "visual", "acuity", "at", "the", "12", "month", "time", "point.", "<tag3>"], "wordsA": ["We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us."], "wordsB": ["The", "addition", "of", "Fovista", "to", "a", "monthly", "Lucentis", "regimen", "did", "not", "result", "in", "benefit", "as", "measured", "by", "the", "mean", "change", "in", "visual", "acuity", "at", "the", "12", "month", "time", "point."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p0_s4", "idA": "906709_16_item1_p158_s3", "sentA": "Please refer to Item 1A, Risk Factors, including without limitation, We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.", "sentB": "We refer to our drug candidates where we retain at least U.S. commercial rights as proprietary programs and our other drug candidate programs that we have licensed U.S. and potentially other commercial rights to collaboration partners as collaboration partner programs.", "type": 1, "words": ["<tag1>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "may", "not", "be", "able", "to", "obtain", "intellectual", "property", "licenses", "related", "to", "the", "development", "of", "our", "drug", "candidates", "on", "a", "commercially", "reasonable", "basis,", "if", "at", "all.", "<tag2>", "We", "refer", "to", "our", "drug", "candidates", "where", "we", "retain", "at", "least", "U.S.", "commercial", "rights", "as", "proprietary", "programs", "and", "our", "other", "drug", "candidate", "programs", "that", "we", "have", "licensed", "U.S.", "and", "potentially", "other", "commercial", "rights", "to", "collaboration", "partners", "as", "collaboration", "partner", "programs.", "<tag3>"], "wordsA": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "may", "not", "be", "able", "to", "obtain", "intellectual", "property", "licenses", "related", "to", "the", "development", "of", "our", "drug", "candidates", "on", "a", "commercially", "reasonable", "basis,", "if", "at", "all."], "wordsB": ["We", "refer", "to", "our", "drug", "candidates", "where", "we", "retain", "at", "least", "U.S.", "commercial", "rights", "as", "proprietary", "programs", "and", "our", "other", "drug", "candidate", "programs", "that", "we", "have", "licensed", "U.S.", "and", "potentially", "other", "commercial", "rights", "to", "collaboration", "partners", "as", "collaboration", "partner", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p45_s0", "idA": "906709_16_item1_p174_s0", "sentA": "Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time.", "sentB": "body and must be administered frequently and in high doses limiting its utility due to toxicity.", "type": 1, "words": ["<tag1>", "Environmental", "laws", "and", "regulations", "are", "complex,", "change", "frequently", "and", "have", "tended", "to", "become", "more", "stringent", "over", "time.", "<tag2>", "body", "and", "must", "be", "administered", "frequently", "and", "in", "high", "doses", "limiting", "its", "utility", "due", "to", "toxicity.", "<tag3>"], "wordsA": ["Environmental", "laws", "and", "regulations", "are", "complex,", "change", "frequently", "and", "have", "tended", "to", "become", "more", "stringent", "over", "time."], "wordsB": ["body", "and", "must", "be", "administered", "frequently", "and", "in", "high", "doses", "limiting", "its", "utility", "due", "to", "toxicity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p29_s3", "idA": "906709_16_item1_p17_s0", "sentA": "With our expertise and proprietary technology in PEGylation, we have created the next generation of PEGylation technology.", "sentB": "By biasing the receptor binding of these molecules in complementary ways, we have made two different drug candidates: NKTR-214, which selectively activates effector T-cells, which kill tumors; and NKTR-358, which selectively activates regulatory T-cells, which can reduce the pathological immune activation that underlies many autoimmune diseases.", "type": 1, "words": ["<tag1>", "With", "our", "expertise", "and", "proprietary", "technology", "in", "PEGylation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology.", "<tag2>", "By", "biasing", "the", "receptor", "binding", "of", "these", "molecules", "in", "complementary", "ways,", "we", "have", "made", "two", "different", "drug", "candidates:", "NKTR-214,", "which", "selectively", "activates", "effector", "T-cells,", "which", "kill", "tumors;", "and", "NKTR-358,", "which", "selectively", "activates", "regulatory", "T-cells,", "which", "can", "reduce", "the", "pathological", "immune", "activation", "that", "underlies", "many", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["With", "our", "expertise", "and", "proprietary", "technology", "in", "PEGylation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology."], "wordsB": ["By", "biasing", "the", "receptor", "binding", "of", "these", "molecules", "in", "complementary", "ways,", "we", "have", "made", "two", "different", "drug", "candidates:", "NKTR-214,", "which", "selectively", "activates", "effector", "T-cells,", "which", "kill", "tumors;", "and", "NKTR-358,", "which", "selectively", "activates", "regulatory", "T-cells,", "which", "can", "reduce", "the", "pathological", "immune", "activation", "that", "underlies", "many", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p48_s0", "idA": "906709_16_item1_p21_s2", "sentA": "With our releasable polymer conjugate technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "NKTR-358 targets the CD25 sub-receptor in the interleukin-2 pathway in order to stimulate proliferation and growth of T regulatory cells, which are specific immune cells in the body that modulate the immune system and prevent auto-immune disease by maintaining self-tolerance.", "type": 1, "words": ["<tag1>", "With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "NKTR-358", "targets", "the", "CD25", "sub-receptor", "in", "the", "interleukin-2", "pathway", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "T", "regulatory", "cells,", "which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance.", "<tag3>"], "wordsA": ["With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["NKTR-358", "targets", "the", "CD25", "sub-receptor", "in", "the", "interleukin-2", "pathway", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "T", "regulatory", "cells,", "which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p45_s1", "idA": "906709_16_item1_p56_s1", "sentA": "NKTR-181 is designed with the objective to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies.", "sentB": "NKTR-255 is designed with IL-15 receptor alpha specificity to optimize biological a ctivity and is uniquely engineered to provide optimal exposure and an improved safety profile.", "type": 1, "words": ["<tag1>", "NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag2>", "NKTR-255", "is", "designed", "with", "IL-15", "receptor", "alpha", "specificity", "to", "optimize", "biological", "a", "ctivity", "and", "is", "uniquely", "engineered", "to", "provide", "optimal", "exposure", "and", "an", "improved", "safety", "profile.", "<tag3>"], "wordsA": ["NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "wordsB": ["NKTR-255", "is", "designed", "with", "IL-15", "receptor", "alpha", "specificity", "to", "optimize", "biological", "a", "ctivity", "and", "is", "uniquely", "engineered", "to", "provide", "optimal", "exposure", "and", "an", "improved", "safety", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p47_s0", "idA": "906709_16_item1_p56_s1", "sentA": "NKTR-181 is designed with the objective to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies.", "sentB": "Current systemic treatments for autoimmune disease, including corticosteroids and anti-TNF agents, suppress the immune system broadly and come with severe side effects.", "type": 1, "words": ["<tag1>", "NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag2>", "Current", "systemic", "treatments", "for", "autoimmune", "disease,", "including", "corticosteroids", "and", "anti-TNF", "agents,", "suppress", "the", "immune", "system", "broadly", "and", "come", "with", "severe", "side", "effects.", "<tag3>"], "wordsA": ["NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "wordsB": ["Current", "systemic", "treatments", "for", "autoimmune", "disease,", "including", "corticosteroids", "and", "anti-TNF", "agents,", "suppress", "the", "immune", "system", "broadly", "and", "come", "with", "severe", "side", "effects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p48_s2", "idA": "906709_16_item1_p60_s2", "sentA": "We enrolled the first patient in this first Phase 3 study in February 2015 .", "sentB": "We filed an IND for Nektar-358 in February 2017.", "type": 1, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "in", "February", "2015", ".", "<tag2>", "We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "in", "February", "2015", "."], "wordsB": ["We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p4_s0", "idA": "906709_16_item1_p64_s2", "sentA": "Unlike irinotecan, which is a first generation topo I inhibitor that exhibits a high initial peak concentration and short half-life, NKTR-102 s pro-drug design results in a lower initial peak concentration of active topo I inhibitor in the blood.", "sentB": "The breakdown of mechanisms assuring recognition of self and non-self is what underlies all autoimmune diseases.", "type": 1, "words": ["<tag1>", "Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "NKTR-102", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood.", "<tag2>", "The", "breakdown", "of", "mechanisms", "assuring", "recognition", "of", "self", "and", "non-self", "is", "what", "underlies", "all", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "NKTR-102", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood."], "wordsB": ["The", "breakdown", "of", "mechanisms", "assuring", "recognition", "of", "self", "and", "non-self", "is", "what", "underlies", "all", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p55_s2", "idA": "906709_16_item1_p69_s12", "sentA": "We are currently evaluating next steps for this program.", "sentB": "We are now conducting blinded data verification activities and currently plan to un-blind and announce the top-line data from SUMMIT-07 in March 2017.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program.", "<tag2>", "We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "un-blind", "and", "announce", "the", "top-line", "data", "from", "SUMMIT-07", "in", "March", "2017.", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program."], "wordsB": ["We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "un-blind", "and", "announce", "the", "top-line", "data", "from", "SUMMIT-07", "in", "March", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p9_s2", "idA": "906709_16_item1_p69_s12", "sentA": "We are currently evaluating next steps for this program.", "sentB": "We are now conducting blinded data verification activities and currently plan to un-blind and announce the top-line data from SUMMIT-07 in March 2017.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program.", "<tag2>", "We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "un-blind", "and", "announce", "the", "top-line", "data", "from", "SUMMIT-07", "in", "March", "2017.", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program."], "wordsB": ["We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "un-blind", "and", "announce", "the", "top-line", "data", "from", "SUMMIT-07", "in", "March", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p8_s1", "idA": "906709_16_item1_p69_s4", "sentA": "We also announced that we observed a significant overall survival benefit in two pre-specified subgroups patients with a history of brain metastases and patients with baseline liver metastases at study entry.", "sentB": "In 2017, clinical trials are planned for NKTR-358 in healthy volunteers and patients with systemic lupus erythematous (SLE) and other indications.", "type": 1, "words": ["<tag1>", "We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroups", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry.", "<tag2>", "In", "2017,", "clinical", "trials", "are", "planned", "for", "NKTR-358", "in", "healthy", "volunteers", "and", "patients", "with", "systemic", "lupus", "erythematous", "(SLE)", "and", "other", "indications.", "<tag3>"], "wordsA": ["We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroups", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry."], "wordsB": ["In", "2017,", "clinical", "trials", "are", "planned", "for", "NKTR-358", "in", "healthy", "volunteers", "and", "patients", "with", "systemic", "lupus", "erythematous", "(SLE)", "and", "other", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s1", "idA": "906709_16_item1_p81_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "We are developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.", "type": 1, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "We", "are", "developing", "medicines", "designed", "to", "directly", "or", "indirectly", "modulate", "the", "activity", "of", "key", "immune", "cells,", "such", "as", "cytotoxic", "T", "cells", "and", "Natural", "Killer", "(NK)", "cells,", "to", "increase", "their", "numbers", "and", "improve", "their", "function", "to", "recognize", "and", "attack", "cancer", "cells.", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["We", "are", "developing", "medicines", "designed", "to", "directly", "or", "indirectly", "modulate", "the", "activity", "of", "key", "immune", "cells,", "such", "as", "cytotoxic", "T", "cells", "and", "Natural", "Killer", "(NK)", "cells,", "to", "increase", "their", "numbers", "and", "improve", "their", "function", "to", "recognize", "and", "attack", "cancer", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s2", "idA": "906709_16_item1_p81_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "NKTR-214, our lead I-O candidate, is a biologic with biased signaling through one of the IL-2 receptor subunits (CD 122) that can stimulate proliferation and growth of tumor-killing immune cells in the tumor micro-environment and increase expression of PD-1 on these immune cells.", "type": 1, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "NKTR-214,", "our", "lead", "I-O", "candidate,", "is", "a", "biologic", "with", "biased", "signaling", "through", "one", "of", "the", "IL-2", "receptor", "subunits", "(CD", "122)", "that", "can", "stimulate", "proliferation", "and", "growth", "of", "tumor-killing", "immune", "cells", "in", "the", "tumor", "micro-environment", "and", "increase", "expression", "of", "PD-1", "on", "these", "immune", "cells.", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["NKTR-214,", "our", "lead", "I-O", "candidate,", "is", "a", "biologic", "with", "biased", "signaling", "through", "one", "of", "the", "IL-2", "receptor", "subunits", "(CD", "122)", "that", "can", "stimulate", "proliferation", "and", "growth", "of", "tumor-killing", "immune", "cells", "in", "the", "tumor", "micro-environment", "and", "increase", "expression", "of", "PD-1", "on", "these", "immune", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p44_s1", "idA": "906709_16_item1_p81_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "Through optimal engagement of the IL-15R /IL-2R receptor complex, NKTR-255 stimulates proliferation and survival of CD8+ T cells, natural killer (NK) cells and enhances formation of long-term immunological memory which may lead to sustained anti-tumor immune response.", "type": 1, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "Through", "optimal", "engagement", "of", "the", "IL-15R", "/IL-2R", "receptor", "complex,", "NKTR-255", "stimulates", "proliferation", "and", "survival", "of", "CD8+", "T", "cells,", "natural", "killer", "(NK)", "cells", "and", "enhances", "formation", "of", "long-term", "immunological", "memory", "which", "may", "lead", "to", "sustained", "anti-tumor", "immune", "response.", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["Through", "optimal", "engagement", "of", "the", "IL-15R", "/IL-2R", "receptor", "complex,", "NKTR-255", "stimulates", "proliferation", "and", "survival", "of", "CD8+", "T", "cells,", "natural", "killer", "(NK)", "cells", "and", "enhances", "formation", "of", "long-term", "immunological", "memory", "which", "may", "lead", "to", "sustained", "anti-tumor", "immune", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p29_s1", "idA": "906709_16_item1_p84_s1", "sentA": "NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "sentB": "For instance, the cytokine Interleukin-2 (IL-2) has two different receptor complexes in the body that cause opposing effects on the immune system.", "type": 1, "words": ["<tag1>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag2>", "For", "instance,", "the", "cytokine", "Interleukin-2", "(IL-2)", "has", "two", "different", "receptor", "complexes", "in", "the", "body", "that", "cause", "opposing", "effects", "on", "the", "immune", "system.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "wordsB": ["For", "instance,", "the", "cytokine", "Interleukin-2", "(IL-2)", "has", "two", "different", "receptor", "complexes", "in", "the", "body", "that", "cause", "opposing", "effects", "on", "the", "immune", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p11_s2", "idA": "906709_16_item1_p90_s0", "sentA": "Baxalta commenced patient enrollment in a Phase 3 clinical study of ADYNOVATE TM in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "In January 2017, we started enrollment in a second HAL study where we are assessing abuse liability of supra-therapeutic doses of NKTR-181 in order to further evaluate NKTR-181 for labeling and scheduling purposes.", "type": 1, "words": ["<tag1>", "Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "In", "January", "2017,", "we", "started", "enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "purposes.", "<tag3>"], "wordsA": ["Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["In", "January", "2017,", "we", "started", "enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "purposes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p55_s0", "idA": "906709_16_item1_p90_s0", "sentA": "Baxalta commenced patient enrollment in a Phase 3 clinical study of ADYNOVATE TM in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "enrollment in a second HAL study where we are assessing abuse liability of supra-therapeutic doses of NKTR-181 in order to further evaluate NKTR-181 for labeling and scheduling p urposes.", "type": 1, "words": ["<tag1>", "Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "p", "urposes.", "<tag3>"], "wordsA": ["Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "p", "urposes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p17_s3", "idA": "906709_16_item1_p90_s5", "sentA": "In December 2015, Baxalta announced positive study results from its prospective, uncontrolled, open-label, multi-center Phase 3 study designed to assess the safety and immunogenicity of ADYNOVATE TM .", "sentB": "The second Phase 3 trial (RESPIRE 2) completed recruitment in September 2016 and Bayer Schering has not yet reported the results from RESPIRE 2.", "type": 1, "words": ["<tag1>", "In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", ".", "<tag2>", "The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2.", "<tag3>"], "wordsA": ["In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", "."], "wordsB": ["The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p99_s1", "idA": "906709_16_item1_p90_s5", "sentA": "In December 2015, Baxalta announced positive study results from its prospective, uncontrolled, open-label, multi-center Phase 3 study designed to assess the safety and immunogenicity of ADYNOVATE TM .", "sentB": "The second Phase 3 trial (RESPIRE 2) completed recruitment in September 2016 and Bayer Schering has not yet reported the results from RESPIRE 2.", "type": 1, "words": ["<tag1>", "In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", ".", "<tag2>", "The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2.", "<tag3>"], "wordsA": ["In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", "."], "wordsB": ["The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p18_s0", "idA": "906709_17_item1_p109_s4", "sentA": "Either party may terminate the agreement upon a material, uncured default of the other party.", "sentB": "GmbH (Daiichi), exercising its right to terminate the Collaboration and License Agreement between us and Daiich i (the Daiichi Collaboration Agreement), which termination became effective on February 4, 2018.", "type": 1, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party.", "<tag2>", "GmbH", "(Daiichi),", "exercising", "its", "right", "to", "terminate", "the", "Collaboration", "and", "License", "Agreement", "between", "us", "and", "Daiich", "i", "(the", "Daiichi", "Collaboration", "Agreement),", "which", "termination", "became", "effective", "on", "February", "4,", "2018.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party."], "wordsB": ["GmbH", "(Daiichi),", "exercising", "its", "right", "to", "terminate", "the", "Collaboration", "and", "License", "Agreement", "between", "us", "and", "Daiich", "i", "(the", "Daiichi", "Collaboration", "Agreement),", "which", "termination", "became", "effective", "on", "February", "4,", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p69_s11", "idA": "906709_17_item1_p109_s4", "sentA": "Either party may terminate the agreement upon a material, uncured default of the other party.", "sentB": "On December 6, 2017 we received notice of termination from Daiichi exercising its right to terminate the Daiichi Collaboration Agreement, which termination became effective on February 4, 2018.", "type": 1, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party.", "<tag2>", "On", "December", "6,", "2017", "we", "received", "notice", "of", "termination", "from", "Daiichi", "exercising", "its", "right", "to", "terminate", "the", "Daiichi", "Collaboration", "Agreement,", "which", "termination", "became", "effective", "on", "February", "4,", "2018.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party."], "wordsB": ["On", "December", "6,", "2017", "we", "received", "notice", "of", "termination", "from", "Daiichi", "exercising", "its", "right", "to", "terminate", "the", "Daiichi", "Collaboration", "Agreement,", "which", "termination", "became", "effective", "on", "February", "4,", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p156_s4", "idA": "906709_17_item1_p110_s0", "sentA": "SEMPRANA is a self-administered formulation of DHE using an inhaler device that is currently under review by the FDA.", "sentB": "Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $10,781 and $21,916 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes.", "type": 1, "words": ["<tag1>", "SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA.", "<tag2>", "Penalties", "for", "a", "False", "Claims", "Act", "violation", "include", "three", "times", "the", "actual", "damages", "sustained", "by", "the", "government,", "plus", "mandatory", "civil", "penalties", "of", "between", "$10,781", "and", "$21,916", "for", "each", "separate", "false", "claim,", "the", "potential", "for", "exclusion", "from", "participation", "in", "federal", "healthcare", "programs,", "and,", "although", "the", "federal", "False", "Claims", "Act", "is", "a", "civil", "statute,", "conduct", "that", "results", "in", "a", "False", "Claims", "Act", "violation", "may", "also", "implicate", "various", "federal", "criminal", "statutes.", "<tag3>"], "wordsA": ["SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA."], "wordsB": ["Penalties", "for", "a", "False", "Claims", "Act", "violation", "include", "three", "times", "the", "actual", "damages", "sustained", "by", "the", "government,", "plus", "mandatory", "civil", "penalties", "of", "between", "$10,781", "and", "$21,916", "for", "each", "separate", "false", "claim,", "the", "potential", "for", "exclusion", "from", "participation", "in", "federal", "healthcare", "programs,", "and,", "although", "the", "federal", "False", "Claims", "Act", "is", "a", "civil", "statute,", "conduct", "that", "results", "in", "a", "False", "Claims", "Act", "violation", "may", "also", "implicate", "various", "federal", "criminal", "statutes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s13", "idA": "906709_17_item1_p11_s1", "sentA": "In this study, NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "sentB": "Key secondary endpoints of Area Under Effect for Drug Liking (0-1 hours, 0-2 hours, 0-3 hours), Drug High and Take Drug Again scores met statistical significance for all doses of NKTR-181 (1200 mg, 600 mg, 400 mg) compared to oxycodone (60 mg).", "type": 1, "words": ["<tag1>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag2>", "Key", "secondary", "endpoints", "of", "Area", "Under", "Effect", "for", "Drug", "Liking", "(0-1", "hours,", "0-2", "hours,", "0-3", "hours),", "Drug", "High", "and", "Take", "Drug", "Again", "scores", "met", "statistical", "significance", "for", "all", "doses", "of", "NKTR-181", "(1200", "mg,", "600", "mg,", "400", "mg)", "compared", "to", "oxycodone", "(60", "mg).", "<tag3>"], "wordsA": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "wordsB": ["Key", "secondary", "endpoints", "of", "Area", "Under", "Effect", "for", "Drug", "Liking", "(0-1", "hours,", "0-2", "hours,", "0-3", "hours),", "Drug", "High", "and", "Take", "Drug", "Again", "scores", "met", "statistical", "significance", "for", "all", "doses", "of", "NKTR-181", "(1200", "mg,", "600", "mg,", "400", "mg)", "compared", "to", "oxycodone", "(60", "mg)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p157_s0", "idA": "906709_17_item1_p130_s0", "sentA": "The research and development, clinical testing, manufacture and marketing of products using our technologies are subject to regulation by the FDA and by comparable regulatory agencies in other countries.", "sentB": "Legislative and Regulatory Landscape From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage and reimbursement of products regulated by the FDA or other government agencies.", "type": 1, "words": ["<tag1>", "The", "research", "and", "development,", "clinical", "testing,", "manufacture", "and", "marketing", "of", "products", "using", "our", "technologies", "are", "subject", "to", "regulation", "by", "the", "FDA", "and", "by", "comparable", "regulatory", "agencies", "in", "other", "countries.", "<tag2>", "Legislative", "and", "Regulatory", "Landscape", "From", "time", "to", "time,", "legislation", "is", "drafted,", "introduced", "and", "passed", "in", "Congress", "that", "could", "significantly", "change", "the", "statutory", "provisions", "governing", "the", "testing,", "approval,", "manufacturing,", "marketing,", "coverage", "and", "reimbursement", "of", "products", "regulated", "by", "the", "FDA", "or", "other", "government", "agencies.", "<tag3>"], "wordsA": ["The", "research", "and", "development,", "clinical", "testing,", "manufacture", "and", "marketing", "of", "products", "using", "our", "technologies", "are", "subject", "to", "regulation", "by", "the", "FDA", "and", "by", "comparable", "regulatory", "agencies", "in", "other", "countries."], "wordsB": ["Legislative", "and", "Regulatory", "Landscape", "From", "time", "to", "time,", "legislation", "is", "drafted,", "introduced", "and", "passed", "in", "Congress", "that", "could", "significantly", "change", "the", "statutory", "provisions", "governing", "the", "testing,", "approval,", "manufacturing,", "marketing,", "coverage", "and", "reimbursement", "of", "products", "regulated", "by", "the", "FDA", "or", "other", "government", "agencies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p156_s3", "idA": "906709_17_item1_p135_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "For example, pharmaceutical companies have been prosecuted under the federal False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product.", "type": 1, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "For", "example,", "pharmaceutical", "companies", "have", "been", "prosecuted", "under", "the", "federal", "False", "Claims", "Act", "in", "connection", "with", "their", "alleged", "off-label", "promotion", "of", "drugs,", "purportedly", "concealing", "price", "concessions", "in", "the", "pricing", "information", "submitted", "to", "the", "government", "for", "government", "price", "reporting", "purposes,", "and", "allegedly", "providing", "free", "product", "to", "customers", "with", "the", "expectation", "that", "the", "customers", "would", "bill", "federal", "health", "care", "programs", "for", "the", "product.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["For", "example,", "pharmaceutical", "companies", "have", "been", "prosecuted", "under", "the", "federal", "False", "Claims", "Act", "in", "connection", "with", "their", "alleged", "off-label", "promotion", "of", "drugs,", "purportedly", "concealing", "price", "concessions", "in", "the", "pricing", "information", "submitted", "to", "the", "government", "for", "government", "price", "reporting", "purposes,", "and", "allegedly", "providing", "free", "product", "to", "customers", "with", "the", "expectation", "that", "the", "customers", "would", "bill", "federal", "health", "care", "programs", "for", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p153_s0", "idA": "906709_17_item1_p135_s5", "sentA": "The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted.", "sentB": "The Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act (collectively, the Affordable Care Act ), enacted in 2010, expanded the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal fraud statutes contained within 42 U.S.C. 1320a-7b.", "type": 1, "words": ["<tag1>", "The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted.", "<tag2>", "The", "Patient", "Protection", "and", "Affordable", "Care", "Act,", "as", "amended", "by", "the", "Health", "Care", "Education", "Reconciliation", "Act", "(collectively,", "the", "Affordable", "Care", "Act", "),", "enacted", "in", "2010,", "expanded", "the", "reach", "of", "the", "fraud", "and", "abuse", "laws", "by,", "among", "other", "things,", "amending", "the", "intent", "requirement", "of", "the", "federal", "Anti-Kickback", "Statute", "and", "the", "applicable", "criminal", "fraud", "statutes", "contained", "within", "42", "U.S.C.", "1320a-7b.", "<tag3>"], "wordsA": ["The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted."], "wordsB": ["The", "Patient", "Protection", "and", "Affordable", "Care", "Act,", "as", "amended", "by", "the", "Health", "Care", "Education", "Reconciliation", "Act", "(collectively,", "the", "Affordable", "Care", "Act", "),", "enacted", "in", "2010,", "expanded", "the", "reach", "of", "the", "fraud", "and", "abuse", "laws", "by,", "among", "other", "things,", "amending", "the", "intent", "requirement", "of", "the", "federal", "Anti-Kickback", "Statute", "and", "the", "applicable", "criminal", "fraud", "statutes", "contained", "within", "42", "U.S.C.", "1320a-7b."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p156_s0", "idA": "906709_17_item1_p135_s5", "sentA": "The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted.", "sentB": "The federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent.", "type": 1, "words": ["<tag1>", "The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted.", "<tag2>", "The", "federal", "False", "Claims", "Act", "prohibits", "anyone", "from,", "among", "other", "things,", "knowingly", "presenting,", "or", "causing", "to", "be", "presented,", "for", "payment", "to", "federal", "programs", "(including", "Medicare", "and", "Medicaid)", "claims", "for", "items", "or", "services", "that", "are", "false", "or", "fraudulent.", "<tag3>"], "wordsA": ["The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted."], "wordsB": ["The", "federal", "False", "Claims", "Act", "prohibits", "anyone", "from,", "among", "other", "things,", "knowingly", "presenting,", "or", "causing", "to", "be", "presented,", "for", "payment", "to", "federal", "programs", "(including", "Medicare", "and", "Medicaid)", "claims", "for", "items", "or", "services", "that", "are", "false", "or", "fraudulent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s10", "idA": "906709_17_item1_p140_s0", "sentA": "The FDA, the clinical trial sponsor, the investigators or the IRB may suspend clinical trials at any time if any one of them believes that study participants are being subjected to an unacceptable health risk.", "sentB": "Coverage policies and third-party reimbursement rates may change at any time.", "type": 1, "words": ["<tag1>", "The", "FDA,", "the", "clinical", "trial", "sponsor,", "the", "investigators", "or", "the", "IRB", "may", "suspend", "clinical", "trials", "at", "any", "time", "if", "any", "one", "of", "them", "believes", "that", "study", "participants", "are", "being", "subjected", "to", "an", "unacceptable", "health", "risk.", "<tag2>", "Coverage", "policies", "and", "third-party", "reimbursement", "rates", "may", "change", "at", "any", "time.", "<tag3>"], "wordsA": ["The", "FDA,", "the", "clinical", "trial", "sponsor,", "the", "investigators", "or", "the", "IRB", "may", "suspend", "clinical", "trials", "at", "any", "time", "if", "any", "one", "of", "them", "believes", "that", "study", "participants", "are", "being", "subjected", "to", "an", "unacceptable", "health", "risk."], "wordsB": ["Coverage", "policies", "and", "third-party", "reimbursement", "rates", "may", "change", "at", "any", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p150_s1", "idA": "906709_17_item1_p141_s2", "sentA": "Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy all of the criteria for approval.", "sentB": "Third-party payors may limit coverage to specific products on an approved list or formulary which might not include all of the FDA-approved products for a particular indication.", "type": 1, "words": ["<tag1>", "Even", "if", "such", "data", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "or", "BLA", "does", "not", "satisfy", "all", "of", "the", "criteria", "for", "approval.", "<tag2>", "Third-party", "payors", "may", "limit", "coverage", "to", "specific", "products", "on", "an", "approved", "list", "or", "formulary", "which", "might", "not", "include", "all", "of", "the", "FDA-approved", "products", "for", "a", "particular", "indication.", "<tag3>"], "wordsA": ["Even", "if", "such", "data", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "or", "BLA", "does", "not", "satisfy", "all", "of", "the", "criteria", "for", "approval."], "wordsB": ["Third-party", "payors", "may", "limit", "coverage", "to", "specific", "products", "on", "an", "approved", "list", "or", "formulary", "which", "might", "not", "include", "all", "of", "the", "FDA-approved", "products", "for", "a", "particular", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p154_s1", "idA": "906709_17_item1_p149_s2", "sentA": "In addition, the Orphan Drug Act provides for protocol assistance, tax credits, research grants, and exclusions from user fees for sponsors of orphan products.", "sentB": "In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute.", "type": 1, "words": ["<tag1>", "In", "addition,", "the", "Orphan", "Drug", "Act", "provides", "for", "protocol", "assistance,", "tax", "credits,", "research", "grants,", "and", "exclusions", "from", "user", "fees", "for", "sponsors", "of", "orphan", "products.", "<tag2>", "In", "addition,", "the", "Affordable", "Care", "Act", "provides", "that", "the", "government", "may", "assert", "that", "a", "claim", "including", "items", "or", "services", "resulting", "from", "a", "violation", "of", "the", "federal", "Anti-Kickback", "Statute", "constitutes", "a", "false", "or", "fraudulent", "claim", "for", "purposes", "of", "the", "civil", "False", "Claims", "Act", "or", "the", "civil", "monetary", "penalties", "statute.", "<tag3>"], "wordsA": ["In", "addition,", "the", "Orphan", "Drug", "Act", "provides", "for", "protocol", "assistance,", "tax", "credits,", "research", "grants,", "and", "exclusions", "from", "user", "fees", "for", "sponsors", "of", "orphan", "products."], "wordsB": ["In", "addition,", "the", "Affordable", "Care", "Act", "provides", "that", "the", "government", "may", "assert", "that", "a", "claim", "including", "items", "or", "services", "resulting", "from", "a", "violation", "of", "the", "federal", "Anti-Kickback", "Statute", "constitutes", "a", "false", "or", "fraudulent", "claim", "for", "purposes", "of", "the", "civil", "False", "Claims", "Act", "or", "the", "civil", "monetary", "penalties", "statute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s2", "idA": "906709_17_item1_p150_s0", "sentA": "Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the exclusivity period only if the second product is shown to be clinically superior to the original orphan drug in that it is more effective, safer or otherwise makes a major contribution to patient care or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated.", "sentB": "For example, the Medicaid Drug Rebate Program, which is part of the Medicaid program (a program for financially needy patients, amon g others), requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services under which the manufacturer agrees to report certain prices to the government a nd pay rebates to state Medicaid programs on outpatient drugs furnished to Medicaid patients, as a condition for receiving federal reimbursement for the manufacturer s outpatient drugs furnished to Medicaid patients.", "type": 1, "words": ["<tag1>", "Once", "a", "product", "receives", "orphan", "drug", "exclusivity,", "a", "second", "product", "that", "is", "considered", "to", "be", "the", "same", "drug", "for", "the", "same", "indication", "generally", "may", "be", "approved", "during", "the", "exclusivity", "period", "only", "if", "the", "second", "product", "is", "shown", "to", "be", "clinically", "superior", "to", "the", "original", "orphan", "drug", "in", "that", "it", "is", "more", "effective,", "safer", "or", "otherwise", "makes", "a", "major", "contribution", "to", "patient", "care", "or", "the", "holder", "of", "exclusive", "approval", "cannot", "assure", "the", "availability", "of", "sufficient", "quantities", "of", "the", "orphan", "drug", "to", "meet", "the", "needs", "of", "patients", "with", "the", "disease", "or", "condition", "for", "which", "the", "drug", "was", "designated.", "<tag2>", "For", "example,", "the", "Medicaid", "Drug", "Rebate", "Program,", "which", "is", "part", "of", "the", "Medicaid", "program", "(a", "program", "for", "financially", "needy", "patients,", "amon", "g", "others),", "requires", "pharmaceutical", "manufacturers", "to", "enter", "into", "and", "have", "in", "effect", "a", "national", "rebate", "agreement", "with", "the", "Secretary", "of", "the", "Department", "of", "Health", "and", "Human", "Services", "under", "which", "the", "manufacturer", "agrees", "to", "report", "certain", "prices", "to", "the", "government", "a", "nd", "pay", "rebates", "to", "state", "Medicaid", "programs", "on", "outpatient", "drugs", "furnished", "to", "Medicaid", "patients,", "as", "a", "condition", "for", "receiving", "federal", "reimbursement", "for", "the", "manufacturer", "s", "outpatient", "drugs", "furnished", "to", "Medicaid", "patients.", "<tag3>"], "wordsA": ["Once", "a", "product", "receives", "orphan", "drug", "exclusivity,", "a", "second", "product", "that", "is", "considered", "to", "be", "the", "same", "drug", "for", "the", "same", "indication", "generally", "may", "be", "approved", "during", "the", "exclusivity", "period", "only", "if", "the", "second", "product", "is", "shown", "to", "be", "clinically", "superior", "to", "the", "original", "orphan", "drug", "in", "that", "it", "is", "more", "effective,", "safer", "or", "otherwise", "makes", "a", "major", "contribution", "to", "patient", "care", "or", "the", "holder", "of", "exclusive", "approval", "cannot", "assure", "the", "availability", "of", "sufficient", "quantities", "of", "the", "orphan", "drug", "to", "meet", "the", "needs", "of", "patients", "with", "the", "disease", "or", "condition", "for", "which", "the", "drug", "was", "designated."], "wordsB": ["For", "example,", "the", "Medicaid", "Drug", "Rebate", "Program,", "which", "is", "part", "of", "the", "Medicaid", "program", "(a", "program", "for", "financially", "needy", "patients,", "amon", "g", "others),", "requires", "pharmaceutical", "manufacturers", "to", "enter", "into", "and", "have", "in", "effect", "a", "national", "rebate", "agreement", "with", "the", "Secretary", "of", "the", "Department", "of", "Health", "and", "Human", "Services", "under", "which", "the", "manufacturer", "agrees", "to", "report", "certain", "prices", "to", "the", "government", "a", "nd", "pay", "rebates", "to", "state", "Medicaid", "programs", "on", "outpatient", "drugs", "furnished", "to", "Medicaid", "patients,", "as", "a", "condition", "for", "receiving", "federal", "reimbursement", "for", "the", "manufacturer", "s", "outpatient", "drugs", "furnished", "to", "Medicaid", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p4_s1", "idA": "906709_17_item1_p150_s0", "sentA": "Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the exclusivity period only if the second product is shown to be clinically superior to the original orphan drug in that it is more effective, safer or otherwise makes a major contribution to patient care or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated.", "sentB": "The closings are expected to occur during the second quarter of 2018, upon which the BMS Collaboration Agreement will supersede and replace the existing BMS Agreement.", "type": 1, "words": ["<tag1>", "Once", "a", "product", "receives", "orphan", "drug", "exclusivity,", "a", "second", "product", "that", "is", "considered", "to", "be", "the", "same", "drug", "for", "the", "same", "indication", "generally", "may", "be", "approved", "during", "the", "exclusivity", "period", "only", "if", "the", "second", "product", "is", "shown", "to", "be", "clinically", "superior", "to", "the", "original", "orphan", "drug", "in", "that", "it", "is", "more", "effective,", "safer", "or", "otherwise", "makes", "a", "major", "contribution", "to", "patient", "care", "or", "the", "holder", "of", "exclusive", "approval", "cannot", "assure", "the", "availability", "of", "sufficient", "quantities", "of", "the", "orphan", "drug", "to", "meet", "the", "needs", "of", "patients", "with", "the", "disease", "or", "condition", "for", "which", "the", "drug", "was", "designated.", "<tag2>", "The", "closings", "are", "expected", "to", "occur", "during", "the", "second", "quarter", "of", "2018,", "upon", "which", "the", "BMS", "Collaboration", "Agreement", "will", "supersede", "and", "replace", "the", "existing", "BMS", "Agreement.", "<tag3>"], "wordsA": ["Once", "a", "product", "receives", "orphan", "drug", "exclusivity,", "a", "second", "product", "that", "is", "considered", "to", "be", "the", "same", "drug", "for", "the", "same", "indication", "generally", "may", "be", "approved", "during", "the", "exclusivity", "period", "only", "if", "the", "second", "product", "is", "shown", "to", "be", "clinically", "superior", "to", "the", "original", "orphan", "drug", "in", "that", "it", "is", "more", "effective,", "safer", "or", "otherwise", "makes", "a", "major", "contribution", "to", "patient", "care", "or", "the", "holder", "of", "exclusive", "approval", "cannot", "assure", "the", "availability", "of", "sufficient", "quantities", "of", "the", "orphan", "drug", "to", "meet", "the", "needs", "of", "patients", "with", "the", "disease", "or", "condition", "for", "which", "the", "drug", "was", "designated."], "wordsB": ["The", "closings", "are", "expected", "to", "occur", "during", "the", "second", "quarter", "of", "2018,", "upon", "which", "the", "BMS", "Collaboration", "Agreement", "will", "supersede", "and", "replace", "the", "existing", "BMS", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p3_s0", "idA": "906709_17_item1_p155_s6", "sentA": "Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to, or disclose, our trade secrets.", "sentB": "Other than as described above, Nektar may independently develop and commercialize NKTR-214 either alone or in com bination with other Nektar proprietary compounds or third party compounds.", "type": 1, "words": ["<tag1>", "Others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to,", "or", "disclose,", "our", "trade", "secrets.", "<tag2>", "Other", "than", "as", "described", "above,", "Nektar", "may", "independently", "develop", "and", "commercialize", "NKTR-214", "either", "alone", "or", "in", "com", "bination", "with", "other", "Nektar", "proprietary", "compounds", "or", "third", "party", "compounds.", "<tag3>"], "wordsA": ["Others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to,", "or", "disclose,", "our", "trade", "secrets."], "wordsB": ["Other", "than", "as", "described", "above,", "Nektar", "may", "independently", "develop", "and", "commercialize", "NKTR-214", "either", "alone", "or", "in", "com", "bination", "with", "other", "Nektar", "proprietary", "compounds", "or", "third", "party", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p48_s0", "idA": "906709_17_item1_p155_s6", "sentA": "Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to, or disclose, our trade secrets.", "sentB": "Other than as described above, Nektar may independently develop and commercialize NKTR-214 either alone or in combination with other Nektar proprietary compounds or third party compounds.", "type": 1, "words": ["<tag1>", "Others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to,", "or", "disclose,", "our", "trade", "secrets.", "<tag2>", "Other", "than", "as", "described", "above,", "Nektar", "may", "independently", "develop", "and", "commercialize", "NKTR-214", "either", "alone", "or", "in", "combination", "with", "other", "Nektar", "proprietary", "compounds", "or", "third", "party", "compounds.", "<tag3>"], "wordsA": ["Others", "may", "independently", "develop", "substantially", "equivalent", "confidential", "and", "proprietary", "information", "or", "otherwise", "gain", "access", "to,", "or", "disclose,", "our", "trade", "secrets."], "wordsB": ["Other", "than", "as", "described", "above,", "Nektar", "may", "independently", "develop", "and", "commercialize", "NKTR-214", "either", "alone", "or", "in", "combination", "with", "other", "Nektar", "proprietary", "compounds", "or", "third", "party", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p157_s3", "idA": "906709_17_item1_p155_s8", "sentA": "In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs.", "sentB": "While specific changes and their timing are not yet apparent, there may be significant changes to the healthcare environment in the future that could have an adverse effect on anticipated revenues from therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval.", "type": 1, "words": ["<tag1>", "In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs.", "<tag2>", "While", "specific", "changes", "and", "their", "timing", "are", "not", "yet", "apparent,", "there", "may", "be", "significant", "changes", "to", "the", "healthcare", "environment", "in", "the", "future", "that", "could", "have", "an", "adverse", "effect", "on", "anticipated", "revenues", "from", "therapeutic", "candidates", "that", "we", "may", "successfully", "develop", "and", "for", "which", "we", "may", "obtain", "regulatory", "approval.", "<tag3>"], "wordsA": ["In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs."], "wordsB": ["While", "specific", "changes", "and", "their", "timing", "are", "not", "yet", "apparent,", "there", "may", "be", "significant", "changes", "to", "the", "healthcare", "environment", "in", "the", "future", "that", "could", "have", "an", "adverse", "effect", "on", "anticipated", "revenues", "from", "therapeutic", "candidates", "that", "we", "may", "successfully", "develop", "and", "for", "which", "we", "may", "obtain", "regulatory", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p156_s1", "idA": "906709_17_item1_p156_s1", "sentA": "There can be no assurance that patents that have issued will be held valid and enforceable in a court of law.", "sentB": "Although we would not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to cause the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label.", "type": 1, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law.", "<tag2>", "Although", "we", "would", "not", "submit", "claims", "directly", "to", "payors,", "manufacturers", "can", "be", "held", "liable", "under", "these", "laws", "if", "they", "are", "deemed", "to", "cause", "the", "submission", "of", "false", "or", "fraudulent", "claims", "by,", "for", "example,", "providing", "inaccurate", "billing", "or", "coding", "information", "to", "customers", "or", "promoting", "a", "product", "off-label.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law."], "wordsB": ["Although", "we", "would", "not", "submit", "claims", "directly", "to", "payors,", "manufacturers", "can", "be", "held", "liable", "under", "these", "laws", "if", "they", "are", "deemed", "to", "cause", "the", "submission", "of", "false", "or", "fraudulent", "claims", "by,", "for", "example,", "providing", "inaccurate", "billing", "or", "coding", "information", "to", "customers", "or", "promoting", "a", "product", "off-label."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s3", "idA": "906709_17_item1_p156_s6", "sentA": "We may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us.", "sentB": "Further, in order for a pharmaceutical product to receive federal reimbursement under Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the Public Health Service s 340B drug pr icing program.", "type": 1, "words": ["<tag1>", "We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us.", "<tag2>", "Further,", "in", "order", "for", "a", "pharmaceutical", "product", "to", "receive", "federal", "reimbursement", "under", "Medicare", "Part", "B", "and", "Medicaid", "programs", "or", "to", "be", "sold", "directly", "to", "U.S.", "government", "agencies,", "the", "manufacturer", "must", "extend", "discounts", "to", "entities", "eligible", "to", "participate", "in", "the", "Public", "Health", "Service", "s", "340B", "drug", "pr", "icing", "program.", "<tag3>"], "wordsA": ["We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us."], "wordsB": ["Further,", "in", "order", "for", "a", "pharmaceutical", "product", "to", "receive", "federal", "reimbursement", "under", "Medicare", "Part", "B", "and", "Medicaid", "programs", "or", "to", "be", "sold", "directly", "to", "U.S.", "government", "agencies,", "the", "manufacturer", "must", "extend", "discounts", "to", "entities", "eligible", "to", "participate", "in", "the", "Public", "Health", "Service", "s", "340B", "drug", "pr", "icing", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s7", "idA": "906709_17_item1_p157_s3", "sentA": "Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad and could result in the award of substantial damages.", "sentB": "Adoption of price controls or other cost-containment measures could limit coverage for or the amounts that federal and state governments or private payors will pay for health care products and services, which could also result in reduced demand for our drug candidates or additional pricing pressures and affect our ultimate profitability.", "type": 1, "words": ["<tag1>", "Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages.", "<tag2>", "Adoption", "of", "price", "controls", "or", "other", "cost-containment", "measures", "could", "limit", "coverage", "for", "or", "the", "amounts", "that", "federal", "and", "state", "governments", "or", "private", "payors", "will", "pay", "for", "health", "care", "products", "and", "services,", "which", "could", "also", "result", "in", "reduced", "demand", "for", "our", "drug", "candidates", "or", "additional", "pricing", "pressures", "and", "affect", "our", "ultimate", "profitability.", "<tag3>"], "wordsA": ["Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages."], "wordsB": ["Adoption", "of", "price", "controls", "or", "other", "cost-containment", "measures", "could", "limit", "coverage", "for", "or", "the", "amounts", "that", "federal", "and", "state", "governments", "or", "private", "payors", "will", "pay", "for", "health", "care", "products", "and", "services,", "which", "could", "also", "result", "in", "reduced", "demand", "for", "our", "drug", "candidates", "or", "additional", "pricing", "pressures", "and", "affect", "our", "ultimate", "profitability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p157_s5", "idA": "906709_17_item1_p157_s3", "sentA": "Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad and could result in the award of substantial damages.", "sentB": "Any proposed or actual changes could limit coverage for or the amounts that federal and state governments will pay for health care products and services, which could also result in reduced demand for our products or additional pricing pressures and affect our ultimate profitability.", "type": 1, "words": ["<tag1>", "Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages.", "<tag2>", "Any", "proposed", "or", "actual", "changes", "could", "limit", "coverage", "for", "or", "the", "amounts", "that", "federal", "and", "state", "governments", "will", "pay", "for", "health", "care", "products", "and", "services,", "which", "could", "also", "result", "in", "reduced", "demand", "for", "our", "products", "or", "additional", "pricing", "pressures", "and", "affect", "our", "ultimate", "profitability.", "<tag3>"], "wordsA": ["Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages."], "wordsB": ["Any", "proposed", "or", "actual", "changes", "could", "limit", "coverage", "for", "or", "the", "amounts", "that", "federal", "and", "state", "governments", "will", "pay", "for", "health", "care", "products", "and", "services,", "which", "could", "also", "result", "in", "reduced", "demand", "for", "our", "products", "or", "additional", "pricing", "pressures", "and", "affect", "our", "ultimate", "profitability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p49_s0", "idA": "906709_17_item1_p161_s3", "sentA": "In our partnered programs where we provide contract research services, those services are typically provided under a work plan that is subject to frequent revisions that change based on the development needs and status of the program.", "sentB": "The closing under the BMS Collaboration Agreement will occur simultaneously with the closing under a Share Purchase Agreement entered into between us and BMS on February 13, 2018, which is subject to the expiration or early termination of the wai ting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions.", "type": 1, "words": ["<tag1>", "In", "our", "partnered", "programs", "where", "we", "provide", "contract", "research", "services,", "those", "services", "are", "typically", "provided", "under", "a", "work", "plan", "that", "is", "subject", "to", "frequent", "revisions", "that", "change", "based", "on", "the", "development", "needs", "and", "status", "of", "the", "program.", "<tag2>", "The", "closing", "under", "the", "BMS", "Collaboration", "Agreement", "will", "occur", "simultaneously", "with", "the", "closing", "under", "a", "Share", "Purchase", "Agreement", "entered", "into", "between", "us", "and", "BMS", "on", "February", "13,", "2018,", "which", "is", "subject", "to", "the", "expiration", "or", "early", "termination", "of", "the", "wai", "ting", "period", "(and", "any", "extension", "thereof)", "under", "the", "Hart-Scott-Rodino", "Antitrust", "Improvements", "Act", "of", "1976", "and", "other", "customary", "closing", "conditions.", "<tag3>"], "wordsA": ["In", "our", "partnered", "programs", "where", "we", "provide", "contract", "research", "services,", "those", "services", "are", "typically", "provided", "under", "a", "work", "plan", "that", "is", "subject", "to", "frequent", "revisions", "that", "change", "based", "on", "the", "development", "needs", "and", "status", "of", "the", "program."], "wordsB": ["The", "closing", "under", "the", "BMS", "Collaboration", "Agreement", "will", "occur", "simultaneously", "with", "the", "closing", "under", "a", "Share", "Purchase", "Agreement", "entered", "into", "between", "us", "and", "BMS", "on", "February", "13,", "2018,", "which", "is", "subject", "to", "the", "expiration", "or", "early", "termination", "of", "the", "wai", "ting", "period", "(and", "any", "extension", "thereof)", "under", "the", "Hart-Scott-Rodino", "Antitrust", "Improvements", "Act", "of", "1976", "and", "other", "customary", "closing", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p4_s0", "idA": "906709_17_item1_p161_s3", "sentA": "In our partnered programs where we provide contract research services, those services are typically provided under a work plan that is subject to frequent revisions that change based on the development needs and status of the program.", "sentB": "The closing date under the BMS Collaboration Agreement will occur simultaneously with the closing under the Purchase Agreement, which is subject to the expiration or early termination of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions.", "type": 1, "words": ["<tag1>", "In", "our", "partnered", "programs", "where", "we", "provide", "contract", "research", "services,", "those", "services", "are", "typically", "provided", "under", "a", "work", "plan", "that", "is", "subject", "to", "frequent", "revisions", "that", "change", "based", "on", "the", "development", "needs", "and", "status", "of", "the", "program.", "<tag2>", "The", "closing", "date", "under", "the", "BMS", "Collaboration", "Agreement", "will", "occur", "simultaneously", "with", "the", "closing", "under", "the", "Purchase", "Agreement,", "which", "is", "subject", "to", "the", "expiration", "or", "early", "termination", "of", "the", "waiting", "period", "(and", "any", "extension", "thereof)", "under", "the", "Hart-Scott-Rodino", "Antitrust", "Improvements", "Act", "of", "1976", "and", "other", "customary", "closing", "conditions.", "<tag3>"], "wordsA": ["In", "our", "partnered", "programs", "where", "we", "provide", "contract", "research", "services,", "those", "services", "are", "typically", "provided", "under", "a", "work", "plan", "that", "is", "subject", "to", "frequent", "revisions", "that", "change", "based", "on", "the", "development", "needs", "and", "status", "of", "the", "program."], "wordsB": ["The", "closing", "date", "under", "the", "BMS", "Collaboration", "Agreement", "will", "occur", "simultaneously", "with", "the", "closing", "under", "the", "Purchase", "Agreement,", "which", "is", "subject", "to", "the", "expiration", "or", "early", "termination", "of", "the", "waiting", "period", "(and", "any", "extension", "thereof)", "under", "the", "Hart-Scott-Rodino", "Antitrust", "Improvements", "Act", "of", "1976", "and", "other", "customary", "closing", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p17_s11", "idA": "906709_17_item1_p166_s1", "sentA": "Prior to its 2014 approval, the fusion protein in ELOCTATE was not used outside of the clinical trial setting for Hemophilia A patients.", "sentB": "On July 26, 2017, we filed a request for re-examination of the opinion adopted by the CHMP (the CHMP Appeal ) but such request was not successful.", "type": 1, "words": ["<tag1>", "Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients.", "<tag2>", "On", "July", "26,", "2017,", "we", "filed", "a", "request", "for", "re-examination", "of", "the", "opinion", "adopted", "by", "the", "CHMP", "(the", "CHMP", "Appeal", ")", "but", "such", "request", "was", "not", "successful.", "<tag3>"], "wordsA": ["Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients."], "wordsB": ["On", "July", "26,", "2017,", "we", "filed", "a", "request", "for", "re-examination", "of", "the", "opinion", "adopted", "by", "the", "CHMP", "(the", "CHMP", "Appeal", ")", "but", "such", "request", "was", "not", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p69_s10", "idA": "906709_17_item1_p166_s1", "sentA": "Prior to its 2014 approval, the fusion protein in ELOCTATE was not used outside of the clinical trial setting for Hemophilia A patients.", "sentB": "On July 26, 2017, we filed a request for re-examination of the opinion adopted by the CHMP (the CHMP Appeal ) but we were informed by the CHMP in November 2017 that our request was not successful.", "type": 1, "words": ["<tag1>", "Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients.", "<tag2>", "On", "July", "26,", "2017,", "we", "filed", "a", "request", "for", "re-examination", "of", "the", "opinion", "adopted", "by", "the", "CHMP", "(the", "CHMP", "Appeal", ")", "but", "we", "were", "informed", "by", "the", "CHMP", "in", "November", "2017", "that", "our", "request", "was", "not", "successful.", "<tag3>"], "wordsA": ["Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients."], "wordsB": ["On", "July", "26,", "2017,", "we", "filed", "a", "request", "for", "re-examination", "of", "the", "opinion", "adopted", "by", "the", "CHMP", "(the", "CHMP", "Appeal", ")", "but", "we", "were", "informed", "by", "the", "CHMP", "in", "November", "2017", "that", "our", "request", "was", "not", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s1", "idA": "906709_17_item1_p176_s2", "sentA": "We would be subject to significant penalties for failure to comply with these laws and regulations.", "sentB": "Further, private payors often follow the coverage and payment policies established by certain government programs, such as Medicare and Medicaid, which require manufacturers to comply with certain rebate, price reporting, and other obligations.", "type": 1, "words": ["<tag1>", "We", "would", "be", "subject", "to", "significant", "penalties", "for", "failure", "to", "comply", "with", "these", "laws", "and", "regulations.", "<tag2>", "Further,", "private", "payors", "often", "follow", "the", "coverage", "and", "payment", "policies", "established", "by", "certain", "government", "programs,", "such", "as", "Medicare", "and", "Medicaid,", "which", "require", "manufacturers", "to", "comply", "with", "certain", "rebate,", "price", "reporting,", "and", "other", "obligations.", "<tag3>"], "wordsA": ["We", "would", "be", "subject", "to", "significant", "penalties", "for", "failure", "to", "comply", "with", "these", "laws", "and", "regulations."], "wordsB": ["Further,", "private", "payors", "often", "follow", "the", "coverage", "and", "payment", "policies", "established", "by", "certain", "government", "programs,", "such", "as", "Medicare", "and", "Medicaid,", "which", "require", "manufacturers", "to", "comply", "with", "certain", "rebate,", "price", "reporting,", "and", "other", "obligations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s12", "idA": "906709_17_item1_p176_s2", "sentA": "We would be subject to significant penalties for failure to comply with these laws and regulations.", "sentB": "Other Healthcare Laws and Regulations If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry.", "type": 1, "words": ["<tag1>", "We", "would", "be", "subject", "to", "significant", "penalties", "for", "failure", "to", "comply", "with", "these", "laws", "and", "regulations.", "<tag2>", "Other", "Healthcare", "Laws", "and", "Regulations", "If", "we", "obtain", "regulatory", "approval", "of", "our", "products,", "we", "may", "be", "subject", "to", "various", "federal", "and", "state", "laws", "targeting", "fraud", "and", "abuse", "in", "the", "healthcare", "industry.", "<tag3>"], "wordsA": ["We", "would", "be", "subject", "to", "significant", "penalties", "for", "failure", "to", "comply", "with", "these", "laws", "and", "regulations."], "wordsB": ["Other", "Healthcare", "Laws", "and", "Regulations", "If", "we", "obtain", "regulatory", "approval", "of", "our", "products,", "we", "may", "be", "subject", "to", "various", "federal", "and", "state", "laws", "targeting", "fraud", "and", "abuse", "in", "the", "healthcare", "industry."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s6", "idA": "906709_17_item1_p178_s0", "sentA": "Of the 468 employees, 392 were located in the U.S. and 76 were located in India.", "sentB": "The U.S. government and state legislatures have shown significant interest in implementing cost-containment programs, including price controls and restrictions on reimbursement, among other controls.", "type": 1, "words": ["<tag1>", "Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India.", "<tag2>", "The", "U.S.", "government", "and", "state", "legislatures", "have", "shown", "significant", "interest", "in", "implementing", "cost-containment", "programs,", "including", "price", "controls", "and", "restrictions", "on", "reimbursement,", "among", "other", "controls.", "<tag3>"], "wordsA": ["Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India."], "wordsB": ["The", "U.S.", "government", "and", "state", "legislatures", "have", "shown", "significant", "interest", "in", "implementing", "cost-containment", "programs,", "including", "price", "controls", "and", "restrictions", "on", "reimbursement,", "among", "other", "controls."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s11", "idA": "906709_17_item1_p1_s3", "sentA": "A Phase 1 trial for NKTR-214 as a single-agent in cancer patients with solid tumors has completed recruitment.", "sentB": "We will book all worldwide sales and revenue for NKTR-214.", "type": 1, "words": ["<tag1>", "A", "Phase", "1", "trial", "for", "NKTR-214", "as", "a", "single-agent", "in", "cancer", "patients", "with", "solid", "tumors", "has", "completed", "recruitment.", "<tag2>", "We", "will", "book", "all", "worldwide", "sales", "and", "revenue", "for", "NKTR-214.", "<tag3>"], "wordsA": ["A", "Phase", "1", "trial", "for", "NKTR-214", "as", "a", "single-agent", "in", "cancer", "patients", "with", "solid", "tumors", "has", "completed", "recruitment."], "wordsB": ["We", "will", "book", "all", "worldwide", "sales", "and", "revenue", "for", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s7", "idA": "906709_17_item1_p1_s3", "sentA": "A Phase 1 trial for NKTR-214 as a single-agent in cancer patients with solid tumors has completed recruitment.", "sentB": "We will book all worldwide sales and revenue for NKTR-214.", "type": 1, "words": ["<tag1>", "A", "Phase", "1", "trial", "for", "NKTR-214", "as", "a", "single-agent", "in", "cancer", "patients", "with", "solid", "tumors", "has", "completed", "recruitment.", "<tag2>", "We", "will", "book", "all", "worldwide", "sales", "and", "revenue", "for", "NKTR-214.", "<tag3>"], "wordsA": ["A", "Phase", "1", "trial", "for", "NKTR-214", "as", "a", "single-agent", "in", "cancer", "patients", "with", "solid", "tumors", "has", "completed", "recruitment."], "wordsB": ["We", "will", "book", "all", "worldwide", "sales", "and", "revenue", "for", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s12", "idA": "906709_17_item1_p1_s7", "sentA": "The first stage of the large Phase 1/2 clinical program for NKTR-214 is underway with BMS and is evaluating a potential combination treatment regimen of NKTR-214 with BMS PD-1 immune checkpoint inhibitor, Opdivo in up to 260 patients.", "sentB": "We will share global commercialization profits and losses with BMS for NKTR-214, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses.", "type": 1, "words": ["<tag1>", "The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients.", "<tag2>", "We", "will", "share", "global", "commercialization", "profits", "and", "losses", "with", "BMS", "for", "NKTR-214,", "with", "Nektar", "sharing", "65%", "and", "BMS", "sharing", "35%", "of", "the", "net", "profits", "and", "losses.", "<tag3>"], "wordsA": ["The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients."], "wordsB": ["We", "will", "share", "global", "commercialization", "profits", "and", "losses", "with", "BMS", "for", "NKTR-214,", "with", "Nektar", "sharing", "65%", "and", "BMS", "sharing", "35%", "of", "the", "net", "profits", "and", "losses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s8", "idA": "906709_17_item1_p1_s7", "sentA": "The first stage of the large Phase 1/2 clinical program for NKTR-214 is underway with BMS and is evaluating a potential combination treatment regimen of NKTR-214 with BMS PD-1 immune checkpoint inhibitor, Opdivo in up to 260 patients.", "sentB": "We will share global commercialization profits and losses with BMS for NKTR-214, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses.", "type": 1, "words": ["<tag1>", "The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients.", "<tag2>", "We", "will", "share", "global", "commercialization", "profits", "and", "losses", "with", "BMS", "for", "NKTR-214,", "with", "Nektar", "sharing", "65%", "and", "BMS", "sharing", "35%", "of", "the", "net", "profits", "and", "losses.", "<tag3>"], "wordsA": ["The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients."], "wordsB": ["We", "will", "share", "global", "commercialization", "profits", "and", "losses", "with", "BMS", "for", "NKTR-214,", "with", "Nektar", "sharing", "65%", "and", "BMS", "sharing", "35%", "of", "the", "net", "profits", "and", "losses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s5", "idA": "906709_17_item1_p20_s0", "sentA": "Polymer conjugation or PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Amgen s Neulasta (pegfilgrastim) and Roche s PEGASYS (PEG-interferon alfa-2a).", "sentB": "Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the price of therapeutics have been a focus in this effort.", "type": 1, "words": ["<tag1>", "Polymer", "conjugation", "or", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a).", "<tag2>", "Additionally,", "the", "containment", "of", "healthcare", "costs", "has", "become", "a", "priority", "of", "federal", "and", "state", "governments,", "and", "the", "price", "of", "therapeutics", "have", "been", "a", "focus", "in", "this", "effort.", "<tag3>"], "wordsA": ["Polymer", "conjugation", "or", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)."], "wordsB": ["Additionally,", "the", "containment", "of", "healthcare", "costs", "has", "become", "a", "priority", "of", "federal", "and", "state", "governments,", "and", "the", "price", "of", "therapeutics", "have", "been", "a", "focus", "in", "this", "effort."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s8", "idA": "906709_17_item1_p23_s2", "sentA": "We have also developed robust manufacturing processes for generating second generation PEGylation reagents that allow us to utilize the full potential of these newer approaches.", "sentB": "If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.", "type": 1, "words": ["<tag1>", "We", "have", "also", "developed", "robust", "manufacturing", "processes", "for", "generating", "second", "generation", "PEGylation", "reagents", "that", "allow", "us", "to", "utilize", "the", "full", "potential", "of", "these", "newer", "approaches.", "<tag2>", "If", "third-party", "payors", "do", "not", "consider", "a", "product", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "an", "approved", "product", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "at", "a", "profit.", "<tag3>"], "wordsA": ["We", "have", "also", "developed", "robust", "manufacturing", "processes", "for", "generating", "second", "generation", "PEGylation", "reagents", "that", "allow", "us", "to", "utilize", "the", "full", "potential", "of", "these", "newer", "approaches."], "wordsB": ["If", "third-party", "payors", "do", "not", "consider", "a", "product", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "an", "approved", "product", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "at", "a", "profit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p152_s0", "idA": "906709_17_item1_p23_s3", "sentA": "Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts.", "type": 1, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "state", "law", "equivalents", "of", "each", "of", "the", "above", "federal", "laws,", "such", "as", "anti-kickback", "and", "false", "claims", "laws", "which", "may", "apply", "to", "items", "or", "services", "reimbursed", "by", "any", "third-party", "payor,", "including", "commercial", "insurers,", "state", "transparency", "reporting", "and", "compliance", "laws;", "and", "state", "laws", "governing", "the", "privacy", "and", "security", "of", "health", "information", "in", "certain", "circumstances,", "many", "of", "which", "differ", "from", "each", "other", "in", "significant", "ways", "and", "which", "may", "not", "have", "the", "same", "effect,", "thus", "complicating", "compliance", "efforts.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["state", "law", "equivalents", "of", "each", "of", "the", "above", "federal", "laws,", "such", "as", "anti-kickback", "and", "false", "claims", "laws", "which", "may", "apply", "to", "items", "or", "services", "reimbursed", "by", "any", "third-party", "payor,", "including", "commercial", "insurers,", "state", "transparency", "reporting", "and", "compliance", "laws;", "and", "state", "laws", "governing", "the", "privacy", "and", "security", "of", "health", "information", "in", "certain", "circumstances,", "many", "of", "which", "differ", "from", "each", "other", "in", "significant", "ways", "and", "which", "may", "not", "have", "the", "same", "effect,", "thus", "complicating", "compliance", "efforts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s14", "idA": "906709_17_item1_p23_s3", "sentA": "Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "We will have the final decision-making authority regarding the pricing for NKTR-214.", "type": 1, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "We", "will", "have", "the", "final", "decision-making", "authority", "regarding", "the", "pricing", "for", "NKTR-214.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["We", "will", "have", "the", "final", "decision-making", "authority", "regarding", "the", "pricing", "for", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s10", "idA": "906709_17_item1_p23_s3", "sentA": "Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "We will have the final decision-making authority regarding the pricing for NKTR-214.", "type": 1, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "We", "will", "have", "the", "final", "decision-making", "authority", "regarding", "the", "pricing", "for", "NKTR-214.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["We", "will", "have", "the", "final", "decision-making", "authority", "regarding", "the", "pricing", "for", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p157_s4", "idA": "906709_17_item1_p29_s2", "sentA": "We have engineered different novel conjugates of IL-2 with optimized differential receptor binding to the IL-2 receptor categories in the immune system.", "sentB": "Furthermore, federal agencies, Congress, state legislatures, and the privacy sector have shown significant interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system.", "type": 1, "words": ["<tag1>", "We", "have", "engineered", "different", "novel", "conjugates", "of", "IL-2", "with", "optimized", "differential", "receptor", "binding", "to", "the", "IL-2", "receptor", "categories", "in", "the", "immune", "system.", "<tag2>", "Furthermore,", "federal", "agencies,", "Congress,", "state", "legislatures,", "and", "the", "privacy", "sector", "have", "shown", "significant", "interest", "in", "implementing", "cost", "containment", "programs", "to", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "other", "fundamental", "changes", "to", "the", "healthcare", "delivery", "system.", "<tag3>"], "wordsA": ["We", "have", "engineered", "different", "novel", "conjugates", "of", "IL-2", "with", "optimized", "differential", "receptor", "binding", "to", "the", "IL-2", "receptor", "categories", "in", "the", "immune", "system."], "wordsB": ["Furthermore,", "federal", "agencies,", "Congress,", "state", "legislatures,", "and", "the", "privacy", "sector", "have", "shown", "significant", "interest", "in", "implementing", "cost", "containment", "programs", "to", "limit", "the", "growth", "of", "health", "care", "costs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "other", "fundamental", "changes", "to", "the", "healthcare", "delivery", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s0", "idA": "906709_17_item1_p29_s4", "sentA": "Our customized approaches with large molecule polymer conjugates have expanded to include a new approach with biologics, in particular cytokines, which utilizes the polymer as a means to bias action to a certain receptor or receptor sub-type.", "sentB": "may also refuse to include a particular branded drug on their formul aries or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available.", "type": 1, "words": ["<tag1>", "Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "expanded", "to", "include", "a", "new", "approach", "with", "biologics,", "in", "particular", "cytokines,", "which", "utilizes", "the", "polymer", "as", "a", "means", "to", "bias", "action", "to", "a", "certain", "receptor", "or", "receptor", "sub-type.", "<tag2>", "may", "also", "refuse", "to", "include", "a", "particular", "branded", "drug", "on", "their", "formul", "aries", "or", "otherwise", "restrict", "patient", "access", "to", "a", "branded", "drug", "when", "a", "less", "costly", "generic", "equivalent", "or", "other", "alternative", "is", "available.", "<tag3>"], "wordsA": ["Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "expanded", "to", "include", "a", "new", "approach", "with", "biologics,", "in", "particular", "cytokines,", "which", "utilizes", "the", "polymer", "as", "a", "means", "to", "bias", "action", "to", "a", "certain", "receptor", "or", "receptor", "sub-type."], "wordsB": ["may", "also", "refuse", "to", "include", "a", "particular", "branded", "drug", "on", "their", "formul", "aries", "or", "otherwise", "restrict", "patient", "access", "to", "a", "branded", "drug", "when", "a", "less", "costly", "generic", "equivalent", "or", "other", "alternative", "is", "available."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p156_s5", "idA": "906709_17_item1_p33_s2", "sentA": "In addition, in certain instances we have the opportunity to develop new treatments for patients for which the parent drugs are not currently approved.", "sentB": "In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act.", "type": 1, "words": ["<tag1>", "In", "addition,", "in", "certain", "instances", "we", "have", "the", "opportunity", "to", "develop", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved.", "<tag2>", "In", "addition,", "private", "individuals", "have", "the", "ability", "to", "bring", "actions", "under", "the", "federal", "False", "Claims", "Act", "and", "certain", "states", "have", "enacted", "laws", "modeled", "after", "the", "federal", "False", "Claims", "Act.", "<tag3>"], "wordsA": ["In", "addition,", "in", "certain", "instances", "we", "have", "the", "opportunity", "to", "develop", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved."], "wordsB": ["In", "addition,", "private", "individuals", "have", "the", "ability", "to", "bring", "actions", "under", "the", "federal", "False", "Claims", "Act", "and", "certain", "states", "have", "enacted", "laws", "modeled", "after", "the", "federal", "False", "Claims", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p154_s0", "idA": "906709_17_item1_p3_s0", "sentA": "NKTR-255 is a biologic that targets the interleukin-15 pathway in order to activate the body s innate and adaptive immunity.", "sentB": "Pursuant to the Affordable Care Act, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.", "type": 1, "words": ["<tag1>", "NKTR-255", "is", "a", "biologic", "that", "targets", "the", "interleukin-15", "pathway", "in", "order", "to", "activate", "the", "body", "s", "innate", "and", "adaptive", "immunity.", "<tag2>", "Pursuant", "to", "the", "Affordable", "Care", "Act,", "a", "person", "or", "entity", "no", "longer", "needs", "to", "have", "actual", "knowledge", "of", "this", "statute", "or", "specific", "intent", "to", "violate", "it", "in", "order", "to", "have", "committed", "a", "violation.", "<tag3>"], "wordsA": ["NKTR-255", "is", "a", "biologic", "that", "targets", "the", "interleukin-15", "pathway", "in", "order", "to", "activate", "the", "body", "s", "innate", "and", "adaptive", "immunity."], "wordsB": ["Pursuant", "to", "the", "Affordable", "Care", "Act,", "a", "person", "or", "entity", "no", "longer", "needs", "to", "have", "actual", "knowledge", "of", "this", "statute", "or", "specific", "intent", "to", "violate", "it", "in", "order", "to", "have", "committed", "a", "violation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s17", "idA": "906709_17_item1_p41_s2", "sentA": "We plan to study NKTR-214 in combination with a number of therapeutic approaches where we believe there is a strong biologic rationale for complimentary mechanisms of action.", "sentB": "The parties will share the development costs for NKTR-214 in combination regimens based on each party s relative own ership interest in the compounds included in the regimens.", "type": 1, "words": ["<tag1>", "We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action.", "<tag2>", "The", "parties", "will", "share", "the", "development", "costs", "for", "NKTR-214", "in", "combination", "regimens", "based", "on", "each", "party", "s", "relative", "own", "ership", "interest", "in", "the", "compounds", "included", "in", "the", "regimens.", "<tag3>"], "wordsA": ["We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action."], "wordsB": ["The", "parties", "will", "share", "the", "development", "costs", "for", "NKTR-214", "in", "combination", "regimens", "based", "on", "each", "party", "s", "relative", "own", "ership", "interest", "in", "the", "compounds", "included", "in", "the", "regimens."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s13", "idA": "906709_17_item1_p41_s2", "sentA": "We plan to study NKTR-214 in combination with a number of therapeutic approaches where we believe there is a strong biologic rationale for complimentary mechanisms of action.", "sentB": "The parties will share the development costs for NKTR-214 in combination regimens based on each party s relative ownership interest in the compounds included in the regimens.", "type": 1, "words": ["<tag1>", "We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action.", "<tag2>", "The", "parties", "will", "share", "the", "development", "costs", "for", "NKTR-214", "in", "combination", "regimens", "based", "on", "each", "party", "s", "relative", "ownership", "interest", "in", "the", "compounds", "included", "in", "the", "regimens.", "<tag3>"], "wordsA": ["We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action."], "wordsB": ["The", "parties", "will", "share", "the", "development", "costs", "for", "NKTR-214", "in", "combination", "regimens", "based", "on", "each", "party", "s", "relative", "ownership", "interest", "in", "the", "compounds", "included", "in", "the", "regimens."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p49_s1", "idA": "906709_17_item1_p41_s3", "sentA": "On September 21, 2016, we entered into a Clinical Trial Collaboration Agreement (BMS Agreement) with Bristol-Myers Squibb Company (BMS), pursuant to which we and BMS are collaborating to conduct Phase 1/2 clinical trials evaluating NKTR-214 and BMS human monoclonal antibody that binds PD-1, known as Opdivo (nivolumab), as a potential combination treatment regimen in five tumor types and eight potential indications, and such other clinical trials evaluating the combined therapy as may be mutually agreed upon by the parties (each, a Combined Therapy Trial).", "sentB": "The closings are expected to occur during the second quarter of 2018, upon which the BMS Collaboration Agreement will supersede and replace the existing Clinical Trial Collaboration Agreement.", "type": 1, "words": ["<tag1>", "On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial).", "<tag2>", "The", "closings", "are", "expected", "to", "occur", "during", "the", "second", "quarter", "of", "2018,", "upon", "which", "the", "BMS", "Collaboration", "Agreement", "will", "supersede", "and", "replace", "the", "existing", "Clinical", "Trial", "Collaboration", "Agreement.", "<tag3>"], "wordsA": ["On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial)."], "wordsB": ["The", "closings", "are", "expected", "to", "occur", "during", "the", "second", "quarter", "of", "2018,", "upon", "which", "the", "BMS", "Collaboration", "Agreement", "will", "supersede", "and", "replace", "the", "existing", "Clinical", "Trial", "Collaboration", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s4", "idA": "906709_17_item1_p41_s6", "sentA": "The second phase of the expansion cohorts is expected to evaluate the safety and efficacy of combining NKTR-214 with Opdivo .", "sentB": "Third-party payors are increasingly challenging the prices charged for medical products and services, and examining the medical necessity and cost- effectiveness of medical products and services, in addition to their safety and efficacy.", "type": 1, "words": ["<tag1>", "The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "expected", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", ".", "<tag2>", "Third-party", "payors", "are", "increasingly", "challenging", "the", "prices", "charged", "for", "medical", "products", "and", "services,", "and", "examining", "the", "medical", "necessity", "and", "cost-", "effectiveness", "of", "medical", "products", "and", "services,", "in", "addition", "to", "their", "safety", "and", "efficacy.", "<tag3>"], "wordsA": ["The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "expected", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", "."], "wordsB": ["Third-party", "payors", "are", "increasingly", "challenging", "the", "prices", "charged", "for", "medical", "products", "and", "services,", "and", "examining", "the", "medical", "necessity", "and", "cost-", "effectiveness", "of", "medical", "products", "and", "services,", "in", "addition", "to", "their", "safety", "and", "efficacy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s11", "idA": "906709_17_item1_p62_s4", "sentA": "The Phase 2 clinical study was designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "The HAP study was designed to confirm and assess the relative oral abuse potential of NKTR-181, at its maximum analgesic therapeutic, dose (400 mg) studied in the SUMMIT-07 trial and at a supratherapeutic dose (3 times to 12 times greater than the analgesic dose range of 100 mg to 400 mg used in the SUMMIT-07 trial), compared to common therapeutic doses of oxycodone (40 mg and 60 mg) in 54 healthy non-dependent recreational drug users.", "type": 1, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "was", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "The", "HAP", "study", "was", "designed", "to", "confirm", "and", "assess", "the", "relative", "oral", "abuse", "potential", "of", "NKTR-181,", "at", "its", "maximum", "analgesic", "therapeutic,", "dose", "(400", "mg)", "studied", "in", "the", "SUMMIT-07", "trial", "and", "at", "a", "supratherapeutic", "dose", "(3", "times", "to", "12", "times", "greater", "than", "the", "analgesic", "dose", "range", "of", "100", "mg", "to", "400", "mg", "used", "in", "the", "SUMMIT-07", "trial),", "compared", "to", "common", "therapeutic", "doses", "of", "oxycodone", "(40", "mg", "and", "60", "mg)", "in", "54", "healthy", "non-dependent", "recreational", "drug", "users.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "was", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["The", "HAP", "study", "was", "designed", "to", "confirm", "and", "assess", "the", "relative", "oral", "abuse", "potential", "of", "NKTR-181,", "at", "its", "maximum", "analgesic", "therapeutic,", "dose", "(400", "mg)", "studied", "in", "the", "SUMMIT-07", "trial", "and", "at", "a", "supratherapeutic", "dose", "(3", "times", "to", "12", "times", "greater", "than", "the", "analgesic", "dose", "range", "of", "100", "mg", "to", "400", "mg", "used", "in", "the", "SUMMIT-07", "trial),", "compared", "to", "common", "therapeutic", "doses", "of", "oxycodone", "(40", "mg", "and", "60", "mg)", "in", "54", "healthy", "non-dependent", "recreational", "drug", "users."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p157_s1", "idA": "906709_17_item1_p64_s1", "sentA": "In addition to the clinical study of ONZEALD TM being conducted by us, we have also provided support for f our investigator-initiated Phase 2 studies being conducted for ONZEALD TM .", "sentB": "In addition to new legislation, FDA and healthcare fraud and abuse and coverage and reimbursement regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "f", "our", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", ".", "<tag2>", "In", "addition", "to", "new", "legislation,", "FDA", "and", "healthcare", "fraud", "and", "abuse", "and", "coverage", "and", "reimbursement", "regulations", "and", "policies", "are", "often", "revised", "or", "interpreted", "by", "the", "agency", "in", "ways", "that", "may", "significantly", "affect", "our", "business", "and", "our", "products.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "f", "our", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", "."], "wordsB": ["In", "addition", "to", "new", "legislation,", "FDA", "and", "healthcare", "fraud", "and", "abuse", "and", "coverage", "and", "reimbursement", "regulations", "and", "policies", "are", "often", "revised", "or", "interpreted", "by", "the", "agency", "in", "ways", "that", "may", "significantly", "affect", "our", "business", "and", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s9", "idA": "906709_17_item1_p66_s0", "sentA": "A total of ten products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement.", "type": 1, "words": ["<tag1>", "A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "The", "marketability", "of", "any", "products", "for", "which", "we", "receive", "regulatory", "approval", "for", "commercial", "sale", "may", "suffer", "if", "the", "government", "and", "third-party", "payors", "fail", "to", "provide", "adequate", "coverage", "and", "reimbursement.", "<tag3>"], "wordsA": ["A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["The", "marketability", "of", "any", "products", "for", "which", "we", "receive", "regulatory", "approval", "for", "commercial", "sale", "may", "suffer", "if", "the", "government", "and", "third-party", "payors", "fail", "to", "provide", "adequate", "coverage", "and", "reimbursement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p27_s1", "idA": "906709_17_item1_p67_s1", "sentA": "Filed an application for approval and marketing has been filed with the applicable government health authority.", "sentB": "Its primary use to date has been in currently approved biologic drugs to favorably alter their pharmacokinetic or pharmacodynamic properties.", "type": 1, "words": ["<tag1>", "Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority.", "<tag2>", "Its", "primary", "use", "to", "date", "has", "been", "in", "currently", "approved", "biologic", "drugs", "to", "favorably", "alter", "their", "pharmacokinetic", "or", "pharmacodynamic", "properties.", "<tag3>"], "wordsA": ["Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority."], "wordsB": ["Its", "primary", "use", "to", "date", "has", "been", "in", "currently", "approved", "biologic", "drugs", "to", "favorably", "alter", "their", "pharmacokinetic", "or", "pharmacodynamic", "properties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p85_s1", "idA": "906709_17_item1_p78_s9", "sentA": "For both MOVANTIK and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sa les in the U.S. and 18% of net sales in the EU and rest of world, varying by country of sale and level of annual net sales.", "sentB": "Nektar receives a 40% share of royalty payments made by Kirin to AstraZeneca will be financially equivalent to Nektar receiving high single-digit to low double-digit royalties depending on Kirin s annual net sales levels.", "type": 1, "words": ["<tag1>", "For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sa", "les", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "Nektar", "receives", "a", "40%", "share", "of", "royalty", "payments", "made", "by", "Kirin", "to", "AstraZeneca", "will", "be", "financially", "equivalent", "to", "Nektar", "receiving", "high", "single-digit", "to", "low", "double-digit", "royalties", "depending", "on", "Kirin", "s", "annual", "net", "sales", "levels.", "<tag3>"], "wordsA": ["For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sa", "les", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["Nektar", "receives", "a", "40%", "share", "of", "royalty", "payments", "made", "by", "Kirin", "to", "AstraZeneca", "will", "be", "financially", "equivalent", "to", "Nektar", "receiving", "high", "single-digit", "to", "low", "double-digit", "royalties", "depending", "on", "Kirin", "s", "annual", "net", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p155_s0", "idA": "906709_17_item1_p80_s0", "sentA": "There are a number of patents relevant to MOVANTIK , some of which are listed in the FDA s Orange Book.", "sentB": "Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.", "type": 1, "words": ["<tag1>", "There", "are", "a", "number", "of", "patents", "relevant", "to", "MOVANTIK", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book.", "<tag2>", "Many", "states", "have", "adopted", "laws", "similar", "to", "the", "federal", "Anti-Kickback", "Statute,", "some", "of", "which", "apply", "to", "the", "referral", "of", "patients", "for", "healthcare", "items", "or", "services", "reimbursed", "by", "any", "source,", "not", "only", "the", "Medicare", "and", "Medicaid", "programs.", "<tag3>"], "wordsA": ["There", "are", "a", "number", "of", "patents", "relevant", "to", "MOVANTIK", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book."], "wordsB": ["Many", "states", "have", "adopted", "laws", "similar", "to", "the", "federal", "Anti-Kickback", "Statute,", "some", "of", "which", "apply", "to", "the", "referral", "of", "patients", "for", "healthcare", "items", "or", "services", "reimbursed", "by", "any", "source,", "not", "only", "the", "Medicare", "and", "Medicaid", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p157_s2", "idA": "906709_17_item1_p92_s0", "sentA": "Amikacin Inhale is designed to be an adjunctive therapy to the current antibiotic therapies administered intravenously as standard of care.", "sentB": "Further, the 2016 Presidential and Congressional elections and subsequent developments have caused the future state of many core aspects of the current health care marketplace to be uncertain, as the new Presidential Administration and Congress have repeatedly expressed a desire to repeal all or portions of the Affordable Care Act.", "type": 1, "words": ["<tag1>", "Amikacin", "Inhale", "is", "designed", "to", "be", "an", "adjunctive", "therapy", "to", "the", "current", "antibiotic", "therapies", "administered", "intravenously", "as", "standard", "of", "care.", "<tag2>", "Further,", "the", "2016", "Presidential", "and", "Congressional", "elections", "and", "subsequent", "developments", "have", "caused", "the", "future", "state", "of", "many", "core", "aspects", "of", "the", "current", "health", "care", "marketplace", "to", "be", "uncertain,", "as", "the", "new", "Presidential", "Administration", "and", "Congress", "have", "repeatedly", "expressed", "a", "desire", "to", "repeal", "all", "or", "portions", "of", "the", "Affordable", "Care", "Act.", "<tag3>"], "wordsA": ["Amikacin", "Inhale", "is", "designed", "to", "be", "an", "adjunctive", "therapy", "to", "the", "current", "antibiotic", "therapies", "administered", "intravenously", "as", "standard", "of", "care."], "wordsB": ["Further,", "the", "2016", "Presidential", "and", "Congressional", "elections", "and", "subsequent", "developments", "have", "caused", "the", "future", "state", "of", "many", "core", "aspects", "of", "the", "current", "health", "care", "marketplace", "to", "be", "uncertain,", "as", "the", "new", "Presidential", "Administration", "and", "Congress", "have", "repeatedly", "expressed", "a", "desire", "to", "repeal", "all", "or", "portions", "of", "the", "Affordable", "Care", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p98_s3", "idA": "906709_17_item1_p97_s0", "sentA": "Cipro DPI has completed Phase 2 clinical development for the treatment of chronic lung infections.", "sentB": "A pooled analysis of the primary efficacy results of RESPIRE 1 and RESPIRE 2 is positive and the data of both RESPIRE 1 and RESPIRE 2 indicated that Cipro DPI has a positive safety profile.", "type": 1, "words": ["<tag1>", "Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections.", "<tag2>", "A", "pooled", "analysis", "of", "the", "primary", "efficacy", "results", "of", "RESPIRE", "1", "and", "RESPIRE", "2", "is", "positive", "and", "the", "data", "of", "both", "RESPIRE", "1", "and", "RESPIRE", "2", "indicated", "that", "Cipro", "DPI", "has", "a", "positive", "safety", "profile.", "<tag3>"], "wordsA": ["Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections."], "wordsB": ["A", "pooled", "analysis", "of", "the", "primary", "efficacy", "results", "of", "RESPIRE", "1", "and", "RESPIRE", "2", "is", "positive", "and", "the", "data", "of", "both", "RESPIRE", "1", "and", "RESPIRE", "2", "indicated", "that", "Cipro", "DPI", "has", "a", "positive", "safety", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p2_s0", "idA": "906709_17_item1_p9_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study, which we call SUMMIT-07 in February 2015 and we completed enrollment in the study in late 2016.", "sentB": "If a registration-enabling study included in the joint development plan does not have the first patient enrolled prior to the date which is 14 months from the closing date, subject to allowable delays, the indication covered by that study is no longer subject to the above exclusivity.", "type": 1, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016.", "<tag2>", "If", "a", "registration-enabling", "study", "included", "in", "the", "joint", "development", "plan", "does", "not", "have", "the", "first", "patient", "enrolled", "prior", "to", "the", "date", "which", "is", "14", "months", "from", "the", "closing", "date,", "subject", "to", "allowable", "delays,", "the", "indication", "covered", "by", "that", "study", "is", "no", "longer", "subject", "to", "the", "above", "exclusivity.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016."], "wordsB": ["If", "a", "registration-enabling", "study", "included", "in", "the", "joint", "development", "plan", "does", "not", "have", "the", "first", "patient", "enrolled", "prior", "to", "the", "date", "which", "is", "14", "months", "from", "the", "closing", "date,", "subject", "to", "allowable", "delays,", "the", "indication", "covered", "by", "that", "study", "is", "no", "longer", "subject", "to", "the", "above", "exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p47_s0", "idA": "906709_17_item1_p9_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study, which we call SUMMIT-07 in February 2015 and we completed enrollment in the study in late 2016.", "sentB": "If a registration-enabling study included in the joint development plan does not have the first patient enrolled prior to the date which is 14 months from the closing date, subject to allowable delays, the indication covered by that study is no longer subject to the above exclusivity.", "type": 1, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016.", "<tag2>", "If", "a", "registration-enabling", "study", "included", "in", "the", "joint", "development", "plan", "does", "not", "have", "the", "first", "patient", "enrolled", "prior", "to", "the", "date", "which", "is", "14", "months", "from", "the", "closing", "date,", "subject", "to", "allowable", "delays,", "the", "indication", "covered", "by", "that", "study", "is", "no", "longer", "subject", "to", "the", "above", "exclusivity.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016."], "wordsB": ["If", "a", "registration-enabling", "study", "included", "in", "the", "joint", "development", "plan", "does", "not", "have", "the", "first", "patient", "enrolled", "prior", "to", "the", "date", "which", "is", "14", "months", "from", "the", "closing", "date,", "subject", "to", "allowable", "delays,", "the", "indication", "covered", "by", "that", "study", "is", "no", "longer", "subject", "to", "the", "above", "exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
